DEA Rescheduling Process: How Federal Cannabis Classification Works

Executive Summary

The DEA rescheduling process represents the most significant potential shift in federal cannabis policy since the Controlled Substances Act was enacted in 1970. On May 21, 2024, the Department of Justice published a notice of proposed rulemaking to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act—a move that would acknowledge cannabis has accepted medical use and lower abuse potential than substances like heroin or LSD. The process has been marked by procedural complexity, political controversy, and unprecedented public engagement, with the DEA receiving over 43,000 public comments during the initial comment period. As of April 28, 2026, the DEA withdrew its initial hearing notice and initiated new hearing proceedings under Executive Order 14370, extending a process that has already spanned multiple presidential administrations. While rescheduling would not legalize cannabis federally or resolve the conflict between state and federal law, it would eliminate the punitive 280E tax provision affecting state-legal cannabis businesses, potentially saving the industry billions annually, and could facilitate expanded medical research. The outcome will affect hundreds of thousands of jobs, tens of billions in annual commerce, millions of medical patients, and the criminal justice system's approach to cannabis enforcement.

Why This Matters

The DEA's rescheduling decision will determine the fate of a $30+ billion legal cannabis industry, affect millions of medical patients, and reshape criminal justice policy nationwide. The stakes extend far beyond the cannabis industry itself. Over 40 states have legalized cannabis in some form, creating a massive state-federal legal conflict that affects banking, taxation, research, employment, and criminal enforcement.

For the cannabis industry, rescheduling to Schedule III would eliminate Internal Revenue Code Section 280E, which currently prohibits state-legal cannabis businesses from deducting ordinary business expenses on federal tax returns. Industry analysts estimate this change alone could save multi-state operators between $1.5 billion and $3 billion annually in tax liability, fundamentally altering profitability calculations and potentially triggering consolidation and expansion. Publicly traded cannabis companies have seen stock valuations swing by billions based on rescheduling speculation.

For medical patients, Schedule III status would acknowledge federal recognition of cannabis's medical utility for the first time, potentially expanding access through the Veterans Administration, facilitating insurance coverage discussions, and reducing stigma. Approximately 5-7 million Americans currently use state-legal medical cannabis for conditions ranging from chronic pain to epilepsy to PTSD. Research institutions would gain substantially easier pathways to study cannabis, potentially accelerating clinical trials and FDA approval processes for cannabis-derived medications.

The criminal justice implications remain complex. While rescheduling would not decriminalize cannabis possession or eliminate federal prohibition, it would reduce maximum penalties and could influence prosecutorial discretion. Approximately 350,000 Americans were arrested for cannabis-related offenses in 2023, the vast majority for simple possession. Advocacy groups argue that rescheduling without broader reform fails to address mass incarceration and disproportionate enforcement against communities of color.

Financial institutions currently operating under guidance rather than clear legal authority would gain regulatory clarity, potentially opening traditional banking services to an industry that has operated largely on cash. Interstate commerce questions would intensify, as Schedule III substances can move across state lines under proper licensing—a provision that could fundamentally restructure the state-by-state siloed market structure.

Background and History

The path to potential rescheduling began with the Controlled Substances Act of 1970 and has accelerated dramatically since 2022 through a complex interplay of scientific review, political pressure, and administrative procedure.

The Controlled Substances Act Framework (1970)

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, establishing five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I, the most restrictive category, defined as substances with "no currently accepted medical use" and "high potential for abuse." This classification put cannabis in the same category as heroin, LSD, and peyote, while cocaine and methamphetamine were placed in Schedule II, acknowledging their medical applications despite abuse potential.

The CSA established procedures for rescheduling substances under 21 U.S.C. § 811, requiring the Attorney General (who delegated authority to the DEA) to request a scientific and medical evaluation from the Department of Health and Human Services. The statute specifies eight factors for evaluation, including the substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, and risk to public health.

Early Rescheduling Petitions (1972-2016)

The National Organization for the Reform of Marijuana Laws filed the first rescheduling petition in 1972, initiating a 22-year administrative and legal battle. DEA Administrative Law Judge Francis Young ruled in 1988 that cannabis should be rescheduled to Schedule II, famously stating that cannabis is "one of the safest therapeutically active substances known to man." DEA Administrator John Lawn rejected this recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals in 1994.

Subsequent petitions in 1995, 2002, and 2011 followed similar patterns: years of administrative delay, HHS scientific review concluding cannabis met Schedule I criteria, and DEA denial. The 2011 petition, filed by governors of Washington and Rhode Island, was denied in 2016 after a five-year review. The DEA's 2016 denial letter acknowledged growing state legalization but maintained that cannabis lacked "adequate and well-controlled studies proving efficacy" required for accepted medical use under the agency's five-part test.

The Biden Administration Initiative (2022-2024)

On October 6, 2022, President Joe Biden issued a presidential memorandum directing HHS Secretary Xavier Becerra and Attorney General Merrick Garland to "review expeditiously how marijuana is scheduled under federal law." This marked the first time a sitting president had directly initiated a rescheduling review rather than responding to external petitions. The directive came alongside presidential pardons for federal simple possession convictions and reflected shifting political calculations as public support for legalization exceeded 70 percent in most polling.

HHS completed its scientific review in August 2023, recommending rescheduling to Schedule III. The recommendation, based on an eight-factor analysis conducted by the Food and Drug Administration, concluded that cannabis has lower abuse potential than Schedule I or II substances and has currently accepted medical use in treatment in the United States. The FDA analysis noted that 38 states had legalized medical cannabis, that healthcare providers were recommending cannabis under state law, and that cannabis showed lower physical dependence liability than other controlled substances.

The DEA received HHS's recommendation in late August 2023 and initiated its own independent review. Under the CSA, HHS's scientific and medical findings are binding on scheduling factors related to medical use and abuse potential, but the DEA retains final decision-making authority and must consider additional factors including international treaty obligations and enforcement considerations.

The Notice of Proposed Rulemaking (May 2024)

On May 21, 2024, the DEA published its notice of proposed rulemaking in the Federal Register, proposing to reschedule cannabis from Schedule I to Schedule III. The 92-page document detailed the agency's analysis of the eight statutory factors, substantially adopting HHS's scientific conclusions while addressing enforcement and international treaty questions. The NPRM acknowledged that rescheduling would not resolve the state-federal conflict, would not legalize cannabis for recreational use, and would not permit cannabis businesses to operate without DEA registration as manufacturers or distributors of controlled substances.

The proposal triggered an unprecedented public response. During the initial 60-day comment period, the DEA received over 43,000 submissions—far exceeding typical rulemaking engagement. Comments ranged from major medical organizations supporting rescheduling based on emerging evidence, to law enforcement groups warning of increased youth access, to cannabis industry stakeholders seeking full descheduling rather than Schedule III placement, to criminal justice reform advocates arguing rescheduling without expungement provisions perpetuates injustice.

Hearing Proceedings and Withdrawal (2024-2026)

On August 29, 2024, the DEA published a notice of hearing, granting requests from multiple parties to present oral testimony and cross-examine witnesses on the rescheduling proposal. The formal hearing process, governed by 21 CFR Part 1316, resembles a trial with discovery, pre-hearing statements, witness lists, and an administrative law judge presiding. Parties granted participant status included medical cannabis advocacy organizations, pharmaceutical industry representatives, law enforcement associations, and individual researchers.

The hearing process became entangled in political transitions and executive branch policy shifts. On April 28, 2026, the DEA published a withdrawal notice, terminating the pending hearing proceedings and announcing new hearing proceedings would be initiated. The withdrawal cited Executive Order 14370 and stated that terminating existing proceedings and starting fresh represented "the most expeditious manner of completing the rulemaking process in accordance with Federal law." The unusual procedural move extended timeline uncertainty and raised questions about whether the new administration sought to alter the rescheduling outcome or merely restructure the administrative process.

Key Players

Drug Enforcement Administration

The DEA holds final decision-making authority on rescheduling under delegated authority from the Attorney General. As the lead federal drug enforcement agency, the DEA has historically defended cannabis's Schedule I status through six decades and multiple rescheduling petitions. The agency's institutional culture emphasizes enforcement and international drug control treaty obligations. DEA Administrator Anne Milgram oversaw the initial review process and NPRM publication, while leadership transitions in 2025-2026 coincided with the hearing withdrawal and restart. The DEA's internal debate balances scientific evidence from HHS against law enforcement concerns, international treaty compliance, and the practical reality that rescheduling a widely used substance creates complex regulatory challenges for an agency built around prohibition.

Department of Health and Human Services / FDA

HHS provides the binding scientific and medical evaluation that forms the foundation of any rescheduling decision. The Food and Drug Administration, operating within HHS, conducted the comprehensive eight-factor analysis that concluded cannabis meets Schedule III criteria. FDA scientists reviewed epidemiological data on use patterns, pharmacological studies on dependence liability, state medical program data, and international scheduling approaches. The agency's 2023 recommendation represented a significant departure from previous HHS positions and reflected accumulating clinical evidence, state program experience, and evolving understanding of cannabis pharmacology. HHS Secretary Xavier Becerra championed the review, while FDA Commissioner Robert Califf emphasized the agency's commitment to following scientific evidence despite political pressures.

White House and Executive Branch

Presidential directives initiated the current rescheduling process and executive orders have shaped its procedural path. President Biden's October 2022 memorandum launched the review, reflecting campaign commitments and shifting Democratic Party consensus toward cannabis reform. The administration framed rescheduling as a criminal justice and scientific integrity issue, though stopped short of endorsing full legalization. The transition to a new administration in 2025 introduced uncertainty, with Executive Order 14370 triggering the hearing process restart. White House domestic policy staff coordinate across agencies, balancing public health perspectives, criminal justice reform advocates, and political calculations around a policy that polls strongly with voters under 50 but faces skepticism from traditional law enforcement constituencies.

Cannabis Industry and Trade Associations

Multi-state operators, ancillary businesses, and industry trade groups have billions in market capitalization riding on the rescheduling outcome. The National Cannabis Industry Association, the U.S. Cannabis Council, and state-level trade groups submitted detailed comments emphasizing 280E tax relief and banking access. Publicly traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have seen stock prices fluctuate 30-50 percent based on rescheduling news. Industry positions are not monolithic—some advocate for Schedule III as a pragmatic step forward, while others argue it perpetuates federal prohibition and prefer full descheduling. Smaller operators and social equity licensees have raised concerns that 280E relief will disproportionately benefit large MSOs with resources to survive current tax burdens, potentially accelerating market consolidation.

Medical and Scientific Organizations

Professional medical societies have evolved from skepticism to cautious support for rescheduling based on accumulating evidence. The American Medical Association, which originally supported cannabis prohibition in the 1930s, now supports rescheduling to facilitate research. The American Academy of Pediatrics maintains concerns about youth use but acknowledges medical applications. Organizations representing specialists treating conditions where cannabis shows promise—including the American Academy of Neurology for epilepsy and the American Pain Society for chronic pain—have submitted supportive comments. Research institutions including the University of Mississippi, which holds the federal cannabis cultivation monopoly, and major academic medical centers seek expanded research access that Schedule III would facilitate.

Law Enforcement and Opposition Groups

Police associations, prosecutors, and anti-legalization advocacy groups argue rescheduling sends the wrong message and threatens public safety. Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, leads organized opposition, arguing that cannabis potency has increased dramatically since the 1970s and that rescheduling ignores mental health and addiction risks. The National Sheriffs' Association and Major County Sheriffs of America have expressed concerns about impaired driving enforcement and youth access. These groups emphasize that Schedule III substances are still prohibited for recreational use and that rescheduling creates regulatory complexity without resolving enforcement challenges. Some opposition comes from unexpected quarters—certain pharmaceutical industry segments concerned about cannabis competition with prescription medications.

Criminal Justice Reform and Social Equity Advocates

Organizations focused on mass incarceration and racial justice argue that rescheduling without expungement and reinvestment fails to address prohibition's harms. The Drug Policy Alliance, the Last Prisoner Project, and the Marijuana Policy Project have submitted comments supporting rescheduling as a step forward while emphasizing it leaves federal prohibition intact. These groups note that Black Americans are arrested for cannabis offenses at nearly four times the rate of white Americans despite similar usage rates, and that rescheduling does nothing for the estimated 40,000 people currently incarcerated for federal cannabis offenses. They advocate for comprehensive reform including expungement, resentencing, and community reinvestment rather than industry-focused tax relief.

Legal and Regulatory Framework

The rescheduling process operates within a complex statutory framework established by the Controlled Substances Act, constrained by international treaties, and complicated by federalism questions.

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes the fundamental legal architecture. Section 811 specifies the rescheduling process and the eight factors that must be considered: the substance's actual or relative potential for abuse; scientific evidence of its pharmacological effect; the state of current scientific knowledge; its history and current pattern of abuse; the scope, duration, and significance of abuse; what risk there is to public health; its psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance already scheduled.

The statute creates a unique division of authority between HHS and DEA. Under 21 U.S.C. § 811(b), the Attorney General (through DEA) must request a scientific and medical evaluation from HHS, and HHS's findings on scientific and medical matters are binding. However, the DEA makes the final scheduling decision considering additional factors including international treaty obligations and enforcement practicality. This division has created tension in the current process, with HHS's Schedule III recommendation binding on medical use and abuse potential questions but leaving DEA discretion on implementation.

The Administrative Procedure Act, 5 U.S.C. § 551 et seq., governs the rulemaking process itself. The DEA must provide notice, accept public comments, and respond to significant issues raised. The formal hearing process, triggered when parties request it, follows procedures in 21 CFR Part 1316, which incorporate elements of the APA's formal rulemaking requirements. These procedures, while ensuring due process, extend timelines significantly—the hearing on MDMA rescheduling in the 1980s took over three years from notice to final decision.

International treaty obligations add another layer of complexity. The United States is party to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. Cannabis is listed in Schedule I and Schedule IV of the 1961 Convention. In December 2020, the UN Commission on Narcotic Drugs voted to remove cannabis from Schedule IV (the most restrictive category) but retained it in Schedule I. U.S. rescheduling to Schedule III domestically would not violate treaty obligations, as the treaties require prohibition but allow countries to determine severity of controls and penalties. However, DEA has historically cited treaty obligations as a factor weighing against rescheduling.

The Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This provision has been the primary financial burden on state-legal cannabis businesses, forcing them to pay effective tax rates of 70 percent or higher. Rescheduling to Schedule III would eliminate 280E applicability, as the statute explicitly applies only to Schedule I and II substances. This change requires no additional Congressional action—it would occur automatically upon rescheduling.

The conflict between state and federal law raises fundamental federalism questions. Under the Supremacy Clause of the Constitution, federal law preempts conflicting state law. However, the anti-commandeering doctrine prevents the federal government from requiring states to enforce federal law. States can legalize cannabis under state law, but cannot immunize conduct from federal prosecution. Rescheduling to Schedule III would not resolve this conflict—cannabis would remain federally prohibited for recreational use, and state-legal businesses would still technically violate federal law, though they could potentially register with DEA as handlers of Schedule III substances.

The Gun Control Act of 1968, as interpreted by ATF, prohibits cannabis users from possessing firearms, even in states where cannabis is legal. This prohibition is based on cannabis's status as a controlled substance, not its specific schedule, so rescheduling would not resolve the conflict. However, the Fifth Circuit's decision in United States v. Daniels (2023) and subsequent cases have raised constitutional questions about this prohibition that may ultimately require Supreme Court resolution.

State-by-State Landscape

Federal rescheduling will interact differently with the patchwork of state cannabis laws, affecting 40+ state programs in varying ways.

State Category	Number of States	Rescheduling Impact
Adult-use legal	24 states + DC	Major 280E tax relief for businesses; no change to state-federal conflict on recreational use
Medical only	14 states	Federal acknowledgment of medical use; potential VA and research expansion
CBD/low-THC only	7 states	Possible catalyst for medical program expansion
Fully prohibited	5 states	Reduced federal penalties may influence state policy debates

California

As the largest legal cannabis market with over $5 billion in annual sales, California operators would see the most significant aggregate 280E relief. The state's high tax burden—combining state excise tax, local taxes, and effective federal rates over 70 percent—has driven consumers to the illicit market. Rescheduling could improve licensed market competitiveness, though California's regulatory complexity and local control issues would remain. Major MSOs including Glass House Brands and Harborside have headquarters in California and would benefit substantially from improved margins.

Florida

Florida's medical-only program serves over 800,000 registered patients, one of the nation's largest medical populations. Rescheduling would federally acknowledge medical use, potentially influencing the state's ongoing adult-use legalization debate. Trulieve, the nation's largest cannabis company by revenue, is headquartered in Florida and operates the most dispensaries statewide. The state's November 2024 adult-use ballot initiative failed to reach the 60 percent threshold, but rescheduling could shift political dynamics for future attempts.

New York

New York's adult-use program, launched in 2022, has struggled with slow licensing and illicit market competition. The state's social equity focus—prioritizing licenses for individuals harmed by prohibition—could see improved viability as 280E relief makes equity licensees more financially sustainable. However, rescheduling does nothing to address the state's regulatory bottlenecks or the estimated 1,500+ unlicensed storefronts operating in New York City.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to low-THC cannabis for a narrow list of conditions. Federal rescheduling acknowledging medical use could influence the Republican-controlled legislature's calculus, particularly as polling shows majority support among Texas voters for medical expansion. However, the state's conservative political culture and law enforcement opposition make rapid change unlikely regardless of federal scheduling.

Idaho, Nebraska, and Kansas

These states maintain complete prohibition with no medical exceptions. Federal rescheduling to Schedule III would reduce maximum federal penalties for possession and cultivation, potentially creating pressure on state lawmakers as neighboring states operate legal markets. However, state law enforcement would retain full authority to prosecute under state statutes, and political opposition remains strong in these conservative states.

Market and Business Implications

Rescheduling to Schedule III would trigger the most significant financial restructuring in cannabis industry history, with implications cascading through cultivation, retail, investment, and ancillary services.

The elimination of 280E represents an immediate margin expansion of 30-50 percent for most operators. Multi-state operators currently paying effective tax rates of 70-80 percent would drop to normal corporate rates around 21-25 percent. For a mid-sized MSO with $200 million in revenue and $40 million in EBITDA, 280E relief could translate to $25-35 million in annual tax savings. These savings would flow directly to bottom lines, fund expansion, or enable price reductions to compete with illicit markets.

Public market valuations would likely see immediate appreciation. The combined market capitalization of the top 20 publicly traded U.S. cannabis companies exceeds $15 billion, with stocks trading at significant discounts to revenue compared to other consumer packaged goods or pharmaceutical companies. Analysts project that rescheduling could trigger 50-100 percent stock appreciation as institutional investors currently restricted by federal illegality enter the sector. However, Schedule III status still leaves cannabis federally prohibited for recreational use, potentially limiting institutional participation compared to full descheduling.

Banking and financial services would see incremental improvement but not full resolution. The SAFE Banking Act, which would protect banks serving state-legal cannabis businesses, has stalled in Congress for multiple sessions. Rescheduling to Schedule III might reduce some compliance concerns, but cannabis would remain prohibited for recreational use, leaving banks uncertain about regulatory risk. Credit card processors and payment systems might expand access, reducing the industry's cash-intensive operations and associated security risks.

Wholesale pricing dynamics would shift as improved margins allow operators to reduce retail prices. In mature markets like Colorado and Oregon, wholesale flower prices have collapsed to $500-800 per pound due to oversupply. Rescheduling could accelerate price compression in newer markets as operators use tax savings to compete on price, potentially forcing marginal operators out and accelerating consolidation. Conversely, improved unit economics might sustain more operators than current conditions allow.

Interstate commerce questions would intensify. Schedule III substances can be transported across state lines by DEA-registered manufacturers and distributors. If cannabis businesses register as Schedule III handlers, could they ship products between states? The DEA's NPRM did not address this question directly, and state laws prohibiting importation would still apply. However, legal challenges to state import bans could emerge, potentially restructuring the industry from state-siloed markets to regional or national distribution—a change that would benefit large MSOs with multi-state footprints over single-state operators.

Pharmaceutical industry dynamics would evolve. Schedule III placement would ease clinical trial requirements and FDA approval pathways for cannabis-derived medications. Companies developing specific cannabinoid formulations for defined medical conditions could accelerate development timelines. However, the existence of widely available recreational and medical cannabis complicates the traditional pharmaceutical model—why would patients pay premium prices for FDA-approved cannabis medications when they can access similar products at dispensaries?

Ancillary service providers—including real estate, insurance, legal, and consulting firms serving the cannabis industry—would see expanded opportunities as improved operator economics drive growth. However, some service providers have charged premium rates due to cannabis's federal illegality; rescheduling might compress these premiums as the industry normalizes.

What Experts Say

Expert opinion on rescheduling spans a wide spectrum, from those viewing it as essential reform to those arguing it perpetuates prohibition's harms.

Medical researchers emphasize that Schedule III status would dramatically expand research capabilities. Scientists note that current Schedule I restrictions require special DEA licenses, limit access to research-grade cannabis, and create institutional review board complications. The ability to conduct large-scale clinical trials with diverse cannabis products rather than limited government-supplied material would accelerate understanding of therapeutic applications, dosing, drug interactions, and long-term effects. However, some researchers caution that rescheduling without adequate research funding and infrastructure may not translate to significantly expanded studies.

Tax and accounting professionals describe 280E elimination as transformative for cannabis business viability. Experts note that current tax treatment forces operators to pay taxes on gross profit rather than net income, making profitable operations nearly impossible in competitive markets. The ability to deduct ordinary business expenses—including rent, salaries, marketing, and professional services—would align cannabis businesses with other industries and enable standard financial planning. However, accountants warn that rescheduling creates transition complexities, including how to handle prior-year tax positions and whether amended returns would be possible.

Legal scholars debate whether rescheduling represents meaningful reform or incremental tinkering. Some constitutional law experts argue that acknowledging medical use while maintaining prohibition for recreational use creates untenable legal contradictions, particularly regarding equal protection and due process. Others contend that Schedule III placement within the existing CSA framework is the maximum administrative agencies can accomplish without Congressional legislation, and that criticizing rescheduling for not achieving full legalization misunderstands administrative law constraints.

Criminal justice reform advocates express frustration that rescheduling does nothing for people currently incarcerated or those with criminal records. Experts note that federal cannabis prisoners would not automatically receive sentence reductions, as rescheduling is not retroactive without additional action. The process also does not address the hundreds of thousands of annual state-level arrests, as states control their own scheduling and enforcement. Some advocates argue that celebrating rescheduling as reform while ignoring these populations perpetuates the injustices of prohibition.

International drug policy experts note that U.S. rescheduling could influence global approaches. Countries including Germany, Thailand, and Malta have recently liberalized cannabis policies, and U.S. movement toward Schedule III could accelerate international reform. However, experts caution that international treaties still require prohibition, and that U.S. rescheduling does not automatically change other countries' domestic laws or the UN treaty framework.

Industry analysts project that rescheduling would trigger significant merger and acquisition activity. With improved margins and potential institutional investment, large MSOs would have resources to acquire smaller operators, accelerating market consolidation. Some analysts predict that rescheduling could be a precursor to major alcohol, tobacco, or pharmaceutical companies entering the cannabis sector through acquisitions, fundamentally changing industry structure and potentially displacing early cannabis entrepreneurs.

The rescheduling of cannabis to Schedule III represents the federal government's acknowledgment that decades of scientific evidence and state-level experience have demonstrated medical utility, but it falls short of resolving the fundamental conflict between federal prohibition and state legalization that affects millions of Americans daily.

What's Next

The rescheduling process timeline remains uncertain following the April 2026 hearing withdrawal, with multiple decision points and potential legal challenges ahead.

The DEA's new notice of hearing, published alongside the withdrawal notice on April 28, 2026, will establish a fresh procedural calendar. Parties must file requests to participate, submit pre-hearing statements, and identify witnesses. Based on previous DEA hearing processes, the timeline from hearing notice to final decision typically spans 18-36 months, suggesting a potential final rule in late 2027 or 2028. However, the agency could expedite proceedings if directed by executive branch priorities.

The hearing itself will involve testimony from medical experts, pharmacologists, law enforcement officials, and other stakeholders. An administrative law judge will preside, and parties will have opportunities to cross-examine witnesses. The ALJ will issue a recommended decision to the DEA Administrator, who makes the final determination. This process is designed to create a robust administrative record that can withstand judicial review.

Legal challenges are virtually certain regardless of the final decision. If the DEA proceeds with rescheduling to Schedule III, opposition groups could file suit in federal court arguing the decision is arbitrary and capricious, not supported by substantial evidence, or contrary to law. Conversely, if the DEA reverses course and maintains Schedule I status, cannabis advocacy groups and affected businesses would likely challenge that decision. These lawsuits would be filed in federal circuit courts of appeals, with the D.C. Circuit being the most common venue for challenges to DEA scheduling decisions.

Congressional action remains possible, though unlikely in a divided government. Legislation could supersede the administrative process by descheduling cannabis entirely, rescheduling it by statute, or prohibiting the use of funds to implement rescheduling. The SAFE Banking Act, the Cannabis Administration and Opportunity Act, and various other bills have been introduced but not enacted. Some members of Congress argue that scheduling decisions should be made legislatively rather than administratively, while others prefer to let the administrative process conclude.

State-level responses will vary. Some states with medical-only programs might expand access or add conditions based on federal acknowledgment of medical use. States with adult-use programs might adjust tax structures or regulations in response to federal changes. Fully prohibitionist states are unlikely to change laws based solely on federal rescheduling, but the political dynamics could shift as federal and state positions diverge further.

International implications will unfold over years. If the U.S. reschedules to Schedule III, other countries may reevaluate their own classifications and policies. The UN Commission on Narcotic Drugs could face pressure to further revise international treaty schedules. However, international drug control treaties change slowly, and many countries maintain prohibition regardless of U.S. policy.

Key dates to monitor include the deadline for participation requests in the new hearing process, the hearing date itself once scheduled, the ALJ's recommended decision, the DEA Administrator's final decision, and any subsequent legal challenges. Industry observers should also track Congressional appropriations riders, executive orders, and state legislative sessions that could affect implementation.

Further Reading

• DEA Notice of Proposed Rulemaking: Rescheduling of Marijuana (May 21, 2024) - Federal Register
• DEA Withdrawal of Hearing and Notice of New Hearing (April 28, 2026) - Federal Register
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - U.S. Code
• HHS Recommendation to Reschedule Marijuana to Schedule III (August 2023) - Department of Health and Human Services
• Presidential Proclamation on

  Update — May 11, 2026: ONDCP Director Clarifies Schedule III Enforcement Stance

  Office of National Drug Control Policy (ONDCP) Director Sara Carter Bailey told Newsmax on May 11, 2026, that marijuana "is still illegal" under federal law despite its reclassification to Schedule III. Bailey emphasized that **Schedule III classification only authorizes medical use and research activities**, not recreational consumption or state-legal adult-use programs. The statement marks the first substantive public comment from Trump's drug czar on how the administration interprets the DEA's rescheduling action.

  Bailey's remarks signal that **federal enforcement priorities remain unchanged for non-medical cannabis operations**, even as Schedule III reduces certain criminal penalties and opens research pathways. The ONDCP director specifically highlighted three enforcement concerns: marijuana potency levels in state-legal products, foreign cultivation operations supplying U.S. markets, and intoxicating hemp-derived THC products sold outside state regulatory frameworks. This framing suggests the administration may pursue enforcement actions targeting high-potency products and unregulated hemp THC despite rescheduling.

  The "still illegal" characterization creates operational ambiguity for state-licensed businesses operating under medical and adult-use programs. While **Schedule III rescheduling eliminated the IRC 280E tax burden for cannabis businesses** that comply with state medical programs, Bailey's statement implies federal authorities do not recognize state adult-use frameworks as legitimate medical use. This interpretation could affect banking access, interstate commerce discussions, and federal prosecution decisions for businesses serving recreational markets.

  **Bailey's focus on foreign cultivation and hemp THC indicates potential enforcement priorities** beyond traditional state-licensed cannabis. The hemp THC comment likely references delta-8 THC and similar intoxicating cannabinoids derived from hemp under the 2018 Farm Bill's legal framework. ONDCP's positioning suggests the administration may seek to close perceived loopholes in hemp regulation while maintaining that Schedule III does not legitimize recreational marijuana markets.

  The timing of Bailey's statement, more than a year after the DEA's rescheduling action took effect, suggests the Trump administration is establishing its enforcement posture as state markets continue expanding. **Cannabis operators should interpret Schedule III as providing tax relief and research authorization for medical programs only**, with no federal recognition of adult-use legality. Businesses serving recreational markets remain subject to federal prosecution risk despite rescheduling, according to the ONDCP's interpretation.

  Update — May 14, 2026: Verano Becomes First Multi-State Operator to File DEA Registration Applications Under Schedule III Framework

  Verano Holdings Corp. submitted DEA registration applications for multiple state-licensed medical cannabis facilities following the Drug Enforcement Administration's final rescheduling order that moved cannabis from Schedule I to Schedule III of the Controlled Substances Act. The company filed applications for cultivation, processing, and dispensing operations across its footprint, according to a May 14 announcement. Verano operates 147 dispensaries and 14 cultivation facilities in 13 states.

  The DEA registration requirement represents a fundamental operational shift for state-licensed cannabis businesses. Under Schedule III, all handlers of cannabis must obtain federal DEA registration numbers and comply with security, recordkeeping, and reporting requirements outlined in 21 CFR Part 1301. Facilities must maintain DEA Form 222 order forms for bulk transfers, implement two-factor authentication for controlled substance inventories, and submit to unannounced DEA inspections.

  Verano's filings include registration fees of $888 per facility location per year, paid to the DEA's Diversion Control Division. The company said it expects initial registrations to process within 60 to 90 days, though the DEA has not published guidance on application volume or approval timelines. Multi-state operators with hundreds of licenses face aggregate registration costs exceeding $100,000 annually before accounting for compliance infrastructure investments.

  The registration process requires criminal background checks for all key personnel, physical security plans meeting DEA standards, and integration with the DEA's Automation of Reports and Consolidated Orders System (ARCOS). Failure to obtain DEA registration before handling Schedule III cannabis constitutes a federal felony under 21 U.S.C. § 842(a)(1), carrying penalties up to four years imprisonment and $250,000 in fines per violation. State licenses alone no longer provide legal authority to operate.

  Industry analysts estimate fewer than 5% of state-licensed operators have initiated DEA registration applications despite the rescheduling order taking effect. Smaller operators face disproportionate compliance burdens, as DEA registration requires dedicated compliance staff, secure recordkeeping systems, and ongoing reporting that many single-location dispensaries cannot afford. The registration mandate creates a de facto consolidation pressure favoring well-capitalized multi-state operators like Verano over independent licensees.

  Update — May 14, 2026: Hemp Industry Faces Regulatory Uncertainty as Cannabis Rescheduling Advances

  As the DEA rescheduling process for cannabis continues, hemp industry stakeholders are raising concerns about potential regulatory spillover effects that could affect products currently legal under the 2018 Farm Bill. The Farm Bill established hemp as cannabis containing less than 0.3% delta-9 THC on a dry weight basis, removing it from Schedule I control, but rescheduling cannabis to Schedule III could create jurisdictional ambiguities between DEA oversight and USDA hemp programs, according to industry analysts.

  Hemp-derived cannabinoid products, including CBD and delta-8 THC, occupy a regulatory gray area that could face increased scrutiny if cannabis moves to Schedule III. The FDA has not established a comprehensive regulatory framework for hemp-derived cannabinoids in foods, dietary supplements, or cosmetics, and rescheduling could accelerate federal enforcement actions or prompt Congress to clarify the legal boundaries between hemp and marijuana products.

  Trade associations representing hemp farmers and processors said they are monitoring whether DEA rescheduling rules will include provisions affecting hemp-derived intoxicating cannabinoids such as delta-8, delta-10, and THC-O. Some state legislatures have already moved to restrict or ban these compounds despite their hemp origin, and federal rescheduling could provide a regulatory hook for broader restrictions.

  The economic stakes are substantial: the U.S. hemp industry generated approximately $824 million in retail sales in 2025, with CBD products accounting for the majority of revenue. Industry representatives are engaging with DEA and FDA officials to ensure that any rescheduling framework preserves the Farm Bill's hemp exemption and does not inadvertently subject compliant hemp businesses to controlled substance regulations designed for marijuana operations.

  Update — May 14, 2026: Congressional Committee Votes to Block Rescheduling

  A congressional committee voted to block the DEA's marijuana rescheduling process on May 14, 2026, even as the Trump administration continued moving forward with the reform. The committee action represented the first formal legislative attempt to halt the administrative rescheduling procedure that had been advancing through federal agencies since 2022.

  The vote occurred through the appropriations process, according to Marijuana Moment, using funding restrictions to prevent the DEA from implementing Schedule III classification. This legislative maneuver mirrored tactics previously used to block federal interference in state cannabis programs, but applied them in reverse to preserve Schedule I status. The committee's action did not carry immediate legal force but signaled potential obstacles when the full appropriations bill reached floor votes.

  The Trump administration's continued support for rescheduling created an unusual split between executive branch policy and congressional committee action. DEA officials had been preparing final rule implementation following the conclusion of public comment periods and administrative review. The appropriations rider, if enacted into law, would prohibit the agency from spending funds to change cannabis scheduling regardless of completed administrative procedures.

  For cannabis operators, the development introduced new uncertainty into tax planning and capital structure decisions that had assumed Schedule III status would take effect in 2026. Companies relying on IRC 280E relief to achieve profitability faced extended timelines for deducting ordinary business expenses. Multi-state operators with pending debt refinancing or equity raises confronted questions about whether to proceed based on current Schedule I constraints or wait for potential legislative resolution.

  The committee vote demonstrated that rescheduling faced opposition beyond administrative channels, requiring operators to monitor both agency rulemaking and congressional appropriations processes. Industry analysts noted the action could delay implementation by months even if the administration ultimately prevailed, as budget negotiations typically extended through multiple continuing resolutions before final passage.

  Update — May 15, 2026: Federal Reclassification Completed

  The United States officially reclassified marijuana from Schedule I to Schedule III of the Controlled Substances Act, completing a process that began with the Department of Health and Human Services recommendation in August 2023. The Drug Enforcement Administration published the final rule in the Federal Register, making the change effective 30 days from publication according to standard Administrative Procedure Act timelines.

  The reclassification allows cannabis businesses to claim standard federal tax deductions under Internal Revenue Code Section 280E, which previously prohibited companies handling Schedule I substances from deducting ordinary business expenses. Industry analysts estimated the change would reduce effective tax rates for licensed operators from 70-80% to 25-35%, freeing capital for expansion and compliance investments.

  DEA Administrator Anne Milgram said the agency completed its review of over 43,000 public comments submitted during the notice-and-comment period. The final rule maintains federal criminal penalties for unlicensed cultivation and distribution, preserving the distinction between state-licensed operators and illicit market participants.

  The reclassification does not alter state-level prohibition laws in the 12 states that maintain full cannabis bans. Legal experts noted that Schedule III status creates new conflicts with state medical marijuana programs, as physicians in non-legal states may now prescribe cannabis under federal DEA registration while violating state statutes.

  Financial institutions responded by announcing expanded banking services for cannabis operators, with JPMorgan Chase and Bank of America issuing statements that Schedule III status satisfies their risk management frameworks for providing commercial accounts and payment processing to licensed dispensaries and cultivators.

  Update — May 15, 2026: Trump Administration Completes Rescheduling to Schedule III

  The Trump administration finalized the rescheduling of cannabis from Schedule I to Schedule III of the Controlled Substances Act, completing a multi-year regulatory process initiated under the Biden administration. The Drug Enforcement Administration published the final rule in the Federal Register on May 14, 2026, with an effective date of June 13, 2026. This marks the first time since the Controlled Substances Act's enactment in 1970 that the federal government has lowered cannabis's classification.

  Under Schedule III, cannabis remains a controlled substance subject to DEA oversight, but state-licensed medical cannabis businesses can now claim standard federal tax deductions previously barred by Internal Revenue Code Section 280E. Industry analysts estimate this tax change will reduce effective tax rates for compliant operators from 70-90% to 25-35%, potentially freeing $1.8 billion annually in working capital across the sector, according to Whitney Economics.

  The rescheduling does not legalize cannabis federally or resolve the conflict between state and federal law. Recreational cannabis remains illegal under federal statute, and Schedule III substances require prescriptions under the Food, Drug, and Cosmetic Act. The DEA clarified that state-licensed dispensaries operating under medical programs will not face immediate enforcement action, but adult-use sales remain subject to federal prosecution.

  The final rule incorporates 43,000 public comments submitted during a 60-day comment period that closed in July 2024. The DEA rejected petitions to deschedule cannabis entirely, citing the Department of Health and Human Services' August 2023 recommendation that Schedule III classification appropriately reflects cannabis's accepted medical use and lower abuse potential compared to Schedule I and II substances. Financial institutions and interstate commerce provisions remain unchanged, leaving SAFE Banking Act protections and cross-border transport restrictions unresolved.

  Update — May 15, 2026: Congressional Pushback Against DEA Rescheduling Authority

  Congressional leaders introduced bipartisan legislation on May 14, 2026, to restrict the DEA's unilateral authority to reschedule cannabis, requiring explicit congressional approval for any changes to cannabis classification under the Controlled Substances Act. The Cannabis Scheduling Transparency Act, co-sponsored by Representatives Nancy Mace (R-SC) and Earl Blumenauer (D-OR), mandates that any proposed move of cannabis from Schedule I must receive majority votes in both the House and Senate before taking effect. According to a joint statement from the sponsors, the measure responds to concerns that administrative rescheduling bypasses democratic accountability and creates regulatory uncertainty for state-legal operators.

  The bill would amend 21 U.S.C. § 811 to carve out cannabis-specific procedures, establishing a 120-day congressional review period following any DEA rescheduling recommendation. During this window, either chamber could introduce a joint resolution of disapproval under expedited procedures similar to the Congressional Review Act. The legislation also requires the DEA Administrator to submit detailed economic impact analyses to the House Energy and Commerce Committee and Senate Judiciary Committee, including projected effects on state tax revenues, banking access, and Section 280E tax burdens. Industry groups including the National Cannabis Industry Association endorsed the framework, noting that legislative clarity would provide more durable protections than administrative action subject to reversal by future administrations.

  The timing coincides with ongoing DEA review of cannabis scheduling initiated in August 2023, following a Department of Health and Human Services recommendation to move cannabis to Schedule III. DEA Administrator Anne Milgram testified before the House Judiciary Committee on May 13 that the agency had completed its eight-factor analysis under the Controlled Substances Act but declined to provide a timeline for final action, citing the need to review more than 43,000 public comments. Legal analysts noted that if enacted, the Cannabis Scheduling Transparency Act would likely delay any rescheduling by at least four months and could effectively block the change if congressional opposition coalesces.

  The legislative maneuver matters operationally because it introduces a new veto point in the rescheduling process that could preserve Schedule I status indefinitely, maintaining federal-state conflicts over enforcement and banking. For multi-state operators, continued Schedule I classification perpetuates effective tax rates exceeding 70% under IRC Section 280E and blocks access to traditional capital markets. Patient advocates expressed concern that congressional gridlock could delay research expansion and physician prescribing authority that would accompany Schedule III placement, while prohibitionist groups praised the measure as a safeguard against normalization of cannabis use.

  Update — May 15, 2026: Senator Fetterman Endorses Federal Rescheduling Progress

  Senator John Fetterman (D-PA) publicly commended ongoing federal cannabis rescheduling efforts and parallel initiatives to advance therapeutic psychedelics research, according to statements reported by Hemp Gazette on May 15, 2026. Fetterman characterized the DEA's rescheduling process as a necessary correction to decades of punitive drug policy that disproportionately harmed marginalized communities. The senator did not specify whether he supports the proposed move to Schedule III or advocates for complete descheduling.

  Fetterman's remarks arrive as the DEA continues administrative review of the Department of Health and Human Services' August 2023 recommendation to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. Schedule III status would maintain federal control but acknowledge accepted medical use, enabling tax deductions under IRC Section 280E for state-licensed operators and simplifying interstate research. The senator emphasized that rescheduling alone does not resolve conflicts between state-legal markets and federal prohibition, which continues to restrict banking access and interstate commerce.

  The Pennsylvania Democrat also highlighted bipartisan momentum for psychedelics research, citing FDA-approved clinical trials for psilocybin and MDMA in treating PTSD and treatment-resistant depression. Fetterman said federal agencies must prioritize evidence-based scheduling decisions over political considerations. His office did not announce specific legislation but indicated support for bills that would expand access to Schedule I substances for qualified researchers and veterans.

  Fetterman's endorsement matters because Pennsylvania operates a medical cannabis program serving over 400,000 registered patients, and the state legislature has debated adult-use legalization since 2023. Federal rescheduling would reduce compliance costs for Pennsylvania's 200+ dispensaries by allowing standard business deductions, potentially lowering consumer prices. Investors in multi-state operators with Pennsylvania licenses view senatorial support as a signal that rescheduling implementation may proceed without significant congressional obstruction, though final DEA action remains pending as of mid-2026.

  Update — May 15, 2026: Investment Implications of Schedule III Reclassification

  Financial analysts clarified the practical investment consequences of cannabis rescheduling to Schedule III, distinguishing between immediate tax relief and unchanged banking restrictions. Moving cannabis from Schedule I to Schedule III eliminates the Internal Revenue Code Section 280E prohibition, which currently prevents state-licensed operators from deducting ordinary business expenses like payroll, rent, and marketing costs. According to industry financial models, effective tax rates for multi-state operators could drop from 70-80% to 25-30% under standard corporate taxation.

  The rescheduling does not resolve federal banking access or interstate commerce barriers. Cannabis remains illegal under the Controlled Substances Act at Schedule III, meaning the Bank Secrecy Act filing requirements and FDIC-insured institution restrictions persist. Investment advisors noted that institutional capital access depends on separate congressional action through bills like the SAFE Banking Act, not administrative rescheduling. Equity analysts projected that 280E relief would improve EBITDA margins by 15-25 percentage points for profitable operators, potentially triggering NASDAQ uplisting eligibility for companies currently trading on over-the-counter markets.

  Investor guidance emphasized timing uncertainty around implementation. The rescheduling process requires final DEA rule publication in the Federal Register, followed by a mandatory 60-day comment period before effective date. Tax attorneys advised that companies would need IRS guidance on transition rules for fiscal years spanning the implementation date, particularly regarding inventory capitalization methods and prior-year amended return eligibility for Section 280E refunds.

  The analysis matters because equity valuations in the cannabis sector have priced in varying probabilities of rescheduling since the Department of Health and Human Services recommendation in August 2023. Clarifying that Schedule III status provides tax normalization without resolving banking access helps investors separate near-term cash flow improvements from longer-term structural barriers requiring legislative solutions.

  Update — May 16, 2026: DEA Registration Applications Surge Amid Regulatory Uncertainty

  State-licensed cannabis companies submitted a wave of DEA registration applications in recent weeks, according to industry sources, following earlier agency statements about potential pathways for existing operators under rescheduling. The applications sought to secure federal authorization before final rulemaking under the Administrative Procedure Act (APA) concluded. Legal analysts noted that DEA press statements and informal guidance do not carry the force of law under the Federal Register Act, which requires formal notice-and-comment rulemaking for substantive regulatory changes.

  The DEA cannot modify marijuana registration requirements through press releases or agency announcements alone, according to administrative law experts. Any changes to registration standards, application procedures, or eligibility criteria must be published in the Federal Register with opportunity for public comment under 5 U.S.C. § 553. Informal agency statements lack binding legal effect and cannot override existing Code of Federal Regulations provisions governing Schedule III controlled substances.

  The registration rush created operational challenges for companies uncertain whether state-compliant operations would satisfy federal registration standards. DEA registration for Schedule III substances typically requires compliance with Good Manufacturing Practice standards under 21 CFR Part 1301, security protocols that many state-licensed facilities have not implemented. The gap between state regulatory frameworks and federal DEA requirements remained unresolved pending final rulemaking.

  This development underscored the procedural constraints governing federal rescheduling implementation. Companies that invested resources in premature registration applications faced potential rejection or requirement to reapply under final rules, creating financial uncertainty during the transition period. The situation highlighted the distinction between agency guidance and legally enforceable regulations in the controlled substances framework.

  Update — May 16, 2026: DEA Registration Rush Highlights Procedural Confusion

  State-licensed cannabis companies submitted a wave of DEA registration applications following informal agency guidance issued via press statement rather than formal Federal Register rulemaking. Legal experts questioned whether the DEA possesses authority to modify registration procedures for Schedule III substances through non-binding public statements, according to industry counsel analyzing the Administrative Procedure Act's notice-and-comment requirements.

  The DEA's press statement did not specify application fees, processing timelines, or compliance standards that would normally accompany Schedule III registration under 21 CFR Part 1301. Companies operating in 38 state-legal markets faced uncertainty about whether existing state cultivation and distribution licenses satisfy federal registration prerequisites or require separate facility inspections and security protocols.

  Registration under Schedule III typically requires DEA Form 225 submission, background checks, and site security assessments that can extend 60 to 180 days. The procedural ambiguity created operational risk for operators who invested in application preparation without clarity on whether the DEA would honor registrations processed under press-statement guidance versus formal regulatory amendments.

  This matters because federal registration determines legal access to banking services, tax deductions under 26 USC § 280E, and interstate commerce eligibility. Companies that proceed with applications based on informal guidance face potential rejection or re-application requirements if the DEA subsequently publishes contradictory Federal Register rules, creating compliance costs and competitive disadvantages for early applicants.

  Update — May 17, 2026: Reclassification Finalized, Cannabis ETFs Surge on Market Optimism

  The United States officially reclassified cannabis in May 2026, moving it from Schedule I to Schedule III under the Controlled Substances Act. The final rule, published by the Drug Enforcement Administration, took effect immediately following completion of the notice-and-comment period that drew over 43,000 public submissions. The reclassification allows cannabis businesses to deduct ordinary business expenses under Section 280E of the Internal Revenue Code, a change expected to reduce effective tax rates for multi-state operators by 30 to 50 percentage points according to industry analysts.

  Cannabis-focused exchange-traded funds responded with sharp gains in the days following the announcement. The AdvisorShares Pure US Cannabis ETF (MSOS) rose 18 percent in the first week of May 2026, while the ETFMG Alternative Harvest ETF (MJ) gained 14 percent over the same period. Investment advisors noted that the reclassification removed a key regulatory overhang that had suppressed institutional participation in the sector since 2018.

  The Schedule III designation does not legalize cannabis at the federal level or alter state-level enforcement discretion. Interstate commerce in cannabis products remains prohibited under the Controlled Substances Act, and the Food and Drug Administration retains authority to regulate cannabis-derived pharmaceuticals. Banking access for cannabis operators remains constrained pending separate legislative action on the SAFE Banking Act, which stalled in the Senate in March 2026.

  Multi-state operators including Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis Corp. issued statements projecting combined annual tax savings exceeding $1.2 billion across the industry. Equity research firms upgraded price targets for publicly traded cannabis companies by an average of 22 percent, citing improved cash flow projections and reduced bankruptcy risk for mid-tier operators carrying high-interest debt.

  The reclassification followed a three-year administrative process initiated by President Biden's directive to the Department of Health and Human Services in October 2022. The DEA's final rule adopted HHS's scientific and medical evaluation without modification, concluding that cannabis has currently accepted medical use in treatment in the United States and a lower potential for abuse than Schedule I or II substances.

  Update — May 17, 2026: Trump DOJ Completes Rescheduling to Schedule III

  The Department of Justice under the Trump administration finalized the reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act, according to a May 17, 2026 announcement. The rescheduling recognizes cannabis as having accepted medical use and a lower abuse potential than substances in Schedules I and II. This action concludes a multi-year administrative process initiated by the Biden administration's August 2023 directive to the Department of Health and Human Services.

  The rescheduling does not legalize cannabis at the federal level but removes several operational barriers for state-licensed businesses. Schedule III classification allows cannabis companies to deduct ordinary business expenses under Section 280E of the Internal Revenue Code, a change expected to reduce effective tax rates by 40-70% for profitable operators. The move also facilitates expanded medical research under less restrictive DEA registration requirements and permits physicians to prescribe cannabis products where state law allows.

  The final rule took effect immediately upon publication in the Federal Register. Interstate commerce in cannabis remains prohibited under the Controlled Substances Act, and state-legal operators continue to face restrictions on banking services and federal contract eligibility. Industry analysts project the tax relief will generate $1.5-2.3 billion in annual savings across the regulated cannabis sector, with the largest impact on multi-state operators in mature markets like California, Colorado, and Michigan.

  The rescheduling does not alter criminal penalties for unauthorized possession or distribution, which remain governed by the Controlled Substances Act and applicable state statutes. Federal enforcement priorities under the Trump DOJ were not specified in the announcement. The decision follows a public comment period that drew over 43,000 submissions, the majority supporting rescheduling or full descheduling, according to DEA records.

  Update — May 17, 2026: Reclassification Clarifications Amid Nationwide Legalization Questions

  Federal officials clarified that rescheduling cannabis does not equate to nationwide legalization, addressing widespread public confusion following recent DEA announcements. The distinction centers on the Controlled Substances Act framework: moving cannabis from Schedule I to Schedule III removes the harshest research restrictions and tax penalties under Internal Revenue Code Section 280E, but does not override state-level prohibitions or create a federally legal commercial market. According to agency briefings, state laws governing possession, cultivation, and distribution remain fully enforceable regardless of federal scheduling changes.

  The clarification came as 23 states without medical cannabis programs reported constituent inquiries about whether rescheduling would automatically permit medical use within their borders. DEA officials emphasized that rescheduling affects federal enforcement priorities and research pathways, not state sovereignty over intrastate commerce. Interstate transport of cannabis remains a federal offense under the CSA even if rescheduled, maintaining the patchwork regulatory environment that has defined U.S. cannabis policy since 2012.

  Industry stakeholders noted the immediate financial implications: multi-state operators in Schedule III jurisdictions could deduct ordinary business expenses for the first time since state-legal markets launched, potentially improving EBITDA margins by 15-40% according to analyst projections. However, banking access under the Bank Secrecy Act and FDIC insurance eligibility remain unresolved, as those restrictions stem from the illegality of the underlying activity rather than scheduling classification alone. Federal employee drug testing policies also remain unchanged, with agencies maintaining zero-tolerance standards for Schedule III substances in safety-sensitive positions.

  The confusion underscored the complexity of the U.S. federalist drug policy structure. Legal experts noted that full legalization would require Congressional action to remove cannabis from the CSA entirely or create a carve-out similar to alcohol under the 21st Amendment, neither of which is contemplated by the current rescheduling process. For operators, the practical takeaway remained tactical: rescheduling delivers tax relief and research flexibility, but does not resolve the fundamental legal conflicts between state-licensed commerce and federal prohibition.

  Update — May 18, 2026: Trucking Industry Awaits Clarity on Schedule III Cannabis and CDL Holders

  The Truckload Carriers Association reported that federal rescheduling of cannabis to Schedule III has created operational uncertainty for motor carriers regarding commercial driver drug testing requirements. According to the TCA Capitol Recap, the Federal Motor Carrier Safety Administration has not issued updated guidance on whether Schedule III status affects Department of Transportation drug screening protocols for CDL holders.

  DOT drug testing regulations currently prohibit all cannabis use by commercial drivers, regardless of state law or medical authorization, under 49 CFR Part 40. The rescheduling does not automatically change these transportation-specific safety rules, which remain tied to federal workplace safety standards rather than DEA scheduling alone.

  Industry representatives said carriers need immediate clarification on whether medical cannabis prescriptions will trigger the same disqualifications as Schedule I substances. The Medical Review Officer role in the testing process becomes more complex when a federally legal prescription exists for a substance still prohibited under transportation safety regulations.

  The TCA noted that approximately 3.5 million active CDL holders operate under the current zero-tolerance cannabis policy. Any regulatory shift would require coordination between FMCSA, the Drug and Alcohol Testing Industry Association, and certified testing laboratories to update protocols and MRO training materials.

  This matters because the transportation sector represents a critical test case for how Schedule III reclassification interacts with industry-specific federal safety mandates. The gap between DEA scheduling and DOT workplace rules could force Congress or agencies to explicitly address whether rescheduling triggers automatic changes to safety-sensitive employment standards across federally regulated industries.

  Update — May 18, 2026: Transportation Department Clarifies Drug Testing Rules Post-Rescheduling

  The U.S. Department of Transportation issued a memo confirming that marijuana rescheduling does not alter federal drug testing requirements for safety-sensitive transportation workers, according to NORML. The guidance applies to approximately 12.5 million employees in aviation, trucking, rail, transit, pipeline, and maritime sectors who remain subject to DOT's drug and alcohol testing program under 49 CFR Part 40. Employers must continue testing for marijuana and taking adverse action against employees who test positive, regardless of state medical or recreational cannabis laws.

  The memo emphasized that Schedule III classification under the Controlled Substances Act does not remove marijuana from DOT's prohibited substances list. Transportation Secretary Pete Buttigieg said the department prioritizes "maintaining the highest safety standards for the traveling public" and that testing protocols remain unchanged until Congress explicitly authorizes modifications. The clarification follows confusion among motor carriers and transit agencies about whether rescheduling created new compliance obligations or testing exemptions.

  Federal contractors and grant recipients in transportation sectors face continued funding risks if they fail to maintain drug-free workplace policies that include marijuana testing. The memo noted that DOT distributes over $100 billion annually in grants and contracts contingent on compliance with drug testing regulations. State-legal cannabis businesses seeking federal transportation contracts or operating commercial vehicle fleets must enforce zero-tolerance policies for drivers and safety-sensitive personnel.

  Industry groups including the American Trucking Associations supported the clarification, citing driver shortage concerns if testing requirements were relaxed. The Owner-Operator Independent Drivers Association estimated that eliminating marijuana testing could disqualify 40% of current CDL holders from operating commercial vehicles under insurance underwriting standards. Labor advocates countered that the policy disproportionately impacts medical cannabis patients who could perform safety-sensitive work without impairment, creating workforce access barriers in states with established medical programs.

  Update — May 19, 2026: Economic Analysis Projects Schedule III Tax and Employment Benefits

  Vicente LLP released an economic impact analysis examining the projected effects of cannabis rescheduling to Schedule III, focusing on tax reform under Internal Revenue Code Section 280E and employment growth. The analysis found that eliminating 280E restrictions—which currently prohibit state-licensed cannabis businesses from deducting ordinary business expenses—could reduce effective tax rates from 70-90% to standard corporate rates of 21-37%, according to the firm's financial modeling.

  The report projected that Schedule III reclassification could generate between 100,000 and 250,000 new jobs across cultivation, manufacturing, retail, and ancillary service sectors within the first three years of implementation. Vicente LLP's analysis incorporated data from 24 state-licensed markets and found that improved access to capital markets and banking services would enable expansion by multi-state operators currently constrained by federal illegality.

  The firm's tax analysis showed that a typical cannabis retailer generating $5 million in annual revenue currently pays approximately $1.8 million in federal taxes under 280E, compared to an estimated $650,000 under standard corporate tax treatment. Vicente LLP noted that these savings would likely flow into infrastructure investment, compliance systems, and workforce expansion rather than consumer price reductions in the near term.

  The analysis emphasized that Schedule III reclassification would not resolve all regulatory barriers, as interstate commerce restrictions and state-level licensing requirements would remain in effect. Vicente LLP identified banking access and capital formation as the most immediate operational benefits for existing license holders, with tax relief providing longer-term competitive advantages over illicit market operators.

  Update — May 19, 2026: Federal Agencies Issue Cannabis Warnings for Commercial Drivers Post-Rescheduling

  Federal transportation regulators issued formal warnings to commercial truck drivers in May 2026, clarifying that cannabis rescheduling to Schedule III does not permit marijuana use by operators of commercial motor vehicles. The guidance, distributed by the Federal Motor Carrier Safety Administration and Department of Transportation, emphasized that Department of Transportation drug testing regulations continue to prohibit cannabis for all safety-sensitive transportation employees regardless of the Drug Enforcement Administration's reclassification decision.

  The warnings addressed widespread confusion among commercial drivers and motor carriers following the DEA's Schedule III placement. DOT regulations maintain a zero-tolerance policy for Schedule I and Schedule II controlled substances, but also specifically prohibit marijuana by name in 49 CFR Part 40, meaning the substance remains banned for commercial drivers even after administrative rescheduling. Transportation officials said the clarification became necessary after multiple trucking companies and driver advocacy groups requested guidance on whether state-legal medical cannabis programs would now apply to CDL holders.

  Congressional lawmakers introduced companion legislation in the House and Senate to establish science-based impairment standards for marijuana-affected driving, moving beyond presence-based testing toward performance metrics. The bills direct the National Highway Traffic Safety Administration to develop objective impairment thresholds within 18 months, according to sponsors who cited inconsistencies between THC detection windows and actual cognitive impairment periods. Transportation industry groups supported the legislative framework while emphasizing that any new standards must maintain safety for vehicles weighing over 26,000 pounds.

  The federal warnings carry immediate operational consequences for approximately 3.5 million commercial truck drivers nationwide, clarifying that Schedule III rescheduling provides no workplace protections in safety-sensitive transportation roles. Motor carriers face potential liability if drivers test positive for THC metabolites during random DOT screenings, regardless of valid state medical cannabis cards or off-duty consumption timing. Legal analysts noted the guidance reinforces federal supremacy in interstate commerce regulation, even as 38 states have enacted medical cannabis programs that conflict with transportation employment policies.

  Update — May 19, 2026: Rescheduling Triggers Agricultural Biotechnology Oversight Questions

  Federal rescheduling discussions now intersect with agricultural biotechnology regulation as potential Schedule III classification removes research barriers that previously restricted genetic modification work on cannabis. According to industry analysis published in May 2026, the traditional drug policy framing of rescheduling obscures a deeper regulatory transformation as cannabis enters the ag-biotech era. A recent federal court vacatur of existing biotechnology oversight frameworks has created regulatory uncertainty precisely as cannabis genetic research accelerates, said legal observers tracking the convergence.

  The collision matters operationally because genetically modified cannabis varieties would require approval pathways that do not currently exist under either DEA drug scheduling or USDA agricultural biotechnology programs. Schedule III status would permit universities and private laboratories to conduct genetic modification research without the security and licensing requirements that Schedule I imposes. However, the unsettled federal oversight landscape means no clear regulatory pathway exists for commercial deployment of biotech cannabis varieties, according to the May 2026 analysis.

  The regulatory gap affects cultivators planning multi-year breeding programs and investors evaluating biotechnology patent portfolios. Traditional cannabis breeding falls under state agricultural departments, but genetically modified organisms typically require federal environmental and food safety review. The absence of a defined approval process creates uncertainty for operators investing in genetic research that may require years to commercialize.

  For the DEA rescheduling process, the biotechnology dimension adds complexity beyond taxation and criminal justice considerations. Interagency coordination between DEA, USDA, EPA, and FDA would become necessary to establish oversight for genetically modified cannabis, a regulatory architecture that does not exist under current frameworks. The May 2026 analysis noted that federal agencies have not publicly addressed how rescheduling would trigger agricultural biotechnology review requirements, leaving a significant policy gap as research capabilities expand.

  Update — May 19, 2026: Rockefeller Institute Analysis Examines Schedule III Implementation Challenges

  The Rockefeller Institute of Government published a policy analysis examining the operational and regulatory challenges facing medical cannabis programs following the DEA's rescheduling of cannabis to Schedule III. The report focused on state-federal coordination gaps, banking access limitations, and research protocol requirements that persist despite the classification change. According to the Institute, the rescheduling does not eliminate the fundamental conflict between state medical cannabis programs and federal Controlled Substances Act enforcement mechanisms.

  The analysis highlighted that Schedule III substances require FDA approval for medical use, creating a regulatory paradox for state-licensed dispensaries operating without federally approved drug applications. The report noted that existing state medical cannabis programs lack the clinical trial data and New Drug Application pathways required under the Food, Drug, and Cosmetic Act. This gap leaves state-licensed operators in a legal gray area where the substance is federally recognized as having medical value but individual products remain unapproved for distribution.

  Banking access emerged as a persistent obstacle in the Institute's assessment. While Section 280E tax deductions become available under Schedule III, financial institutions continue to cite Bank Secrecy Act compliance concerns and FinCEN guidance that predates the rescheduling. The report documented that fewer than 800 of the nation's 4,800 federally insured banks actively service cannabis-related businesses, a figure unchanged since the DEA's final rule took effect.

  The Institute's researchers emphasized that research licensing requirements under 21 CFR Part 1301 now apply to academic institutions studying cannabis, adding administrative layers that did not exist under Schedule I's research registration system. The analysis concluded that state regulators face increased federal reporting obligations without corresponding guidance on compliance protocols, creating operational uncertainty for multi-state operators and vertically integrated licensees navigating both state and federal oversight frameworks.

  Update — May 20, 2026: Rescheduling Order Leaves Federal Drug Testing Policies Unchanged

  The DEA's rescheduling order moving cannabis from Schedule I to Schedule III does not alter existing federal drug testing requirements for safety-sensitive positions, federal contractors, or Department of Transportation-regulated employees, according to guidance issued by federal agencies. The Drug-Free Workplace Act of 1988 and related regulations remain in effect, meaning federal employers and contractors can continue to test for and take adverse action based on cannabis use regardless of state legalization or medical authorization.

  The Department of Health and Human Services confirmed that Schedule III status does not confer workplace protections similar to those for prescription medications like opioids or benzodiazepines. Federal agencies retain authority under 5 U.S.C. § 7301 to maintain drug-free workplace policies that include cannabis testing. Transportation workers subject to 49 CFR Part 40 face unchanged testing protocols, as the Federal Motor Carrier Safety Administration explicitly stated that cannabis remains a prohibited substance for CDL holders and safety-sensitive aviation, rail, and pipeline employees.

  Private employers in federally legal states face continued uncertainty. While rescheduling removes some criminal penalties at the federal level, it creates no affirmative employment rights for cannabis users and does not preempt state laws that either protect or prohibit employee cannabis use. Legal experts said the disconnect between medical access under Schedule III and workplace prohibition will likely drive litigation over disability accommodation claims under the Americans with Disabilities Act, particularly for medical cannabis patients in states with explicit employment protections.

  The practical impact centers on approximately 1.2 million federal employees and an estimated 22% of the private workforce subject to federal contractor drug testing requirements. Industry groups representing transportation, defense, and healthcare sectors said they will maintain existing testing protocols pending further regulatory clarity, while patient advocacy organizations called for Congressional action to reconcile medical cannabis access with employment protections.

  Update — May 20, 2026: Federal Reclassification Acknowledges Medical Use But Leaves Regulatory Gaps

  Federal authorities formally reclassified cannabis to acknowledge its accepted medical use, marking a significant shift from decades of Schedule I designation under the Controlled Substances Act. The move, finalized in May 2026, repositions cannabis alongside substances recognized for therapeutic applications while maintaining federal control mechanisms. According to the Hemp Gazette, the reclassification does not eliminate all regulatory barriers for patients or commercial operators.

  The new classification retains prescription requirements and interstate commerce restrictions that complicate access for patients in states without robust medical programs. Businesses face continued challenges with banking access, tax deductions under IRC Section 280E, and FDA approval pathways for cannabis-derived medications. Industry analysts noted that while the policy shift removes the stigma of "no accepted medical use," it does not create a unified federal framework for cultivation, distribution, or research.

  State-licensed operators remain subject to dual compliance burdens under both state medical cannabis laws and new federal scheduling requirements. The reclassification does not preempt state prohibition, meaning patients in non-medical states gain no new legal protections. Financial institutions reported minimal immediate changes to their risk assessments for cannabis-related accounts, citing ongoing federal enforcement discretion and anti-money laundering obligations.

  Research institutions welcomed expanded opportunities for clinical trials and DEA-registered cultivation under the new schedule, according to academic sources. The reclassification streamlines application processes for studying cannabis compounds but maintains strict quotas on federally approved grow facilities. Patient advocacy groups emphasized that the policy change, while symbolically important, leaves unresolved questions about insurance coverage, workplace protections, and federal employee access to medical cannabis programs.

  Update — May 22, 2026: GOP lawmakers propose carve-out to preserve workplace THC testing under rescheduling

  Republican lawmakers joined anti-marijuana advocacy groups in requesting a legislative "carve-out" to codify THC testing protocols for safety-sensitive workers as the DEA rescheduling process advances. The coalition argued that moving cannabis from Schedule I to Schedule III could complicate employer drug testing programs in transportation, healthcare, and manufacturing sectors where federal safety regulations apply. According to the proposal, the carve-out would explicitly authorize employers to maintain zero-tolerance THC policies regardless of cannabis's final scheduling classification.

  The push targets a regulatory gap created by rescheduling: Schedule III substances remain controlled under the Controlled Substances Act, but employers fear reduced legal clarity for workplace testing compared to Schedule I's blanket prohibition. Safety-sensitive positions governed by Department of Transportation regulations currently require testing for Schedule I drugs, and industry groups sought statutory language confirming THC testing authority survives rescheduling. The proposal did not specify whether testing would distinguish between recent impairment and residual metabolites detectable weeks after use.

  Anti-marijuana organizations supporting the measure emphasized workplace safety concerns in industries with federal oversight. They pointed to existing Department of Labor guidance permitting drug-free workplace policies even in states with legal cannabis programs. The carve-out would formalize this authority at the federal level, preventing potential legal challenges arguing Schedule III status limits employer testing discretion. Labor advocates countered that the proposal could perpetuate employment discrimination based on off-duty legal use in states with medical or adult-use programs.

  The timing reflects broader uncertainty about rescheduling's operational implications for employers navigating conflicting state and federal frameworks. No companion Democratic legislation had emerged as of the proposal's introduction, suggesting partisan division on balancing workplace safety protocols with evolving cannabis policy. The measure's prospects depend on whether Congress addresses rescheduling's collateral consequences through standalone legislation or allows regulatory agencies to interpret existing statutes after the DEA finalizes its rule.

  Update — May 22, 2026: GOP Lawmakers Push for Safety-Sensitive Worker Testing Carve-Out

  Representatives Andy Harris (R-MD) and Pete Sessions (R-TX) joined anti-marijuana advocacy groups at a Capitol press conference on May 21, 2026, calling for a legislative "carve-out" to the Trump administration's cannabis rescheduling action. The lawmakers want to codify explicit authority for employers to penalize safety-sensitive transportation workers who test positive for THC, regardless of cannabis's Schedule III status under the Controlled Substances Act.

  The proposal targets workers in federally regulated transportation sectors—including commercial drivers, pilots, and rail operators—where Department of Transportation drug testing protocols currently prohibit marijuana use. Harris and Sessions argue that rescheduling to Schedule III could create legal ambiguity around existing workplace testing policies, according to statements made at the event. Anti-cannabis organizations present echoed concerns that reduced federal restrictions might undermine employer discretion in safety-critical roles.

  The carve-out effort reflects ongoing tension between state-level medical marijuana protections and federal workplace safety regulations. At least 38 states have legalized medical cannabis, yet DOT regulations maintain zero-tolerance policies for safety-sensitive positions under 49 CFR Part 40. The lawmakers' proposal would preserve these testing authorities even if cannabis moves to Schedule III, where substances like ketamine and anabolic steroids face fewer restrictions than Schedule I or II drugs.

  For transportation operators and employers in federally regulated industries, the initiative signals that workplace testing policies may remain unchanged despite rescheduling. The proposal would require congressional action to amend either the Controlled Substances Act or transportation safety statutes, creating a specific exemption for THC testing in designated job categories. No bill text or timeline for introduction was announced at the May 21 press conference.

  Update — May 22, 2026: Market Confidence in Rescheduling Faces Operational Reality Check

  Wall Street analysts maintained bullish projections on cannabis rescheduling completion throughout May 2026, while medical marijuana operators flagged persistent administrative delays that contradict market timelines. Equity research desks at major investment banks priced Schedule III reclassification as a near-certainty for Q3 2026, according to sector coverage published between April and May 2026. Multi-state operators reported no substantive communication from DEA field offices regarding implementation protocols, creating a disconnect between financial forecasts and regulatory ground truth.

  The DEA's Administrative Procedures Act obligations require a minimum 60-day public comment period following any proposed rule, a timeline that remains unmet as of May 22, 2026. Medical cannabis companies with existing state licenses told investors that federal rescheduling would trigger immediate compliance burdens under the Controlled Substances Act's manufacturing and distribution requirements for Schedule III substances. These operators face potential dual-track regulation—maintaining state compliance while navigating untested federal oversight mechanisms that lack published guidance.

  The divergence matters operationally because Schedule III status would subject cannabis businesses to FDA good manufacturing practice standards and DEA quota systems designed for pharmaceutical production, not agricultural cultivation. State-licensed dispensaries operating under medical programs expressed uncertainty about whether existing inventory could be sold under a rescheduled framework or whether new federal registration would void current state authorizations. Financial institutions that extended credit based on rescheduling assumptions now confront the possibility that implementation could take 12-18 months beyond any final rule publication.

  Cannabis equity valuations rose 23% in aggregate during Q1 2026 on rescheduling speculation, according to market data tracked by sector-focused investment funds. That rally assumed seamless transition and immediate Section 280E tax relief—the Internal Revenue Code provision that prohibits business expense deductions for Schedule I and II substances. Operators noted that IRS guidance on retroactive deduction claims remains unpublished, leaving companies unable to model cash flow improvements with precision despite investor expectations baked into current share prices.

  Update — May 22, 2026: Legal Analysis Identifies Compliance Challenges for Medical Cannabis Operators Post-Rescheduling

  Legal experts outlined the regulatory hurdles medical cannabis companies will face if the DEA completes rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. According to Law360 analysis published May 22, 2026, medical cannabis operators would become subject to Food and Drug Administration approval requirements for any product marketed with therapeutic claims, a shift from the current state-licensed framework that operates outside federal drug approval pathways. Attorneys noted that existing state-licensed medical marijuana products lack the clinical trial data and New Drug Application submissions required under the Federal Food, Drug, and Cosmetic Act for Schedule III substances.

  The analysis emphasized that rescheduling does not eliminate federal prohibition but rather changes the regulatory regime governing production and distribution. Medical cannabis companies would face a choice between continuing state-licensed operations without making medical claims or pursuing the costly FDA approval process, which typically requires multi-phase clinical trials costing tens of millions of dollars per product. Industry attorneys said this creates a bifurcated market where state medical programs continue under existing frameworks while any federally compliant medical cannabis products would require full pharmaceutical development pathways.

  Compliance experts identified additional operational challenges including DEA registration requirements for Schedule III manufacturers and distributors, which mandate facility security standards, inventory tracking systems, and periodic inspections distinct from current state regulations. The legal analysis noted that companies would need to maintain dual compliance frameworks during any transition period, increasing operational costs without immediate revenue benefits. Banking access improvements under Schedule III remain uncertain, as financial institutions may still decline cannabis accounts pending clearer federal enforcement guidance.

  The May 2026 assessment matters for medical cannabis operators evaluating capital allocation and business model adjustments ahead of potential rescheduling. Companies must weigh investments in FDA-compliant development programs against maintaining state-licensed operations, with legal counsel advising that rescheduling creates regulatory complexity rather than simplified market access for existing medical marijuana businesses.

  Update — May 22, 2026: Vicente LLP Webinar Addresses DEA Registration and Interstate Commerce Compliance Post-Rescheduling

  Vicente LLP announced a webinar focused on operational compliance requirements for state-licensed cannabis businesses following federal rescheduling. The firm's presentation covered DEA registration trigger rules, interstate commerce restrictions, and Schedule III regulatory obligations that apply once cannabis moves from Schedule I to Schedule III under the Controlled Substances Act.

  The webinar addressed how rescheduling does not automatically authorize interstate cannabis commerce, according to the firm's materials. State-licensed operators remain subject to intrastate-only distribution under existing state frameworks, while DEA registration requirements under 21 CFR Part 1301 would apply to manufacturers, distributors, and dispensaries handling Schedule III controlled substances. The firm outlined specific registration classes and annual renewal obligations that cannabis businesses must navigate to maintain federal compliance.

  Vicente LLP's guidance emphasized that trigger rules for DEA registration activate immediately upon final rescheduling, creating compliance deadlines for thousands of existing state-licensed operators. The presentation detailed Form 225 application procedures for manufacturers and distributors, and Form 224 requirements for dispensaries, including background checks, security protocols, and recordkeeping standards mandated by DEA regulations.

  The webinar reflects growing industry demand for concrete compliance roadmaps as rescheduling implementation approaches. Legal and operational uncertainty around DEA registration costs, timelines, and enforcement priorities has created significant planning challenges for multi-state operators and single-license businesses alike, according to the firm's promotional materials.

  This matters because DEA registration represents a mandatory federal compliance layer that most state-licensed cannabis businesses have never encountered. Failure to register within required timeframes after rescheduling takes effect could expose operators to federal enforcement action, even while maintaining valid state licenses and full compliance with state regulations.

  Update — May 23, 2026: Medical Marijuana Reclassification Completed, Advocacy Groups Push for Full Descheduling

  The Drug Enforcement Administration formally completed the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, according to federal register filings published in May 2026. The move, recommended by the Department of Health and Human Services in August 2023 and finalized after a multi-year administrative review, recognizes accepted medical use for cannabis and acknowledges a lower abuse potential than substances in Schedules I and II. The reclassification took effect 60 days after publication, marking the first federal scheduling change for cannabis since the Controlled Substances Act was enacted in 1970.

  Despite the historic shift, marijuana remains a federally controlled substance, and cultivation, distribution, and possession without proper licensing continue to violate federal law. Schedule III classification subjects cannabis businesses to standard federal tax treatment under Internal Revenue Code Section 280E, allowing deductions for ordinary business expenses previously disallowed for Schedule I operators. Industry analysts estimated the change would reduce effective tax rates for licensed operators by 15 to 25 percentage points, improving cash flow for multi-state operators and smaller dispensaries alike.

  Advocacy organizations including the National Organization for the Reform of Marijuana Laws and the Drug Policy Alliance responded that rescheduling does not address criminal justice disparities or resolve conflicts between state-legal programs and federal enforcement. More than 40,000 individuals remain incarcerated on federal marijuana charges, according to Bureau of Prisons data as of May 2026. Reform groups called for full descheduling through congressional action, citing the need to expunge prior convictions and eliminate federal criminal penalties entirely.

  The reclassification also triggered new FDA oversight obligations for cannabis products marketed with medical claims. Manufacturers seeking to market cannabis-derived pharmaceuticals must now submit New Drug Applications or Abbreviated New Drug Applications, a process that typically requires multi-phase clinical trials and can take years to complete. State-licensed medical marijuana programs remain exempt from FDA premarket approval requirements, but federal regulators warned that interstate commerce in cannabis products without FDA clearance remains prohibited under the Food, Drug, and Cosmetic Act.

  Congressional leaders in both chambers signaled limited appetite for further legislative action in 2026. Senate Majority Leader indicated that banking reform and expungement bills would receive committee hearings but faced uncertain floor prospects. The rescheduling decision resolves a procedural question that had been pending since President Biden directed HHS to review marijuana's classification in October 2022, but it leaves unresolved the broader conflict between 38 state-legal adult-use programs and continuing federal prohibition.

  Update — May 25, 2026: Nebraska Officials Respond to Federal Medical Cannabis Rescheduling

  Nebraska state officials issued divergent responses to the federal rescheduling of cannabis for medical use, reflecting the state's ongoing internal debate over cannabis policy. Governor Jim Pillen reiterated his opposition to any cannabis legalization, stating the rescheduling decision does not alter Nebraska's prohibition on medical or recreational cannabis under state law. Attorney General Mike Hilgers said his office would review the rescheduling's implications for state enforcement priorities but emphasized that federal reclassification does not preempt Nebraska's statutory bans.

  State Senator Anna Wishart, a longtime advocate for medical cannabis access, said the federal move underscores the need for Nebraska to adopt its own medical program. Wishart noted that 38 states now permit medical cannabis, leaving Nebraska among a shrinking minority of prohibition states. She announced plans to introduce legislation in the 2027 session establishing a regulated medical cannabis framework, citing patient testimony and neighboring states' operational models.

  The Nebraska Pharmacy Association released a statement acknowledging the rescheduling but cautioning that pharmacists cannot dispense cannabis under current state law or federal pharmacy regulations. The association called for clarity on whether rescheduling would eventually permit traditional pharmacy distribution, a model distinct from dispensary systems in existing state programs.

  Douglas County Sheriff Aaron Hanson said his department would continue enforcing Nebraska's cannabis laws as written. Hanson reported 1,247 cannabis possession arrests in Douglas County during 2025, the majority involving quantities under one ounce. He said federal rescheduling may complicate jury instructions in state prosecutions if defense attorneys argue reduced federal penalties undermine the state's public safety rationale for prohibition.

  The split reactions highlight Nebraska's position as a holdout state where federal policy shifts intensify pressure on lawmakers to reconcile state prohibitions with evolving national consensus on medical cannabis access.

  Update — May 25, 2026: VA Internal Documents Reveal Rescheduling Impact on Veterans' Medical Cannabis Access

  Internal U.S. Department of Veterans Affairs documents obtained through a Freedom of Information Act request indicate that federal rescheduling of cannabis to Schedule III could enable VA providers to refer veterans to state medical cannabis programs, according to the Veterans Action Council. The documents state that rescheduling "might affect a VA provider's ability to refer VA patients to State medical cannabis treatment programs," marking a potential shift in the agency's longstanding prohibition on cannabis-related services.

  VA physicians currently cannot recommend or discuss medical cannabis with patients due to federal Schedule I classification, even in states with legal programs. The Trump administration's rescheduling initiative, which would move cannabis from Schedule I to Schedule III under the Controlled Substances Act, could remove this barrier by reclassifying the substance as having accepted medical use. However, the documents suggest that VA facilities would still not dispense cannabis directly to veterans, limiting the change to referral capabilities rather than in-house treatment.

  The potential policy shift matters operationally because approximately 9 million veterans receive care through the VA system, many of whom currently seek cannabis treatment outside official channels for conditions including PTSD, chronic pain, and service-related injuries. Legal experts note that Schedule III status would not override existing federal employment restrictions or gun ownership prohibitions under 18 U.S.C. § 922(g)(3), meaning veterans using state-legal cannabis could still face consequences in those areas.

  The Veterans Action Council, which filed the FOIA request, said the documents represent the first official acknowledgment from VA leadership that rescheduling could modify clinical practice guidelines. The agency has not issued formal policy guidance on how providers should handle referrals if rescheduling occurs, leaving implementation timelines and procedural details unresolved as the Drug Enforcement Administration continues its review process.

  Update — May 26, 2026: VA Internal Documents Reveal Rescheduling Impact on Veteran Cannabis Access

  Internal Department of Veterans Affairs documents obtained by Hemp Gazette detailed how cannabis rescheduling to Schedule III would affect medical access for approximately 9 million enrolled veterans. The VA memoranda, dated April 2026, outlined policy changes that would permit VA physicians to discuss cannabis treatment options with patients for the first time since the Controlled Substances Act took effect in 1970. Under current Schedule I classification, VA doctors face federal employment termination if they recommend cannabis, even in states with legal medical programs.

  The documents specified that Schedule III reclassification would allow VA healthcare providers to document cannabis use in patient records without triggering federal benefit penalties. According to the internal guidance, veterans currently risk losing pain management prescriptions or disability benefits if they disclose cannabis use to VA physicians. The policy shift would align VA practices with 38 state medical cannabis programs that already serve an estimated 400,000 veterans who obtain recommendations from non-VA providers.

  VA officials noted in the memoranda that rescheduling would not authorize the agency to dispense cannabis through VA pharmacies or medical centers, as federal facilities cannot distribute controlled substances lacking FDA approval. The guidance said veterans would continue purchasing cannabis from state-licensed dispensaries while VA providers could integrate usage patterns into treatment plans for conditions including PTSD, chronic pain, and traumatic brain injury. The VA estimated that formal integration of cannabis discussions could reduce opioid prescriptions by 12-18% among veteran populations based on state-level data from medical cannabis programs.

  The documents also addressed research implications, stating that Schedule III status would eliminate current DEA licensing barriers that have restricted VA participation in cannabis clinical trials since 2014. VA research facilities would gain access to federally approved cannabis for studies examining efficacy in veteran-specific conditions, according to the internal guidance. The memoranda projected initial research protocols could launch within six months of final rescheduling implementation, pending OMB approval of revised research frameworks.

  Update — May 26, 2026: Cannabis Europa London Convenes First Major International Conference Post-Rescheduling

  Cannabis Europa London 2026 opened on May 26, marking the first major international cannabis industry conference held after the DEA's rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The event drew more than 2,500 attendees from 47 countries, according to conference organizers, with a sharp increase in participation from institutional investors and pharmaceutical companies compared to prior years.

  Industry executives and policy analysts used the conference to assess how rescheduling has altered cross-border cannabis commerce and regulatory harmonization efforts. Panelists noted that Schedule III classification has enabled U.S. cannabis companies to claim standard business tax deductions under Internal Revenue Code Section 280E, improving margins by an estimated 15 to 25 percent for multi-state operators. Several European firms announced partnerships with U.S. cultivators to explore import-export pathways now that cannabis is no longer classified alongside heroin and LSD.

  Regulatory attorneys at the conference emphasized that rescheduling does not legalize cannabis under federal law but removes certain research barriers and banking restrictions. The U.K. Home Office sent observers to track discussions on medical cannabis access frameworks, as British policymakers weigh alignment with U.S. scheduling changes. Conference sessions focused on FDA approval pathways for cannabis-derived pharmaceuticals, intellectual property strategies for cannabinoid formulations, and compliance with Good Manufacturing Practice standards now applicable to Schedule III substances.

  The gathering underscored how DEA rescheduling has accelerated institutional capital flows into the cannabis sector, with venture capital and private equity firms seeking exposure to companies positioned to navigate the new regulatory landscape. Attendees reported heightened interest in clinical trials for cannabinoid therapies, driven by the reduced administrative burden for researchers working with Schedule III substances. The conference concluded with calls for further international coordination on cannabis policy, particularly regarding banking access and cross-border intellectual property protections.

  Update — May 26, 2026: NORML Petitions DEA for Consumer Representation at Rescheduling Hearing

  The National Organization for the Reform of Marijuana Laws filed a formal petition with the Drug Enforcement Administration seeking participant status in the upcoming administrative hearing on marijuana rescheduling. NORML argued that cannabis consumers represent a distinct stakeholder group whose interests differ from industry operators, medical professionals, and law enforcement, according to the organization's May 26 announcement. The petition emphasized that over 50 million Americans currently use cannabis, yet no consumer advocacy organization had been granted formal standing in the DEA's rulemaking process.

  NORML Deputy Director Paul Armentano said the organization would present testimony on criminal justice impacts, patient access barriers, and employment discrimination that persist under Schedule I classification. The petition cited the Administrative Procedure Act's requirement that agencies consider input from all affected parties during notice-and-comment rulemaking. NORML specifically requested the opportunity to cross-examine government witnesses and introduce evidence regarding cannabis use patterns, arrest data, and state-level regulatory outcomes from the 24 states with adult-use programs.

  The DEA has not yet ruled on NORML's petition or announced a hearing date, though the agency's proposed rule to move marijuana from Schedule I to Schedule III remains under White House Office of Management and Budget review. The Administrative Law Judge assigned to the case must approve all participant requests before scheduling proceedings. If granted standing, NORML would join pharmaceutical manufacturers, medical associations, and state attorneys general who have indicated intent to participate in the hearing.

  The petition matters because consumer perspectives on enforcement priorities, possession limits, and home cultivation rights have historically been absent from federal drug scheduling decisions. NORML's participation could force the DEA to address whether Schedule III classification—which maintains criminal penalties for non-medical possession—adequately reflects current public health evidence and state-level policy experiments. The hearing record will form the basis for any legal challenges to the DEA's final rule.

  Update — May 26, 2026: California Attorney Cites Rescheduling in Los Angeles Licensing Appeal

  A California attorney argued that pending federal rescheduling of cannabis maintains the viability of an appeal challenging Los Angeles licensing decisions, according to Law360. The legal argument asserts that changes to cannabis's Controlled Substances Act classification could alter the regulatory framework governing municipal licensing disputes. The appeal remains active in California courts as the DEA rescheduling process continues at the federal level.

  The attorney's position reflects growing intersection between federal rescheduling timelines and state-level cannabis litigation. Courts have historically treated cannabis licensing as a state and local matter, but the potential shift from Schedule I to Schedule III creates novel questions about federal preemption and regulatory authority. Los Angeles operates one of the nation's largest licensed cannabis markets, with over 1,000 active retail and cultivation permits as of early 2026.

  Legal experts note that rescheduling would not automatically invalidate existing state licensing frameworks, but could influence judicial interpretation of administrative law challenges. The appeal's outcome may establish precedent for how California courts weigh federal classification changes in local cannabis disputes. Similar arguments have emerged in licensing cases across multiple states awaiting final DEA action.

  The timing matters for Los Angeles operators facing license renewal deadlines and compliance costs tied to current Schedule I restrictions. If rescheduling occurs before the appeal concludes, parties may seek remand or reconsideration based on changed federal law. The case underscores how prolonged DEA rulemaking creates legal uncertainty for municipal regulators and license applicants alike.

  Update — May 26, 2026: Rescheduling Faces New Delays Amid Constitutional and Treaty Challenges

  The DEA's proposed rescheduling of cannabis from Schedule I to Schedule III encountered additional procedural delays in May 2026 as federal courts began reviewing constitutional challenges to the rulemaking process. According to court filings, petitioners argued that the Administrative Procedure Act requires more extensive public comment periods than the 60-day window initially provided by the DEA in 2024. The challenges also cited potential conflicts with United States obligations under the 1961 Single Convention on Narcotic Drugs, which classifies cannabis as a Schedule I substance under international treaty law.

  Legal experts said the constitutional questions center on whether the DEA's reliance on the Department of Health and Human Services' scheduling recommendation violated the non-delegation doctrine. Federal district courts in three circuits issued stays preventing the final rule from taking effect pending resolution of these claims. The stays effectively suspended the implementation timeline that had projected a Q3 2026 effective date for Schedule III classification.

  Industry analysts noted that the delays create continued uncertainty for cannabis operators who had begun preparing compliance frameworks for the anticipated IRC Section 280E tax relief that would accompany Schedule III status. Multi-state operators had projected $2.1 billion in aggregate federal tax savings for fiscal year 2027 under the proposed rescheduling. The extended legal challenges now push any potential tax benefits into 2027 or beyond, according to financial projections filed with the Securities and Exchange Commission.

  The treaty conflict arguments focus on whether domestic rescheduling would require the United States to formally withdraw from or seek amendments to the Single Convention. State Department officials said in May 2026 that no formal treaty modification process had been initiated, leaving unresolved questions about how federal rescheduling would be reconciled with international obligations. The DEA has not issued a public timeline for addressing the constitutional and treaty issues raised in the federal court challenges.

  Update — May 27, 2026: Cresco Labs Receives First DEA Registrations for Medical Cannabis Facilities Under Schedule III

  Cresco Labs announced it secured DEA registrations for multiple medical cannabis cultivation and manufacturing facilities following the federal rescheduling of cannabis to Schedule III. The company said the registrations mark the first time its operations have received formal DEA approval under the Controlled Substances Act, transitioning facilities that previously operated under state licenses into federally registered entities. Facilities in Pennsylvania, Illinois, and Ohio received initial registrations, according to the company's filing.

  The registrations require Cresco Labs to implement DEA security and recordkeeping protocols including biometric access controls, video surveillance retention, and electronic batch tracking integrated with DEA reporting systems. The company said it invested $12.3 million across registered facilities to meet federal security standards during Q1 2026. Annual registration fees total approximately $3,800 per facility, with triennial renewals subject to DEA inspection and compliance verification.

  Cresco Labs said the registrations enable the company to pursue research partnerships with federally funded institutions and pharmaceutical distribution channels previously unavailable under Schedule I classification. The company announced a memorandum of understanding with a university medical center to supply cannabis for FDA-approved clinical trials examining cannabinoid therapies for chronic pain. DEA-registered facilities can manufacture cannabis-derived pharmaceutical products eligible for interstate commerce under DEA oversight, the company noted.

  The registrations require Cresco Labs to maintain separate inventories for medical and adult-use products, with only medical-grade cannabis eligible for DEA-registered operations. The company said it established dedicated cultivation rooms and processing lines at registered facilities to ensure compliance with Good Manufacturing Practice standards. Adult-use operations at the same locations remain under state jurisdiction without federal registration, creating dual regulatory frameworks at multi-license facilities.

  Industry analysts said the registrations demonstrate the operational complexity of Schedule III compliance for multi-state operators. Companies must navigate overlapping federal DEA requirements and state cannabis regulations that may conflict on testing standards, product formulations, and distribution protocols. The registrations position Cresco Labs to access institutional capital markets and banking services tied to federally compliant operations, according to financial analysts covering the cannabis sector.

  Update — May 27, 2026: Three Republican AGs Sue to Block Trump DOJ Rescheduling

  Attorneys general from Indiana, Nebraska, and Louisiana filed a federal lawsuit on May 27, 2026, seeking to block the Trump administration's cannabis rescheduling action announced the previous month. The complaint alleges the Department of Justice's rescheduling decision "fails to comport with the requirements" of the Controlled Substances Act and administrative law, according to the filing.

  The lawsuit marks the first coordinated state-level legal challenge to the rescheduling process since the Trump DOJ moved forward with implementation. All three plaintiff states are led by Republican attorneys general, representing jurisdictions with restrictive cannabis policies. The complaint targets procedural grounds rather than the scientific merits of rescheduling, focusing on whether the agency followed statutory notice-and-comment requirements.

  The timing creates immediate uncertainty for operators who began adjusting compliance frameworks after the April 2026 announcement. If the court issues a preliminary injunction, rescheduling implementation could be frozen pending full litigation, delaying tax relief under Internal Revenue Code Section 280E and complicating interstate commerce planning. The case will likely be assigned to a federal district court in one of the plaintiff states, with appeals potentially reaching the Fifth Circuit or Eighth Circuit.

  Legal observers note the challenge differs from earlier rescheduling opposition, which centered on scheduling criteria under the CSA's eight-factor analysis. This lawsuit instead argues the administrative process itself was defective, a strategy that could succeed even if courts accept cannabis's medical utility. The outcome will determine whether states can unilaterally halt federal drug policy changes through procedural objections, setting precedent for future Schedule II or III substance modifications.

  Update — May 27, 2026: State Attorneys General Sue to Block Trump Administration Rescheduling Reversal

  A coalition of state attorneys general filed a federal lawsuit on May 27, 2026, seeking to block the Trump administration's attempt to reverse the rescheduling of marijuana from Schedule III back to Schedule I. The complaint, filed in the U.S. District Court for the District of Columbia, argues that the administration violated the Administrative Procedure Act by failing to follow required notice-and-comment rulemaking procedures and disregarded substantial scientific evidence supporting cannabis's accepted medical use. The lawsuit names the Drug Enforcement Administration and the Department of Justice as defendants.

  The states argue that the reversal threatens state-regulated medical cannabis programs serving more than 7 million registered patients nationwide and jeopardizes billions in tax revenue collected under existing frameworks. According to the complaint, the administration's action creates immediate operational chaos for licensed businesses that invested capital based on the Schedule III classification finalized in late 2024. The plaintiffs seek a preliminary injunction to halt enforcement of the reversal pending full judicial review.

  Legal experts said the case hinges on whether the administration provided adequate justification for reversing a rule based on extensive scientific review by the Department of Health and Human Services. The original rescheduling process consumed more than two years and included public comment periods that generated over 43,000 submissions. The Trump administration's reversal order, issued via executive directive in April 2026, bypassed the multi-agency review process that produced the Schedule III determination.

  The lawsuit represents the most significant legal challenge to federal cannabis policy since the rescheduling took effect. Industry analysts estimate that reverting to Schedule I would eliminate Section 280E tax relief for cannabis businesses, increasing effective tax rates from approximately 25% to over 70% and forcing widespread closures. The court has scheduled a hearing on the preliminary injunction motion for June 12, 2026, with expedited briefing ordered due to the immediate economic impact on state-licensed operators.

  Update — May 27, 2026: Three States File Objections as Rescheduling Comment Period Closes

  Three additional states submitted formal objections to the DEA's proposed rescheduling of cannabis from Schedule I to Schedule III as the public comment deadline approached, according to MJBizDaily. The states joined a growing coalition of opponents that includes law enforcement groups and anti-legalization advocacy organizations. The filings arrived during the final days of the comment period established under the Administrative Procedure Act, which requires the DEA to consider all substantive public input before finalizing any rescheduling decision.

  The state objections focused on concerns about potential conflicts between federal rescheduling and existing state-level cannabis control frameworks, as well as questions about enforcement coordination. Several states expressed worry that Schedule III classification could create regulatory gaps, as the Controlled Substances Act imposes different manufacturing, distribution, and prescription requirements for Schedule III substances compared to the complete prohibition under Schedule I. States with existing medical or adult-use programs questioned how federal rescheduling would interact with their licensing systems, particularly regarding product testing standards and interstate commerce restrictions.

  The timing of the filings underscored the compressed timeline facing the DEA. The agency must now review and respond to thousands of public comments, including detailed technical submissions from medical associations, industry groups, and state attorneys general, before publishing a final rule. Legal analysts noted that substantive objections from state governments could extend the rescheduling timeline, as the DEA must address significant concerns raised during the comment period or risk legal challenges under the Administrative Procedure Act.

  For cannabis operators, the state opposition introduces additional uncertainty into capital planning and compliance strategies. Companies operating in states that filed objections may face heightened scrutiny or delayed regulatory clarity even if federal rescheduling proceeds, as state regulators could implement additional requirements to address concerns raised in their federal filings. The development also complicates investor projections about the timeline for potential tax relief under Internal Revenue Code Section 280E, which currently prohibits cannabis businesses from deducting ordinary business expenses.

  Update — May 28, 2026: NORML Petitions for Formal Participant Status in DEA Rescheduling Hearings

  The National Organization for the Reform of Marijuana Laws (NORML) filed a formal petition with the Drug Enforcement Administration seeking participant status in ongoing cannabis rescheduling hearings, according to the organization's May 28 announcement. The petition requests standing to present evidence, cross-examine witnesses, and submit post-hearing briefs during the administrative law judge proceedings that will determine whether cannabis moves from Schedule I to Schedule III under the Controlled Substances Act. NORML's legal team cited the organization's 54-year history of cannabis policy advocacy and its representation of millions of consumers as grounds for direct participation rather than observer status.

  The DEA's Administrative Law Judge has not yet ruled on the petition, but procedural rules under 21 CFR § 1316.47 require the agency to evaluate whether applicants demonstrate sufficient interest in the outcome and expertise relevant to the rescheduling criteria. NORML argued that its participation would provide critical consumer perspective on cannabis's accepted medical use, abuse potential, and public health implications—the three core factors administrative law judges must weigh under the five-part test established in the Controlled Substances Act. The organization specifically highlighted its role in coordinating testimony from over 42,000 public comments submitted during the initial notice-and-comment period that closed in 2024.

  If granted participant status, NORML would join pharmaceutical manufacturers, medical associations, and state regulatory bodies already approved to present direct testimony during hearings expected to begin in late 2026. The organization stated it plans to introduce evidence on state-level medical cannabis programs serving approximately 8.2 million registered patients across 38 states, data the group said remains underrepresented in federal scheduling reviews. Participant status would also allow NORML to challenge DEA and Department of Health and Human Services evidence supporting or opposing rescheduling, a procedural right not available to public commenters.

  The petition comes as the DEA faces mounting pressure to expedite rescheduling proceedings that have extended beyond initial timelines projected in 2024. Legal observers said granting advocacy organizations formal standing could lengthen hearing schedules but would strengthen the administrative record against potential judicial challenges to the final rule. NORML indicated it would focus its testimony on demonstrating cannabis's currently accepted medical use in treatment, the statutory threshold that distinguishes Schedule I substances from those in lower schedules permitting medical applications.

  Update — May 28, 2026: Louisiana Joins Multi-State Lawsuit Challenging Schedule III Reclassification

  Louisiana Attorney General Liz Murrill added the state as a plaintiff in the ongoing multi-state lawsuit seeking to block the Trump administration's reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act. The lawsuit, originally filed by Nebraska, Kansas, and other conservative-leaning states, argues that the DEA's rescheduling decision exceeded statutory authority and failed to adequately consider public health impacts. Louisiana's entry brings the total number of plaintiff states to at least 15, according to court filings.

  The consolidated complaint contends that the DEA relied on insufficient scientific evidence when accepting the Department of Health and Human Services' August 2023 recommendation to reschedule cannabis. Murrill's office emphasized Louisiana's interest in maintaining federal-state coordination on controlled substance enforcement and expressed concern that Schedule III status would complicate state-level prosecution of unauthorized cannabis activity. The lawsuit seeks a preliminary injunction to halt implementation of the final rule pending full judicial review.

  The legal challenge creates immediate uncertainty for cannabis operators preparing for federal tax relief under Internal Revenue Code Section 280E, which currently prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Schedule III reclassification would restore standard deductions, potentially saving the industry billions annually. Multi-state operators with Louisiana exposure now face extended timeline risk as litigation proceeds through the U.S. Court of Appeals for the Eighth Circuit.

  This matters because expanded state opposition increases the likelihood of a nationwide preliminary injunction that would freeze the rescheduling process for months or years. Investors pricing in 280E relief for fiscal 2026 earnings must now account for protracted legal uncertainty, while operators in plaintiff states may face heightened state-level enforcement as attorneys general signal continued hostility to federal liberalization.

  Update — May 28, 2026: Bipartisan lawmakers demand IRS tax guidance following rescheduling

  A bipartisan group of congressional lawmakers sent a letter to the Internal Revenue Service requesting "prompt" guidance on tax treatment for cannabis businesses following the rescheduling of marijuana from Schedule I to Schedule III. The letter, according to Marijuana Moment, emphasized that the administrative change creates immediate uncertainty for operators who have operated under Internal Revenue Code Section 280E restrictions for decades, which prohibit businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses.

  The lawmakers' request focused on clarification of the effective date for 280E relief and whether businesses may amend prior-year tax returns to claim previously disallowed deductions. Industry operators have paid effective tax rates exceeding 70 percent under 280E, with the provision generating an estimated $1.8 billion in additional federal revenue annually from state-legal cannabis businesses. The IRS has not issued formal guidance on how rescheduling affects tax obligations for current or prior tax years.

  The letter also requested clarity on accounting method changes and inventory capitalization rules that cannabis businesses must navigate in transitioning from 280E compliance to standard business tax treatment. According to the lawmakers, operators need guidance on whether they must file Form 3115 to change accounting methods and how to handle cost-of-goods-sold calculations that were previously their only allowable deduction. Without clear IRS direction, businesses face conflicting interpretations from tax preparers and potential audit exposure.

  This development matters because tax uncertainty delays capital investment and operational planning across the $30 billion legal cannabis market. Operators cannot finalize 2026 budgets, adjust pricing strategies, or make hiring decisions without knowing their actual tax burden. The IRS typically issues revenue rulings or procedures within 90 to 180 days of major regulatory changes, but cannabis rescheduling presents unprecedented administrative complexity given the industry's size and the retroactive implications for businesses that overpaid taxes under 280E in recent years.

  Update — May 29, 2026: Medical Cannabis Rescheduling Triggers Consumer Sentiment Shift and Consolidated Legal Challenges

  The DEA's rescheduling of cannabis to Schedule III under the Controlled Substances Act has produced measurable shifts in consumer behavior and prompted consolidated legal challenges from multiple stakeholder groups, according to industry analysts and court filings. Medical cannabis patient registrations increased across state programs following the federal classification change, while opponents filed coordinated petitions challenging the administrative process used to finalize the rule.

  Consumer sentiment surveys conducted in May 2026 showed increased acceptance of medical cannabis among demographics previously hesitant due to federal prohibition status. State health departments in Pennsylvania, Ohio, and Florida reported registration upticks ranging from 12% to 18% month-over-month, with administrators attributing the growth to reduced stigma following Schedule III placement. The reclassification did not alter state-level medical cannabis program structures, but patient advocacy groups said the federal policy shift legitimized physician recommendations in conservative markets.

  Legal challenges to the rescheduling rule were consolidated in federal court, with petitioners including hemp industry trade associations, criminal justice reform organizations, and Schedule I advocacy coalitions. Challengers argued the DEA failed to adequately consider public comments submitted during the notice-and-comment period and that the rule violated the Administrative Procedure Act's requirements for reasoned decision-making. Hemp stakeholders specifically contested the rule's treatment of hemp-derived cannabinoids and the lack of clarity on interstate commerce provisions under the new schedule.

  The consolidated case was assigned to the U.S. Court of Appeals for the District of Columbia Circuit, with oral arguments scheduled for the fourth quarter of 2026. The court declined to issue a stay of the rescheduling rule pending litigation, meaning Schedule III classification remained in effect during the legal proceedings. Industry attorneys said the case's outcome would determine whether the DEA must restart portions of the rulemaking process or whether the agency's scientific and procedural findings withstand judicial scrutiny under Chevron deference standards.

  Financial analysts noted that publicly traded cannabis operators saw stock price volatility tied to litigation developments, with institutional investors monitoring the case for potential impacts on Section 280E tax treatment and FDA regulatory pathways. The rescheduling's durability remained uncertain as stakeholders awaited the appellate court's review of the administrative record and procedural compliance.

  Update — May 29, 2026: Indiana Attorney General Rokita Moves to Block Federal Rescheduling

  Indiana Attorney General Todd Rokita announced legal action to block the federal reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act. Rokita filed a motion to intervene in ongoing litigation challenging the DEA's rescheduling process, joining a coalition of state attorneys general opposing the policy shift. According to a statement from Rokita's office, the move aims to preserve Indiana's prohibition framework and prevent what he described as federal overreach into state drug enforcement authority.

  The intervention comes as the DEA's final rule on rescheduling faces multiple legal challenges in federal court, with opponents arguing the agency failed to adequately consider public health risks and violated Administrative Procedure Act requirements. Rokita's filing specifically cited concerns about increased youth access, impaired driving incidents, and conflicts with Indiana's criminal statutes that maintain marijuana as a controlled substance with criminal penalties for possession and distribution. Indiana remains one of 12 states without any form of legal medical or adult-use cannabis program.

  The legal challenge creates additional uncertainty for multi-state operators and ancillary businesses planning expansion into Schedule III compliance frameworks. Federal rescheduling would maintain marijuana's controlled status but reclassify it alongside substances like ketamine and anabolic steroids, enabling IRS Code Section 280E tax deductions for state-licensed businesses. Industry analysts noted that sustained litigation from multiple state attorneys general could delay implementation of the rescheduling rule beyond the current administrative timeline, potentially extending 280E tax burdens and banking restrictions into 2027.

  Rokita's office indicated it would coordinate with attorneys general from Nebraska, Kansas, and other prohibition states to present unified arguments against rescheduling. The motion represents the latest state-level resistance to federal cannabis policy reform, following similar challenges to FDA guidance on hemp-derived cannabinoids and interstate commerce regulations.

  Update — May 30, 2026: State Attorneys General Challenge Federal Rescheduling Order in Court

  A coalition of state attorneys general filed a lawsuit challenging the federal government's rescheduling of cannabis for medical use, according to reports from May 30, 2026. The legal challenge targets the DEA's implementation of the rescheduling order and raises questions about state sovereignty over cannabis regulation and the scope of federal authority under the Controlled Substances Act. The complaint was filed in federal district court and seeks to halt enforcement of the new classification pending judicial review.

  The lawsuit argues that the rescheduling process violated Administrative Procedure Act requirements for notice-and-comment rulemaking and failed to adequately address conflicts between federal medical cannabis classification and existing state regulatory frameworks. Attorneys general from states with established adult-use cannabis programs contend the federal order creates regulatory uncertainty for licensed operators who have invested billions in state-compliant infrastructure. The complaint also challenges the DEA's interpretation of the "currently accepted medical use" standard under 21 U.S.C. § 812.

  Industry stakeholders face immediate operational questions as the litigation proceeds. Multi-state operators must navigate conflicting compliance obligations between state licenses and the new federal classification, particularly regarding interstate commerce restrictions and banking access. The lawsuit's preliminary injunction motion could freeze implementation of federal rescheduling rules while courts resolve the underlying constitutional and statutory questions, leaving businesses in regulatory limbo.

  Legal experts said the case will likely focus on whether the DEA exceeded its statutory authority and whether the rescheduling order improperly preempts state cannabis laws. The outcome could determine whether states retain primary regulatory control over medical cannabis programs or whether federal classification triggers mandatory compliance requirements that override state frameworks. Financial markets reacted to the uncertainty, with cannabis equity indexes declining on concerns about prolonged legal battles delaying federal reform benefits.

  Update — May 30, 2026: State Regulators Demand Federal Clarity on Rescheduling Implementation

  State cannabis regulators expressed frustration over the lack of federal guidance following the Trump administration's rescheduling directive, according to statements from officials at a multi-state regulatory conference. The Drug Enforcement Administration and Department of Health and Human Services had not issued implementation timelines, compliance protocols, or transition instructions for state-licensed operators as of May 30, 2026. Regulators said the silence created operational uncertainty for businesses navigating tax obligations, banking access, and interstate commerce rules.

  Officials from California, Colorado, and Illinois specifically cited confusion over 280E tax deduction eligibility during the transition period and whether existing state licenses would require federal review or re-approval. One state director said the administration's announcement provided no roadmap for reconciling state regulatory frameworks with the new federal classification. The absence of guidance left state agencies unable to advise licensees on compliance strategies or capital planning.

  The regulatory vacuum also affected banking institutions hesitant to expand cannabis services without explicit federal safe harbor provisions. State officials noted that financial institutions were demanding written confirmation from federal regulators before modifying account policies or lending criteria. Industry attorneys said the delay risked creating a patchwork of state-level interpretations that could expose operators to enforcement actions.

  This matters because state regulators function as the primary compliance enforcers for cannabis businesses, and their inability to provide clear direction based on federal policy creates legal and financial risk for operators. The lack of coordination between federal agencies and state programs could delay the practical benefits of rescheduling, including improved banking access and tax relief that operators expected immediately. Without implementation guidance, businesses face continued uncertainty in financial planning and regulatory compliance strategies.

  Update — May 30, 2026: Three State Attorneys General File Federal Lawsuit Challenging Rescheduling Authority

  Attorneys General from Nebraska, Indiana, and Louisiana filed a federal lawsuit on May 30, 2026, seeking to halt the Trump administration's ongoing marijuana reclassification process. The complaint challenges the Drug Enforcement Administration's statutory authority to move cannabis from Schedule I to a lower schedule under the Controlled Substances Act, according to court filings. The three states argue that rescheduling would undermine their existing state-level enforcement frameworks and create conflicts with federal drug policy objectives.

  The lawsuit targets both the DEA and the Department of Health and Human Services, naming their respective administrators as defendants. Nebraska Attorney General Mike Hilgers said the action seeks to preserve "the integrity of federal drug scheduling standards that protect public health." The complaint requests a preliminary injunction to suspend all rescheduling proceedings pending judicial review of the administrative record and statutory interpretation.

  Legal analysts note the lawsuit mirrors similar multi-state challenges filed in 2024 that delayed earlier rescheduling efforts through procedural motions and discovery requests. The current filing invokes the Administrative Procedure Act, alleging the DEA failed to adequately consider international treaty obligations under the 1961 Single Convention on Narcotic Drugs and domestic law enforcement impacts. Indiana's complaint specifically cites concerns about workplace safety standards and federal contractor compliance requirements.

  This development introduces new litigation risk to the rescheduling timeline, which industry observers had expected to conclude by third quarter 2026. Multi-state operators with operations in the plaintiff states face continued uncertainty regarding federal tax treatment under Internal Revenue Code Section 280E and banking access. The lawsuit also complicates ongoing congressional negotiations over the SAFER Banking Act, as opponents may cite the litigation as grounds to delay legislative action until courts resolve the administrative challenge.

  Update — May 31, 2026: Federal licensing pathway may precede DEA rescheduling decision

  A federal licensing framework for state-legal cannabis operators may arrive before the DEA concludes its rescheduling review, according to congressional staffers briefed on draft legislation circulating in the Senate Finance Committee. The proposed bill would create a provisional federal permit system allowing state-licensed dispensaries and cultivators to operate without Schedule I penalties while the DEA completes its administrative process, which entered its seventh year in May 2026. Senate aides said the measure could advance as a standalone bill or as an amendment to must-pass appropriations legislation before the August recess.

  The licensing proposal would require operators to register with the Treasury Department's Financial Crimes Enforcement Network and maintain compliance with state regulations for a minimum of 24 consecutive months. Permit holders would gain access to federal banking services and standard business tax deductions under Internal Revenue Code Section 280E, which currently prohibits cannabis businesses from writing off ordinary expenses. Treasury officials estimated the framework could generate $1.2 billion in new tax revenue during fiscal year 2027 by bringing an estimated 12,000 state-licensed entities into federal reporting systems.

  The DEA's rescheduling docket remains open for public comment through June 30, 2026, with more than 47,000 submissions filed since the agency published its notice of proposed rulemaking in August 2024. Agency leadership has not committed to a decision timeline, citing the volume of technical comments requiring scientific review. A DEA spokesperson said the rulemaking "will conclude when the administrative record is complete," declining to provide a target date.

  Industry groups including the National Cannabis Industry Association endorsed the licensing approach as a practical interim measure. Operators in 38 states with medical or adult-use programs would qualify for federal permits under the draft bill's eligibility criteria, which exclude businesses with felony drug trafficking convictions in the past decade. The proposal does not alter cannabis's controlled substance classification, leaving final rescheduling authority with the DEA and preserving the agency's regulatory role over manufacturing and distribution standards once rescheduling occurs.

  Update — May 31, 2026: Healthcare and Insurance Implications of Schedule III Rescheduling

  The DEA's rescheduling of cannabis to Schedule III under the Controlled Substances Act triggered immediate operational questions for healthcare providers and insurers. Under Schedule III classification, cannabis joins substances like ketamine and anabolic steroids, which permits prescription dispensing under the Federal Food, Drug, and Cosmetic Act but maintains federal controls absent from state-legal recreational programs.

  Medical practitioners now face dual compliance frameworks: state medical marijuana programs continue operating under existing authorization structures, while FDA-approved cannabis medications may enter traditional prescription pathways. The distinction matters because insurance coverage applies only to FDA-approved formulations, not state-dispensary products, according to Centers for Medicare & Medicaid Services guidance issued in March 2026. Healthcare systems reported confusion over documentation requirements, as Schedule III substances require DEA Form 222 for institutional transfers but state programs use separate tracking systems.

  Pharmacy benefit managers began evaluating prior authorization protocols for Schedule III cannabis products in anticipation of FDA approvals beyond existing Epidiolex and Marinol formulations. The rescheduling does not automatically expand insurance coverage but removes the blanket federal prohibition that previously prevented any consideration of reimbursement. Arizona healthcare compliance officers noted that electronic prescribing systems require updates to accommodate Schedule III cannabis while maintaining separation from state medical marijuana registries.

  The change creates immediate tax implications for medical dispensaries, as Internal Revenue Code Section 280E prohibitions on business deductions no longer apply to Schedule III substances. Operators previously barred from deducting ordinary business expenses can now claim costs of goods sold, rent, and payroll on federal returns. This represents the most concrete financial benefit of rescheduling for existing state-licensed medical programs, though recreational operators remain subject to 280E restrictions.

  Healthcare organizations emphasized that rescheduling does not alter workplace drug testing policies or federal employment restrictions. Department of Transportation regulations continue prohibiting cannabis use for safety-sensitive positions regardless of schedule classification, and federal contractors remain subject to Drug-Free Workplace Act requirements that treat all cannabis use as prohibited conduct.

  Update — June 1, 2026: Legal Challenges Mount Against DEA Rescheduling Authority

  Multiple federal lawsuits filed in May 2026 argue the DEA exceeded its statutory authority in the ongoing cannabis rescheduling process, according to court filings in the U.S. District Court for the District of Columbia. Plaintiffs including state-licensed operators and industry trade groups contend the agency failed to meet procedural requirements under the Administrative Procedure Act, specifically citing inadequate public comment periods and reliance on outdated scientific reviews. The consolidated cases challenge both the timeline and the evidentiary basis for any proposed Schedule III classification.

  Legal experts noted the DEA faces heightened scrutiny after the U.S. Court of Appeals for the D.C. Circuit remanded a related hemp rule in March 2026, finding the agency's interpretation of the 2018 Farm Bill arbitrary and capricious. That precedent strengthens arguments that the DEA's rescheduling methodology lacks the rigorous scientific foundation required by the Controlled Substances Act. The agency has not published a final rule despite announcing its intent to reschedule cannabis in August 2024, leaving the substance in Schedule I for 24 consecutive months beyond the initial proposal.

  Industry stakeholders face operational uncertainty as banking access and tax treatment under Internal Revenue Code Section 280E remain unchanged while litigation proceeds. Multi-state operators reported continued difficulty securing institutional capital, with venture funding for cannabis companies down 41 percent year-over-year through Q1 2026. The legal challenges could delay any rescheduling decision by an additional 18 to 24 months if courts order supplemental rulemaking or environmental impact assessments, according to administrative law attorneys representing respondents.

  The consolidated cases are scheduled for oral arguments in September 2026, with discovery focused on internal DEA communications and the Health and Human Services scientific review completed in 2023. A ruling against the agency would require the DEA to restart portions of the rescheduling process, potentially extending Schedule I classification into 2028 and preserving federal-state enforcement conflicts that have defined cannabis policy since the Obama administration.

  Update — June 1, 2026: Patient First Coalition Calls for Schedule III Transition Moratorium

  The Patient First Coalition announced support for the DEA's ongoing medical cannabis review process while advocating for a moratorium on any immediate Schedule III transition. The coalition, representing patient advocacy organizations, said the agency should prioritize comprehensive medical evidence review before implementing reclassification. According to the coalition's statement, expert testimony from medical professionals should inform the final scheduling determination to ensure patient access protections remain intact during any regulatory transition.

  The coalition emphasized that Schedule III classification could create unintended barriers for medical cannabis patients currently served by state-licensed programs. Moving cannabis to Schedule III would subject it to FDA approval requirements and prescription-only distribution, potentially disrupting access for patients in the 38 states with operational medical programs. The group said any rescheduling framework must address how existing state medical systems would operate under federal pharmaceutical regulations.

  This advocacy effort comes as the DEA continues its administrative review process following the Department of Health and Human Services' August 2023 recommendation to reschedule cannabis to Schedule III. The coalition's call for a transition moratorium represents a shift from industry groups primarily focused on tax benefits under Section 280E reform. Patient advocates said the focus should remain on maintaining current access pathways while federal policy evolves, rather than rushing implementation that could fragment the medical cannabis supply chain.

  The statement matters for state-licensed operators who serve medical patients under current frameworks. If the DEA proceeds with Schedule III reclassification without transition provisions, dispensaries could face legal uncertainty about continuing to serve patients outside FDA-approved channels. The coalition's position adds patient access concerns to the ongoing debate over rescheduling timelines and implementation mechanics.

  Update — June 1, 2026: Three States Petition to Intervene in Federal Rescheduling Litigation

  Three states filed motions to intervene in ongoing federal litigation challenging the DEA's cannabis rescheduling process, according to Harris Sliwoski LLP. The states argue they possess direct standing to participate in the administrative proceedings due to their established medical marijuana programs and regulatory frameworks that would be affected by any federal schedule change. The intervention petitions emphasize that state-level regulatory interests create distinct legal injuries separate from those asserted by private industry plaintiffs already participating in the case.

  The states contend their medical cannabis programs, which collectively serve hundreds of thousands of registered patients, face operational uncertainty during the rescheduling review. State regulators said the federal classification directly impacts their ability to enforce quality standards, taxation structures, and interstate commerce restrictions. Conflicting federal and state schedules create enforcement gaps that state attorneys general argue only direct participation in federal proceedings can address.

  Legal experts note that state intervention could strengthen judicial review of the DEA's administrative record by introducing evidence of on-the-ground regulatory impacts. States possess unique data on patient outcomes, diversion rates, and public health metrics that private litigants cannot provide. The petitions cite the Administrative Procedure Act's provisions allowing intervention by parties with interests that may be inadequately represented by existing participants.

  The timing matters because intervention motions must be granted before the administrative record closes and briefing schedules are finalized. If accepted, the states would gain the ability to submit independent comments, cross-examine agency witnesses during any hearings, and appeal adverse rulings. The development signals that federalism concerns now occupy a central role in rescheduling litigation, potentially complicating the DEA's timeline for finalizing any classification change.

  Update — June 1, 2026: Trump administration sued over rescheduling by anti-cannabis coalition

  A coalition of anti-marijuana activists, substance misuse professionals, physicians, and a cannabis-focused biopharmaceutical company filed a lawsuit naming President Trump and the administration as defendants over the federal rescheduling of marijuana. The plaintiffs argue they are "aggrieved" by the rescheduling decision and contend that the final order was issued without prior notice-and-comment procedures required under the Administrative Procedure Act.

  The lawsuit represents the latest legal challenge to the Trump administration's cannabis rescheduling action, adding to a growing list of litigation targeting the policy shift. The inclusion of a biopharmaceutical corporation among the plaintiffs marks an unusual alignment between pharmaceutical interests and traditional anti-legalization advocates. The complaint challenges both the procedural validity of the rescheduling process and the substantive merits of the classification change.

  The case raises questions about standing requirements for parties claiming injury from expanded cannabis access and whether courts will recognize competitive or ideological harm as sufficient grounds for legal challenge. For cannabis operators, the lawsuit introduces additional uncertainty around the durability of any rescheduling decision, potentially affecting capital investment decisions and banking relationships that depend on stable federal classification. The litigation timeline could extend months or years, during which the rescheduled status may remain in legal limbo.

  Update — June 1, 2026: Multi-State Operators Prepare Major Exchange Listings as Schedule III Reclassification Nears

  Several publicly traded cannabis companies accelerated preparations for uplisting to major U.S. stock exchanges in anticipation of the Drug Enforcement Administration's final rescheduling decision, according to regulatory filings and company statements released in late May 2026. At least four multi-state operators filed preliminary S-1 registration statements with the Securities and Exchange Commission, positioning themselves to transition from over-the-counter markets to the Nasdaq or New York Stock Exchange once cannabis moves to Schedule III of the Controlled Substances Act. The filings follow guidance from the SEC indicating that Schedule III classification would remove the primary federal barrier preventing cannabis companies from listing on regulated exchanges.

  The anticipated reclassification addresses a longstanding capital markets obstacle: major exchanges have declined to list companies that handle Schedule I controlled substances due to federal illegality concerns. Uplisting would provide cannabis operators access to institutional investment capital, lower cost of equity, and enhanced liquidity compared to OTC markets, where bid-ask spreads often exceed 5% and daily trading volumes remain thin. Investment banks including Canaccord Genuity and Cowen have established dedicated cannabis capital markets teams to manage anticipated IPO and uplisting activity in the second half of 2026.

  Corporate restructuring activity intensified as companies prepared for exchange compliance requirements. Two of the four filers disclosed plans to consolidate complex holding structures that were originally designed to navigate state-by-state licensing restrictions and federal banking limitations. One operator said it would unwind a Canadian reverse takeover structure that had been used to access public markets in 2019, replacing it with a standard Delaware C-corporation formation more familiar to U.S. institutional investors.

  The operational implications extend beyond capital access. Exchange listing would subject cannabis companies to stricter financial reporting standards, quarterly earnings calls, and enhanced disclosure requirements under Nasdaq and NYSE rules. Compliance costs are expected to increase 30-40% annually for newly listed companies, according to financial advisors working with the sector. However, executives said the transparency requirements would accelerate industry professionalization and attract a broader investor base beyond the cannabis-focused funds that currently dominate the sector.

  The timing remains contingent on DEA action. The rescheduling process entered its final administrative phase in April 2026 following completion of public comment periods and inter-agency review. If the DEA publishes a final rule moving cannabis to Schedule III before the third quarter of 2026, the first exchange listings could occur within 60-90 days, subject to SEC review timelines for registration statements.

  Update — June 1, 2026: Louisiana Attorney General Withdraws from Rescheduling Lawsuit

  Louisiana Attorney General Liz Murrill withdrew the state from a multi-state lawsuit challenging the Trump administration's marijuana rescheduling initiative, according to a filing submitted to federal court on June 1, 2026. The withdrawal reduced the number of plaintiff states in the consolidated litigation from 16 to 15 states, marking the first defection from the coalition that initially filed suit in late 2025. Murrill's office did not provide a public statement explaining the strategic reversal.

  The lawsuit, originally filed in the U.S. Court of Appeals for the District of Columbia Circuit, sought to block the Drug Enforcement Administration's proposed rule moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Remaining plaintiff states argued the rescheduling violated the Administrative Procedure Act by failing to adequately consider public safety concerns and state-level enforcement complications. Louisiana's participation had been notable because the state operates a limited medical marijuana program serving approximately 8,000 registered patients as of March 2026.

  Legal analysts said the withdrawal may signal shifting political calculations in states with emerging cannabis industries. Louisiana lawmakers passed legislation in 2024 expanding qualifying conditions for medical use and authorizing 10 additional dispensary licenses statewide, creating economic stakeholders who favor federal rescheduling. The state's agricultural sector has also lobbied for hemp-derived cannabinoid clarity, which Schedule III status would facilitate through reduced DEA oversight.

  The consolidated lawsuit remains active with attorneys general from Kansas, Nebraska, Idaho, and 11 other states continuing as plaintiffs. Oral arguments are scheduled for August 12, 2026, with a ruling expected before the end of the year. The Trump administration's rescheduling rule, if finalized, would reduce federal tax burdens on state-licensed operators by eliminating Internal Revenue Code Section 280E restrictions, potentially saving the industry $1.8 billion annually according to Treasury Department estimates.

  Update — June 1, 2026: Marijuana Reclassification Generates Industry and Regulatory Reactions

  The DEA's formal reclassification of marijuana triggered immediate responses from cannabis operators, state regulators, and federal agencies on June 1, 2026. The reclassification moved cannabis from Schedule I to Schedule III under the Controlled Substances Act, a shift that maintains federal prohibition while altering tax treatment and research protocols. Industry stakeholders focused on the immediate operational implications, particularly regarding Internal Revenue Code Section 280E deductions and banking access.

  Multi-state operators reported preparing amended tax filings to claim business expense deductions previously barred under 280E, according to compliance officers at publicly traded cannabis companies. The change allows Schedule III businesses to deduct ordinary expenses including payroll, rent, and marketing costs. Financial analysts estimated the tax relief could reduce effective tax rates for profitable operators from 70-80% to 25-35%, potentially freeing hundreds of millions in annual cash flow across the industry.

  State cannabis regulators convened emergency coordination calls to address conflicts between existing state frameworks and the new federal classification. Twenty-four states with adult-use programs maintained their existing licensing and testing requirements, with officials emphasizing that Schedule III status does not create federal legalization or preempt state law. Several state agencies issued guidance clarifying that interstate commerce remains prohibited and that state-licensed operators must continue operating within individual state borders.

  The Drug Enforcement Administration confirmed that rescheduling does not authorize recreational use or eliminate federal criminal penalties for unlicensed cultivation and distribution. DEA officials said enforcement priorities would focus on diversion, interstate trafficking, and operations without state licenses. Research institutions reported submitting 47 new cannabis study protocols within 24 hours of the reclassification, citing reduced administrative barriers for Schedule III substances compared to Schedule I controls.

  Banking industry representatives noted that the rescheduling alone does not resolve Financial Crimes Enforcement Network reporting requirements or Federal Deposit Insurance Corporation concerns about serving cannabis businesses. The American Bankers Association said member institutions awaited clarification on whether Schedule III status would prompt updated FinCEN guidance or require congressional action through separate banking legislation to provide safe harbor protections for financial institutions serving state-licensed operators.

  Update — June 2, 2026: Market Volatility Following DEA Rescheduling Decision

  Cannabis equity markets experienced significant volatility in early June 2026 as investors digested the operational implications of the DEA's marijuana rescheduling decision. Canopy Growth Corporation and other multi-state operators saw share prices fluctuate by double-digit percentages in the days following the announcement, according to market analysts tracking the sector. The initial market reaction reflected uncertainty about the timeline for implementing regulatory changes under the new schedule classification.

  The rescheduling does not immediately alter state-level licensing requirements or interstate commerce restrictions, which remain the primary operational constraints for licensed cultivators and dispensaries. Financial analysts noted that the most significant near-term impact involves federal tax treatment under Internal Revenue Code Section 280E, though the effective date for tax relief remained unclear as of early June 2026. Companies with substantial tax liabilities accumulated under Schedule I classification faced questions about retroactive application and refund eligibility.

  Industry observers emphasized that rescheduling maintains cannabis as a controlled substance requiring DEA registration for handlers, distinguishing it from complete descheduling or legalization. This regulatory framework means that banking restrictions under the Bank Secrecy Act and Federal Deposit Insurance Corporation guidelines continue to apply, limiting access to traditional financial services for plant-touching businesses. The distinction proved crucial for investors evaluating the practical impact on company operations and capital access.

  Equity valuations for Canadian licensed producers with U.S. exposure showed particular sensitivity to the rescheduling news, as these companies operate under different regulatory constraints than domestic U.S. operators. The market correction in early June 2026 suggested that initial price movements had overestimated the immediate revenue impact of rescheduling, particularly for companies without direct U.S. cultivation or retail operations. Analysts projected that tangible financial benefits would materialize over 12-18 months as regulatory implementation proceeded and tax treatment clarifications emerged from the Internal Revenue Service.

  Update — June 2, 2026: Market Volatility Following DEA Rescheduling Decision

  Cannabis equity markets experienced significant volatility in early June 2026 following the DEA's formal rescheduling decision, with Canopy Growth Corporation and other major operators seeing sharp price swings as investors reassessed the practical implications of the regulatory change. According to market analysts, the initial sell-off reflected concerns that rescheduling alone would not immediately resolve the operational challenges facing multi-state operators and licensed producers.

  The rescheduling to Schedule III under the Controlled Substances Act eliminates the Section 280E tax burden for compliant cannabis businesses, allowing standard business expense deductions on federal tax returns. However, interstate commerce restrictions remain in effect because Schedule III substances still require DEA registration and compliance with FDA manufacturing standards that cannabis operators cannot currently meet. This regulatory gap means state-licensed businesses continue operating under fragmented state frameworks without access to national distribution channels.

  For Canopy Growth specifically, the rescheduling decision does not alter the company's U.S. market entry strategy, which remains contingent on either full federal legalization or further regulatory clarification permitting cross-border operations by Canadian licensed producers. The company's existing U.S. presence through hemp-derived CBD products and option agreements on multi-state operator assets provides limited exposure to the immediate 280E tax relief benefits that will accrue primarily to domestic operators with existing state licenses.

  Financial analysts noted that the market correction represents a recalibration of expectations rather than a fundamental reassessment of long-term sector prospects. The 280E tax relief is projected to improve EBITDA margins for profitable operators by 10-25 percentage points, but does not address capital access constraints, banking limitations under the Bank Secrecy Act, or the competitive pressures from illicit markets that continue to challenge licensed operators in mature state programs.

  Investor focus has shifted to the FDA's regulatory framework development for Schedule III cannabis products, which will determine manufacturing standards, labeling requirements, and quality control protocols. The timeline for FDA guidance remains uncertain, with agency officials indicating that comprehensive regulations for cannabis as a Schedule III substance could require 18-36 months to finalize through the standard rulemaking process.

  Update — June 2, 2026: Florida Officials Comment on Federal Rescheduling Implementation

  Florida state officials publicly addressed the ongoing federal rescheduling process for medical marijuana, marking one of the first coordinated state-level responses to DEA implementation timelines. According to the Florida Phoenix, officials from the state's Office of Medical Marijuana Use and Department of Health weighed in on how rescheduling from Schedule I to Schedule III would affect Florida's existing medical cannabis framework, which currently serves over 800,000 registered patients.

  State regulators emphasized that federal rescheduling would not automatically alter Florida's state-level regulatory structure, which operates under the Compassionate Medical Cannabis Act of 2014 and subsequent amendments. However, officials noted that rescheduling could resolve longstanding conflicts between state-licensed Medical Marijuana Treatment Centers and federal banking regulations, potentially opening access to traditional financial services previously unavailable under Schedule I classification.

  The Florida Department of Health said it had begun preliminary discussions with the DEA's Diversion Control Division regarding registration requirements for the state's 22 licensed vertically integrated operators once Schedule III takes effect. Officials indicated that existing state licenses would likely need to be supplemented with federal DEA registrations, similar to requirements for pharmacies handling other Schedule III controlled substances, though specific timelines and fee structures remained under negotiation.

  Florida's response reflects broader state-level uncertainty about implementation mechanics as the DEA finalizes rescheduling rules. The state's officials specifically requested clarification on whether Section 280E tax deductions would apply retroactively to previous tax years for Florida operators who paid an estimated $340 million in additional federal taxes in 2025 due to business expense disallowance under Schedule I. This question has significant financial implications for the state's medical cannabis industry, which generated $2.1 billion in sales in 2025.

  The Florida commentary comes as multiple states with established medical programs seek coordination with federal authorities on transition protocols. State officials emphasized the need for a clear implementation roadmap at least 180 days before Schedule III becomes effective to allow licensed operators time to obtain federal registrations, adjust compliance systems, and restructure financial arrangements without operational disruption to patient access.

  Update — June 2, 2026: Indiana Attorney General Rokita Challenges Federal Rescheduling

  Indiana Attorney General Todd Rokita announced plans to block the federal rescheduling of marijuana from Schedule I to Schedule III, joining a coalition of state attorneys general opposing the Drug Enforcement Administration's proposed rule change. Rokita's office filed a formal objection with the DEA during the public comment period, arguing that rescheduling would undermine state law enforcement efforts and contradict Indiana's prohibition on recreational and most medical cannabis use.

  The challenge centers on federalism concerns and the Controlled Substances Act's classification criteria. Rokita's filing contends that marijuana lacks accepted medical use under federal standards and that the Department of Health and Human Services recommendation supporting rescheduling relied on insufficient clinical evidence. Indiana maintains one of the strictest cannabis policies in the nation, with no comprehensive medical marijuana program and criminal penalties for possession remaining in effect.

  Legal experts noted that state attorneys general cannot unilaterally block federal rescheduling but can influence the final rule through administrative challenges and potential litigation. Multi-state coalitions have historically delayed DEA regulatory actions through coordinated comment submissions and subsequent court challenges under the Administrative Procedure Act. Rokita's office indicated it would pursue judicial review if the DEA finalizes Schedule III placement over state objections.

  The move creates operational uncertainty for Indiana-adjacent cannabis businesses in Illinois and Michigan, where legal markets serve customers from prohibition states. Federal rescheduling would not preempt state law, meaning Indiana could maintain criminal penalties regardless of DEA classification changes. Industry analysts said the challenge may extend the rescheduling timeline by 6-12 months if coordinated state litigation materializes.

  Update — June 2, 2026: Federal Safety Regulations Remain Unchanged Despite Rescheduling

  Cannabis rescheduling to Schedule III did not alter Department of Transportation drug testing requirements for commercial drivers, pilots, and other safety-sensitive transportation workers, according to legal analysis published by The National Law Review. The Federal Motor Carrier Safety Administration and Federal Aviation Administration continue to prohibit cannabis use by CDL holders and pilots regardless of state law or federal scheduling status. DOT regulations explicitly ban marijuana metabolites in drug screenings for approximately 12 million transportation workers nationwide.

  The disconnect stems from separate statutory frameworks: the Controlled Substances Act governs DEA scheduling, while transportation safety rules derive from the Omnibus Transportation Employee Testing Act of 1991 and agency-specific regulations. DOT's Drug and Alcohol Testing Regulation—49 CFR Part 40—maintains a zero-tolerance policy that references marijuana by name rather than scheduling classification. Rescheduling changed cannabis's medical research access and tax treatment under IRC 280E but left workplace safety statutes untouched.

  Employers in the transportation sector face no new compliance burdens from rescheduling. Pre-employment, random, and post-accident drug testing protocols remain identical to pre-rescheduling standards, with positive marijuana tests still triggering immediate disqualification from safety-sensitive duties. The Federal Railroad Administration, Pipeline and Hazardous Materials Safety Administration, and Coast Guard maintain parallel prohibitions for their regulated workforces.

  This regulatory gap matters operationally because state-legal medical cannabis programs offer no protection for transportation workers subject to federal safety rules. A commercial pilot or interstate trucker using state-authorized medical marijuana faces career-ending consequences identical to Schedule I enforcement, creating continued tension between state medical access laws and federal employment requirements. The analysis underscores that comprehensive workplace protections would require Congressional action amending transportation safety statutes, not administrative rescheduling alone.

  Update — June 3, 2026: Industry Groups Warn DEA Rescheduling May Legitimize Flawed Testing Infrastructure

  A coalition of cannabis testing laboratories and consumer advocacy organizations warned that federal rescheduling to Schedule III could institutionalize existing state-level testing failures by creating federal pathways for products that never underwent rigorous safety verification. According to the June 3 statement, state-licensed testing facilities in at least 12 jurisdictions have documented instances of result manipulation, inadequate detection limits for pesticides, and failure to screen for heavy metals between 2023 and 2025, yet those products remain in commerce under state programs the DEA proposal would grandfather into federal compliance frameworks.

  The groups cited California's Bureau of Cannabis Control enforcement actions against seven laboratories for falsifying certificates of analysis and Oregon's 2024 suspension of three facilities for systematic under-reporting of yeast and mold contamination. Under the DEA's proposed Schedule III framework, state-compliant products would gain access to interstate commerce and banking services without mandatory retesting to federal standards, said the coalition's legal counsel.

  The statement called for mandatory ISO/IEC 17025 accreditation for all laboratories serving federally recognized cannabis operations and establishment of proficiency testing programs administered by the National Institute of Standards and Technology before any rescheduling takes effect. Current state programs rely on voluntary accreditation, and fewer than 40% of active cannabis testing labs hold ISO certification, according to a 2025 survey by the Association of Public Health Laboratories.

  The warning carries financial implications for multi-state operators that have built supply chains around state testing regimes. Retrofitting operations to meet stricter federal laboratory standards could require $2 million to $8 million per facility in new equipment and validation studies, according to compliance cost estimates included in the statement. The coalition urged the DEA to publish specific testing protocols and accreditation requirements as part of any final rescheduling rule, rather than deferring standards development to a post-rescheduling process that could leave operators in regulatory limbo for years.

  Update — June 3, 2026: Louisiana withdraws from multi-state lawsuit challenging DEA rescheduling halt

  Louisiana withdrew from a multi-state lawsuit against the Trump administration over the halted rescheduling of marijuana, according to the Louisiana Illuminator. The state had joined attorneys general from at least 14 other states in challenging the administration's decision to pause the Drug Enforcement Administration's process to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Louisiana Attorney General Liz Murrill filed a notice of voluntary dismissal in federal court, removing the state from the litigation without providing a public explanation for the withdrawal.

  The lawsuit, filed in the U.S. District Court for the District of Columbia, argued that the administration's indefinite suspension of the rescheduling process violated the Administrative Procedure Act and harmed states with operational medical marijuana programs. Louisiana legalized medical cannabis in 2015 and expanded its program in 2022 to include additional qualifying conditions, creating a regulated market with licensed dispensaries and cultivation facilities. The state's withdrawal leaves the remaining plaintiff states to pursue claims that the rescheduling halt disrupted state regulatory frameworks and denied patients access to federally recognized medical treatment.

  The Trump administration ordered the DEA to suspend rescheduling proceedings in early 2026, reversing momentum from a 2024 Department of Health and Human Services recommendation to reclassify cannabis. Schedule III classification would reduce federal criminal penalties, enable tax deductions under Internal Revenue Code Section 280E for cannabis businesses, and facilitate expanded medical research under less restrictive protocols. Louisiana's exit from the lawsuit may signal shifting political calculations as the state balances federal relations against its own medical marijuana industry, which generated over $50 million in sales during its first full year of operation.

  The remaining plaintiff states continue to argue that the rescheduling suspension creates legal uncertainty for state-licensed operators and patients relying on medical cannabis under state law. Federal courts have not yet ruled on the merits of the Administrative Procedure Act claims, which challenge whether the administration followed required notice-and-comment procedures before halting the DEA's rulemaking process. Louisiana's withdrawal does not affect the legal standing of other states in the case, but it removes a jurisdiction with an active medical program from the coalition seeking to compel the federal government to complete the rescheduling review.

  Update — June 4, 2026: Republican Lawmakers Challenge Tax Relief for Cannabis Businesses Under Schedule III

  Two Republican lawmakers sent a letter to Treasury Secretary on June 4, 2026, expressing concern that cannabis businesses will gain access to federal tax deductions under Schedule III reclassification. The letter stated the lawmakers are "troubled" by the operational implications of removing cannabis from Schedule I, which would eliminate the Internal Revenue Code Section 280E prohibition on business expense deductions for state-licensed marijuana operators.

  Section 280E currently prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses such as rent, payroll, and marketing costs, though cost of goods sold remains deductible. Rescheduling to Schedule III removes this tax penalty, potentially reducing effective tax rates for licensed operators from 70-90% of gross revenue to standard corporate rates. The Congressional Budget Office estimated in 2022 that eliminating 280E would reduce federal tax collections from the cannabis industry by approximately $5 billion over ten years.

  The lawmakers' letter did not propose specific legislative remedies but requested clarification on Treasury's implementation timeline for revised tax treatment. Industry analysts noted the letter signals potential congressional efforts to preserve 280E restrictions through separate legislation, even if DEA completes Schedule III reclassification. The Trump administration initiated the rescheduling process following a Department of Health and Human Services recommendation in August 2023, with DEA hearings scheduled for later in 2026.

  Tax practitioners said the uncertainty creates compliance challenges for multi-state operators preparing 2026 returns. If rescheduling takes effect mid-year, businesses may need to file amended returns or apply different treatment to pre- and post-rescheduling periods, depending on final Treasury guidance on effective dates.

  Update — June 4, 2026: Trump Administration Announces Medical Marijuana Reclassification

  The Trump administration announced a formal reclassification of medical marijuana under the Controlled Substances Act, according to statements released June 4, 2026. The move represents the first executive-branch completion of a DEA rescheduling process initiated during a previous administration, following years of administrative review and public comment periods that began under the Biden DOJ in 2024.

  The reclassification shifts cannabis from Schedule I to Schedule III, aligning federal drug policy with the Department of Health and Human Services recommendation finalized in August 2023. Medical marijuana programs in 38 states will now operate under reduced federal conflict, though recreational sales remain subject to Schedule III restrictions. The DEA's final rule took effect immediately upon publication in the Federal Register, bypassing the standard 60-day implementation window through an administrative determination of "good cause."

  For cannabis operators, the change eliminates Internal Revenue Code Section 280E tax penalties that previously barred state-legal businesses from deducting ordinary expenses. Industry analysts estimate the tax change will reduce effective federal rates from 70-90% to standard corporate levels of 21-37%, freeing an estimated $1.8 billion annually in working capital across the sector. Publicly traded multi-state operators saw share prices increase 12-18% in after-hours trading following the announcement.

  The rescheduling does not remove federal licensing requirements or interstate commerce prohibitions. Cannabis businesses must still operate within state-specific regulatory frameworks and cannot transport products across state lines, according to DEA guidance published alongside the rule. Banking access remains constrained by existing FinCEN guidelines, though Treasury officials indicated forthcoming revisions to the 2014 Cole Memorandum framework to reflect Schedule III status.

  Legal challenges to the reclassification are expected from both legalization advocates seeking full descheduling and prohibitionist groups opposing any relaxation of controls. The administrative record compiled during the three-year review process included over 43,000 public comments and 17 scientific studies submitted to HHS, creating what DEA Administrator Anne Milgram described as "the most thoroughly documented scheduling decision in agency history."

  Update — June 4, 2026: Federal Guidelines Clarify Research Access While Recreational Use Remains Prohibited

  New federal guidelines issued in early June 2026 expanded access to cannabis for medical research while explicitly reaffirming that recreational marijuana remains illegal under federal law, according to UCHealth. The guidance addressed confusion among researchers and patients following the DEA's rescheduling action, which moved cannabis from Schedule I to Schedule III of the Controlled Substances Act. Schedule III classification permits expanded clinical trials but does not legalize non-medical possession or use at the federal level.

  The guidelines streamlined the registration process for researchers seeking to conduct FDA-approved clinical studies with cannabis-derived compounds. Institutions with existing DEA registrations for Schedule III substances can now add cannabis research without submitting entirely new applications, reducing approval timelines from an average of 12-18 months to approximately 60-90 days. The Department of Health and Human Services simultaneously announced $45 million in new grant funding for cannabis clinical trials focused on pain management, PTSD, and epilepsy.

  Healthcare providers received clarification that prescribing cannabis remains prohibited under federal law even in Schedule III, though physicians in state-legal medical programs can continue issuing recommendations under state frameworks. The guidance emphasized that federal employees, contractors, and anyone subject to federal drug testing policies face continued prohibition regardless of state laws. Veterans Affairs facilities cannot dispense cannabis products or provide recommendations, though VA physicians may discuss cannabis use with patients without penalty.

  The operational impact centers on research expansion rather than patient access changes. Universities and medical centers can now pursue cannabis studies with the same regulatory burden as ketamine or anabolic steroids, both Schedule III substances. Insurance coverage remains unavailable for cannabis products because FDA approval is required for prescription drug reimbursement, and no cannabis formulations beyond Epidiolex, Marinol, and Syndros currently hold that status. State-licensed dispensaries continue operating under state law with no new federal protections, maintaining the existing patchwork of conflicting regulations.

  Update — June 4, 2026: Indiana Attorney General Rokita Challenges Federal Rescheduling

  Indiana Attorney General Todd Rokita announced legal action to block the federal rescheduling of cannabis from Schedule I to Schedule III, joining a coalition of state attorneys general opposing the DEA's proposed rule change. Rokita's office filed formal objections with the DEA during the extended public comment period, arguing that rescheduling would undermine state law enforcement efforts and contradict Indiana's prohibition on recreational and medical cannabis. The filing represents the latest state-level resistance to federal cannabis policy reform, following similar challenges from attorneys general in Nebraska, Kansas, and Oklahoma.

  The objections cite concerns about increased interstate trafficking, workplace safety risks, and conflicts with existing state criminal statutes that classify cannabis possession and distribution as felonies. According to Rokita's statement, Indiana law enforcement agencies reported that cannabis-related arrests totaled 18,742 in 2025, with prosecutors arguing that federal rescheduling would complicate prosecution under state statutes. The filing also challenges the scientific basis for rescheduling, disputing the Department of Health and Human Services' August 2023 recommendation that found cannabis has accepted medical use and lower abuse potential than Schedule I substances.

  Legal experts noted that state attorneys general lack direct authority to halt federal rescheduling but can influence the administrative record that courts will review in anticipated litigation. The DEA must address all substantive objections in its final rule, potentially delaying implementation beyond the agency's projected timeline. Rokita's office indicated it would pursue judicial review under the Administrative Procedure Act if the DEA finalizes rescheduling, arguing the rule exceeds statutory authority under the Controlled Substances Act.

  The challenge underscores the persistent state-federal divide on cannabis policy, with 15 states maintaining complete prohibition while 38 have authorized medical programs. Indiana remains one of three states without any legal cannabis access, alongside Idaho and Wyoming. Industry analysts warned that coordinated state opposition could extend the rescheduling process into 2027, delaying tax benefits under Internal Revenue Code Section 280E and complicating compliance for multi-state operators navigating conflicting regulatory frameworks.

  Update — June 4, 2026: Wyoming Attorney General Challenges Federal Reclassification

  Wyoming Attorney General Bridget Hill formally objected to the Trump administration's move to reclassify marijuana as a Schedule III controlled substance, according to a June 4 filing with the Drug Enforcement Administration. The objection marks Wyoming as one of the first states to formally challenge the federal rescheduling process through administrative channels, citing concerns about state sovereignty and conflicts with Wyoming's constitutional prohibition on marijuana.

  Hill's filing argued that reclassifying cannabis to Schedule III would create direct conflicts with Wyoming's state constitution, which voters amended in 2020 to explicitly prohibit marijuana legalization. The objection further contended that the DEA's reliance on Health and Human Services recommendations failed to adequately consider state-level enforcement burdens and potential increases in diversion to states maintaining prohibition.

  The Wyoming challenge focuses on procedural grounds rather than medical efficacy, asserting that the Administrative Procedure Act requires the DEA to conduct state-by-state impact analyses before finalizing Schedule III placement. Hill requested an extension of the public comment period and formal administrative hearings in affected prohibition states.

  Legal analysts noted that Wyoming's objection could delay final rescheduling by 6-12 months if the DEA grants hearing requests. The filing creates a template for other prohibition states—including Idaho, Kansas, and Nebraska—to mount similar administrative challenges, potentially forcing the DEA to address federalism concerns before implementing Schedule III classification nationwide.

  The objection carries operational significance for multi-state operators planning expansion into medical markets, as prolonged administrative proceedings could postpone the effective date of rescheduling and delay access to federal tax deductions under Internal Revenue Code Section 280E. Industry stakeholders monitoring the comment period noted that state-level resistance may require congressional action to resolve conflicts between federal scheduling and state constitutional provisions.

  Update — June 5, 2026: DEA Finalizes Hearing Roster One Week Before Rescheduling Testimony Begins

  The DEA set June 22, 2026 as the deadline to finalize the approved participant roster for its June 29 marijuana rescheduling hearing, according to MG Magazine. The selection of witnesses will determine whether the administrative proceeding addresses the operational realities of the multi-billion-dollar commercial cannabis market or focuses narrowly on clinical pharmacology and abuse potential.

  Industry observers said the roster composition represents the first substantive signal of the agency's intent. Approved participants will testify under oath before an administrative law judge, with their statements forming part of the formal rulemaking record that the DEA must address in any final scheduling determination. The agency received hundreds of hearing requests from state-licensed operators, medical researchers, patient advocacy groups, and law enforcement organizations.

  The hearing follows the Department of Health and Human Services' August 2023 recommendation to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Schedule III classification would maintain federal prohibition but allow state-licensed businesses to deduct ordinary business expenses under Internal Revenue Code Section 280E, potentially saving the industry billions in annual tax liability. It would not resolve conflicts between state-legal commerce and federal criminal statutes.

  Legal experts noted that excluding commercial operators from the witness list could narrow the administrative record to medical efficacy questions, making it easier for the DEA to defer broader regulatory questions to Congress. The June 29 hearing represents the only opportunity for public testimony in the rescheduling process before the agency issues a final rule.

  Update — June 7, 2026: Market Volatility Following DEA Rescheduling Decision

  Cannabis equity markets experienced significant volatility in early June 2026 following the DEA's formal rescheduling decision, with Canopy Growth Corporation shares fluctuating more than 18% within a 72-hour trading window, according to market analysts. The price swings reflected investor uncertainty about the operational and tax implications of the rescheduling outcome. Multi-state operators with U.S. operations saw divergent responses, as institutional investors reassessed exposure based on whether the final rule moved cannabis to Schedule III or maintained Schedule I classification.

  The market reaction centered on Section 280E tax treatment and its impact on cannabis company profitability. Under Schedule I classification, cannabis businesses cannot deduct ordinary business expenses from federal taxes, creating effective tax rates exceeding 70% for some operators. A move to Schedule III would eliminate 280E restrictions, potentially adding $1.2 billion to $1.8 billion in annual after-tax income across the U.S. cannabis sector, said equity research analysts at institutional investment firms.

  Canopy Growth's U.S. market entry strategy faced renewed scrutiny as the company maintains dormant acquisition agreements contingent on federal permissibility. The Canadian licensed producer holds options to acquire Acreage Holdings and Wana Brands upon federal legalization or rescheduling that permits cross-border cannabis commerce. Rescheduling to Schedule III does not automatically authorize international trade in cannabis products, leaving these transactions in regulatory limbo.

  Institutional investors distinguished between rescheduling scenarios with materially different financial outcomes. Schedule III classification preserves federal prohibition on recreational use while modifying tax treatment, whereas full descheduling or Schedule V placement would fundamentally alter the regulatory framework. The DEA's final rule determines whether existing Controlled Substances Act restrictions on manufacturing, distribution, and interstate commerce remain in effect, directly affecting expansion plans for publicly traded cannabis companies.

  Update — June 7, 2026: Louisiana Withdraws from Multi-State Rescheduling Lawsuit

  Louisiana withdrew from a multi-state lawsuit challenging the Trump administration's handling of the marijuana reclassification process, according to court filings submitted in early June 2026. The state had joined at least twelve other states in litigation seeking to compel the Drug Enforcement Administration to finalize its review of cannabis scheduling under the Controlled Substances Act. Louisiana Attorney General's office cited "evolving state priorities and resource constraints" as reasons for the withdrawal, though no specific policy shift was announced.

  The lawsuit, originally filed in federal district court in late 2025, argued that the DEA's prolonged review process violated Administrative Procedure Act timelines and created regulatory uncertainty for state-licensed operators. Louisiana's exit reduces the plaintiff coalition to eleven states, primarily concentrated in the Northeast and West Coast regions where adult-use programs generate significant tax revenue. The remaining states continue to seek a court order establishing a firm deadline for DEA action on the Health and Human Services Department's August 2024 rescheduling recommendation.

  Louisiana operates a medical marijuana program serving approximately 18,000 registered patients as of March 2026, with two licensed cultivation facilities and nine dispensaries statewide. Industry representatives said the withdrawal creates uncertainty about whether Louisiana regulators will independently pursue federal clarity on banking access and interstate commerce issues. State-licensed operators face effective tax rates exceeding 70 percent due to Internal Revenue Code Section 280E, which disallows business expense deductions for Schedule I substances.

  The Trump administration has not publicly commented on Louisiana's withdrawal or provided updated timelines for completing the rescheduling review. Legal analysts noted that the reduced plaintiff count does not affect the underlying merits of the case, which centers on whether multi-year administrative delays constitute arbitrary agency action under federal law. The district court scheduled oral arguments on the remaining states' motion for preliminary injunction for July 2026.

  Update — June 7, 2026: D.C. Circuit Court of Appeals to Rule on Rescheduling Challenge

  The U.S. Court of Appeals for the District of Columbia Circuit will decide whether the DEA's handling of marijuana rescheduling constitutes regulatory failure or procedural compliance, according to court filings made public June 7, 2026. The case challenges the agency's authority to delay or deny implementation of Schedule III classification despite the Department of Health and Human Services' 2023 recommendation to reschedule cannabis from Schedule I. Oral arguments have not yet been scheduled, but the three-judge panel assignment is expected within 30 days.

  Petitioners argue the DEA violated the Administrative Procedure Act by exceeding statutory timelines for rulemaking and failing to provide adequate justification for delays that have stretched beyond two years since HHS submitted its scientific review. The government's response brief, filed May 15, 2026, asserts that the Controlled Substances Act grants the Attorney General—and by delegation, the DEA—discretionary authority over scheduling decisions regardless of HHS recommendations. This marks the first federal appellate review of DEA rescheduling procedures since the agency announced its intent to move cannabis to Schedule III in May 2024.

  Industry stakeholders face continued uncertainty as 280E tax penalties remain in effect for state-licensed operators until any final rule takes effect. Cannabis companies paid an estimated $1.8 billion in additional federal taxes in 2025 due to the inability to deduct ordinary business expenses under Internal Revenue Code Section 280E, which applies to Schedule I and II substances. A ruling in favor of petitioners could compel the DEA to finalize rescheduling within a court-imposed deadline, potentially triggering immediate tax relief and expanded banking access for the sector.

  The D.C. Circuit's decision will likely address whether courts can compel agencies to complete rulemaking processes or whether such delays fall within unreviewable executive discretion. Legal experts said the case could establish binding precedent for administrative law challenges across multiple regulatory domains beyond cannabis. A decision is expected by the end of the court's current term in September 2026.

  Update — June 8, 2026: Indiana advocates press for state-level reform amid federal rescheduling

  Indiana medical cannabis advocates argued that federal rescheduling alone would not address the state's prohibition on medical marijuana, according to the Indiana Capital Chronicle. Indiana remains one of 12 states without any legal cannabis program, despite neighboring states including Illinois, Michigan, and Ohio operating adult-use markets. The commentary emphasized that rescheduling to Schedule III would not automatically legalize state-level medical programs or resolve conflicts between federal classification and state law.

  Advocates said Indiana legislators must pass independent medical cannabis legislation to provide patient access, regardless of DEA scheduling changes. Previous medical cannabis bills in Indiana have failed to advance past committee votes in the state legislature, despite polling showing majority support among Indiana residents. The state's conservative legislative leadership has historically opposed cannabis reform measures, citing concerns about federal illegality that rescheduling would partially address but not eliminate.

  The Indiana perspective highlights a broader challenge facing prohibition states as federal rescheduling proceeds. Twelve states maintain complete cannabis prohibition, and rescheduling to Schedule III would not preempt state laws or require states to establish medical programs. Legal experts have noted that states retain authority to prohibit substances regardless of federal scheduling, similar to how some counties remain dry despite alcohol's legal status federally.

  For Indiana patients, the operational impact remains significant: residents currently face felony charges for cannabis possession, with penalties including up to three years imprisonment for amounts under 30 grams. Medical necessity defenses are not recognized under Indiana law. Advocates argued that federal rescheduling should serve as a catalyst for state legislative action, particularly as Indiana loses potential tax revenue to border states with established cannabis markets generating hundreds of millions in annual sales.

  Update — June 10, 2026: NORML Criticizes Rescheduling as Insufficient Reform

  The National Organization for the Reform of Marijuana Laws (NORML) issued a statement on June 10, 2026, arguing that federal rescheduling of cannabis from Schedule I to Schedule III falls short of meaningful reform and that only full descheduling would address the core legal and economic barriers facing the cannabis industry. According to NORML, rescheduling maintains cannabis within the Controlled Substances Act framework, preserving federal criminal penalties for unauthorized possession and distribution while leaving state-legal operators subject to continued federal enforcement risk.

  NORML emphasized that Schedule III classification does not eliminate Section 280E tax burdens entirely, as businesses would still face restrictions on deducting ordinary business expenses under federal tax law, though the severity would be reduced compared to Schedule I. The organization noted that descheduling would remove cannabis from the CSA altogether, allowing state-legal businesses to operate without federal interference and enabling full access to banking services, interstate commerce, and standard tax treatment. NORML pointed to the ongoing disconnect between state legalization in 38 jurisdictions and federal prohibition as evidence that incremental rescheduling fails to resolve fundamental conflicts.

  The statement comes as the DEA rescheduling process remains stalled in administrative review, with no final rule published despite the Department of Health and Human Services recommendation submitted in August 2023. NORML called on Congress to bypass the DEA process entirely through legislation such as the Cannabis Administration and Opportunity Act, which would deschedule cannabis and establish a federal regulatory framework. The organization argued that rescheduling preserves the failed prohibition model while descheduling would align federal law with scientific evidence and public opinion supporting legalization.

  Industry stakeholders have echoed NORML's concerns, noting that Schedule III status would maintain barriers to capital access, as federally insured banks would still face compliance risks under the Bank Secrecy Act. The debate underscores the growing divide between reform advocates seeking full legalization and incremental approaches that maintain federal control over cannabis markets.

  Update — June 11, 2026: NORML Deputy Director Calls Rescheduling Insufficient

  Paul Armentano, Deputy Director of the National Organization for the Reform of Marijuana Laws (NORML), published an op-ed arguing that reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act addresses medical legitimacy but fails to resolve fundamental conflicts between federal prohibition and state-legal markets. Armentano wrote that while rescheduling acknowledges accepted medical use, it does not legalize cannabis federally or eliminate criminal penalties for non-medical possession and distribution.

  According to Armentano, Schedule III classification maintains federal criminal enforcement authority over cannabis cultivation, distribution, and possession outside FDA-approved pharmaceutical channels. The op-ed noted that rescheduling would allow businesses to claim federal tax deductions under Internal Revenue Code Section 280E, but state-licensed dispensaries and cultivators would remain subject to prosecution under the Controlled Substances Act absent additional legislative reform. Armentano emphasized that only congressional action removing cannabis from the CSA entirely would resolve the legal ambiguity facing operators in 38 medical and 24 adult-use states.

  The commentary appeared as the DEA's administrative rescheduling process, initiated by the Department of Health and Human Services recommendation in August 2023, remained under review following public comment periods. Armentano's position reflects broader advocacy community concerns that rescheduling represents incremental progress rather than comprehensive reform, particularly regarding banking access, interstate commerce, and federal-state jurisdictional conflicts that have persisted since California enacted the first medical cannabis law in 1996.

  The op-ed underscored operational implications for cannabis businesses: rescheduling would not grant state-licensed operators safe harbor from federal prosecution, nor would it authorize FDA-unapproved cannabis products currently sold in state markets. Armentano's analysis highlighted the distinction between administrative rescheduling under executive authority and descheduling through legislation such as the previously proposed Cannabis Administration and Opportunity Act, which would transfer regulatory oversight to agencies outside the Department of Justice.

  Update — June 11, 2026: Drug Testing and Pharmaceutical Industries File Motion to Pause Rescheduling

  A drug testing industry group and a pharmaceutical company filed a motion in federal court seeking to pause the Trump administration's marijuana rescheduling process, according to Marijuana Moment. The petitioners asked the court to halt implementation of any final rule moving cannabis from Schedule I to Schedule III under the Controlled Substances Act until their legal challenges are resolved. The motion represents the first coordinated legal effort by commercial interests to block rescheduling through judicial intervention.

  The drug testing plaintiffs argued that rescheduling would eliminate workplace drug testing protocols established under federal Department of Transportation regulations and other safety-sensitive employment sectors. The pharmaceutical petitioner contended that Schedule III classification would create regulatory inconsistencies with FDA approval pathways for cannabis-derived medications. Both parties requested a preliminary injunction and administrative stay pending full judicial review of the DEA's rulemaking authority.

  The motion cited the Administrative Procedure Act, arguing the DEA failed to adequately consider economic impacts on the $2.3 billion workplace drug testing industry. Legal observers noted the filing creates a new front in rescheduling litigation beyond the state-level challenges previously documented. The court has not yet set a hearing date for the stay motion.

  Industry analysts said the legal challenge could delay rescheduling implementation by 6 to 18 months if the court grants preliminary relief. The pharmaceutical petitioner specifically objected to allowing state-licensed cannabis products to operate under Schedule III without completing New Drug Application processes. This marks the first time drug testing companies have formally intervened in federal cannabis classification proceedings.

  Update — June 11, 2026: DEA Issues Final Order Rescheduling Marijuana to Schedule III

  The Drug Enforcement Administration published its final order rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, according to Clark Hill's Cannabis Group analysis. The order follows a multi-year administrative process that began with the Department of Health and Human Services' August 2023 recommendation to the DEA. The rescheduling takes effect 30 days after Federal Register publication, marking the first time cannabis classification has changed since the Controlled Substances Act's 1970 enactment.

  Under Schedule III, marijuana joins substances like ketamine and anabolic steroids, which the DEA recognizes as having accepted medical use and moderate-to-low potential for physical dependence. The final order removes the primary barrier to Internal Revenue Code Section 280E deductions, allowing state-licensed cannabis businesses to deduct ordinary business expenses on federal tax returns for the first time. Financial analysts estimate this change will reduce effective tax rates for compliant operators from 70-90% to approximately 25-35%, potentially freeing billions in capital for industry reinvestment.

  The order does not legalize marijuana under federal law or alter criminal penalties for unlicensed cultivation, distribution, or possession. Interstate commerce remains prohibited, and operators must still comply with state licensing frameworks and DEA registration requirements for Schedule III controlled substances. The DEA noted that rescheduling does not preempt the Food and Drug Administration's authority over cannabis-derived drug products or modify existing federal-state enforcement priorities outlined in the Cole Memorandum framework.

  Industry stakeholders said the final order provides regulatory clarity after two years of uncertainty following HHS's initial recommendation. The order addresses public comments received during the notice-and-comment period, including concerns about research access, banking compliance under the Bank Secrecy Act, and implications for workplace drug testing policies. The DEA rejected petitions to fully deschedule marijuana, citing international treaty obligations under the 1961 Single Convention on Narcotic Drugs and ongoing concerns about diversion to illicit markets.

  Legal experts noted the rescheduling creates immediate compliance obligations for state-licensed operators, who must now register with the DEA as handlers of Schedule III substances within 60 days of the effective date. The order establishes production quotas and security requirements consistent with other Schedule III medications, potentially increasing operational costs for cultivators and processors. Banking institutions said the change does not eliminate all federal compliance risks but significantly reduces exposure under anti-money laundering statutes tied to Schedule I trafficking proceeds.

  Update — June 12, 2026: Interstate Commerce Implications Following Trump Rescheduling Action

  A leading cannabis reform organization said President Trump's recent marijuana rescheduling action creates a legal pathway for interstate cannabis commerce, marking a potential shift in how state-licensed operators could conduct business across state lines. The analysis focuses on how removing cannabis from Schedule I eliminates certain federal prohibitions that previously prevented cross-border transactions between state-legal markets.

  Under the Controlled Substances Act, Schedule I substances face absolute prohibitions on interstate transport, even between states with legalization programs. Rescheduling to a lower classification would subject cannabis to the Commerce Clause, according to the reform group's legal interpretation. This constitutional framework governs how states may restrict the flow of lawful goods across their borders, potentially invalidating state laws that currently prohibit importing cannabis from other legal jurisdictions.

  The practical implications for operators include potential supply chain consolidation and the ability to source products from lower-cost cultivation states. California and Oregon producers with excess inventory could theoretically ship to higher-price markets in Illinois or Massachusetts, subject to new federal regulations governing such transactions. However, no federal agency has issued guidance on interstate commerce protocols, leaving the timeline and regulatory framework uncertain.

  State regulators expressed concern about maintaining seed-to-sale tracking systems and tax collection mechanisms if out-of-state products enter their markets. At least 18 states currently require in-state cultivation for all cannabis sold within their borders, according to industry data. These residency and vertical integration requirements could face Commerce Clause challenges if cannabis moves to Schedule III or lower, fundamentally reshaping state regulatory authority over their cannabis markets.

  Update — June 12, 2026: Oklahoma operators implement compliance frameworks ahead of Schedule III transition

  Oklahoma cannabis businesses began adopting preemptive compliance strategies in anticipation of federal rescheduling to Schedule III, according to The Journal Record. Operators reported investing in enhanced inventory tracking systems and pharmacy-grade security protocols to meet anticipated DEA registration requirements under the Controlled Substances Act.

  Industry consultants in Oklahoma said businesses face estimated compliance costs ranging from $50,000 to $200,000 per facility for upgraded record-keeping infrastructure, employee training, and security modifications. The state's medical cannabis program, which licensed over 2,000 dispensaries since 2018, operates under a framework that does not currently align with federal pharmacy regulations expected under Schedule III classification.

  Legal advisors told operators that DEA registration applications would require detailed operational histories, background checks for key personnel, and proof of secure storage meeting federal pharmaceutical standards. Oklahoma's Cannabis Industry Association recommended members begin compiling documentation now to avoid operational delays when the rescheduling rule takes effect.

  The compliance preparations reflect uncertainty about whether existing state licenses will satisfy federal registration requirements or if businesses must undergo separate DEA approval processes. Oklahoma operators expressed concern that the transition period could create competitive advantages for well-capitalized multi-state operators over smaller local businesses lacking resources for immediate compliance infrastructure investments.

  Update — June 12, 2026: Constitutional Challenge Threatens DEA Rescheduling Timeline

  A constitutional challenge to the DEA's authority over cannabis classification emerged in federal court, threatening to delay or derail the ongoing rescheduling process. Legal scholars and industry advocates filed arguments contending that the Controlled Substances Act's delegation of scheduling authority to the executive branch violates the non-delegation doctrine, a constitutional principle limiting Congress's ability to transfer legislative power. The challenge comes as the DEA continues its review of HHS's recommendation to move cannabis from Schedule I to Schedule III.

  The non-delegation argument centers on whether Congress provided sufficient "intelligible principle" when granting the Attorney General broad discretion to classify substances based on abuse potential and medical use. Plaintiffs contend that the CSA's vague standards allow executive agencies to make policy decisions reserved for the legislative branch. This constitutional question has gained traction following recent Supreme Court decisions that narrowed executive regulatory authority, including the 2022 West Virginia v. EPA ruling on the major questions doctrine.

  If successful, the challenge could invalidate not only the pending cannabis rescheduling but potentially the entire federal scheduling framework affecting hundreds of controlled substances. Legal experts said the case faces significant hurdles, as federal courts have historically upheld the CSA's constitutionality since its 1970 enactment. However, the current Supreme Court's skepticism toward administrative power creates uncertainty. The Justice Department has not yet filed a formal response to the constitutional arguments.

  For cannabis operators, the constitutional challenge introduces regulatory uncertainty that may freeze state-level expansion plans and capital deployment decisions until courts resolve the fundamental question of federal scheduling authority. Industry analysts noted that even a temporary injunction halting the rescheduling process could delay anticipated tax benefits under IRC Section 280E for months or years. The case also complicates congressional efforts to pass standalone cannabis reform legislation, as lawmakers await clarity on the executive branch's constitutional role in drug classification.

  Update — June 12, 2026: Constitutional Challenge Emerges as Potential Barrier to Rescheduling

  Legal scholars and industry observers raised concerns in mid-June 2026 that constitutional challenges could delay or derail the DEA's marijuana rescheduling process, according to analysis published by News-Press NOW. The commentary focused on potential separation-of-powers issues and questions about whether executive agencies possess authority to reclassify substances without explicit congressional authorization under the Controlled Substances Act.

  The constitutional arguments centered on nondelegation doctrine concerns, which limit Congress's ability to transfer legislative power to executive agencies. Critics argued that the broad discretion granted to the DEA and HHS in drug scheduling decisions may exceed constitutional bounds, particularly for a substance as politically and economically significant as cannabis. No formal lawsuit had been filed as of the publication date, but legal experts said standing parties could include state attorneys general, industry groups, or federal lawmakers.

  The timing of these constitutional questions proved significant because the DEA's rescheduling proposal remained under administrative review following public comment periods that closed in 2024. Any constitutional challenge filed before final rule publication could trigger additional procedural delays or force the agency to seek explicit congressional direction. For multistate operators and investors, the prospect of protracted litigation added another layer of regulatory uncertainty beyond the already-extended timeline for Schedule III reclassification.

  Industry attorneys said the constitutional arguments, while novel, faced steep hurdles because federal courts have historically granted agencies substantial deference in scientific and technical determinations under the Controlled Substances Act. The Supreme Court's Chevron doctrine, though narrowed in recent years, traditionally supported agency expertise in drug classification decisions. Whether challengers could overcome this precedent remained uncertain, but the mere threat of litigation complicated projections for when rescheduling might take effect.

  Update — June 12, 2026: Constitutional Challenges Emerge as Potential Barrier to Rescheduling

  Legal scholars and industry observers raised concerns that constitutional challenges could delay or derail the DEA's rescheduling process, according to analysis published in mid-June 2026. The concerns center on potential separation-of-powers questions and the scope of executive agency authority under the Controlled Substances Act. No specific lawsuit had been filed as of June 12, 2026, but commentators noted that opponents of rescheduling could invoke constitutional arguments to challenge the DEA's final rule in federal court.

  The constitutional questions focus on whether the DEA possesses statutory authority to reschedule cannabis without congressional action, particularly given the drug's decades-long Schedule I classification. Some legal analysts pointed to the major questions doctrine, a Supreme Court principle requiring clear congressional authorization for agency decisions of vast economic and political significance. Cannabis rescheduling affects an estimated $30 billion annual U.S. market and conflicts with state-level legalization frameworks in 38 states, potentially triggering heightened judicial scrutiny of the DEA's administrative process.

  Industry stakeholders expressed concern that constitutional litigation could extend the rescheduling timeline by 18 to 36 months if challengers secure preliminary injunctions or appellate review. Federal courts have historically deferred to DEA scheduling decisions under the Administrative Procedure Act, but the unprecedented scope of cannabis rescheduling presents novel legal questions. The DEA has not publicly addressed potential constitutional vulnerabilities in its rulemaking process, which remains pending following the close of the public comment period in 2024.

  For operators, the constitutional threat introduces additional regulatory uncertainty beyond the standard administrative review timeline. Multi-state operators have delayed capital expenditures and expansion plans pending final rescheduling, and prolonged litigation could force companies to maintain dual compliance frameworks for Schedule I and Schedule III scenarios. Investors face extended timelines for anticipated tax benefits under Internal Revenue Code Section 280E, which currently prohibits cannabis businesses from deducting ordinary business expenses on federal returns.

  Update — June 14, 2026: Confusion Persists Over Rescheduling Implementation Timeline

  Ongoing uncertainty surrounding the operational implementation of cannabis rescheduling continued to generate confusion among state regulators, operators, and patients in mid-June 2026, according to reporting from Bleeding Heartland. Despite the Drug Enforcement Administration's formal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, conflicting guidance from federal agencies left stakeholders unclear on compliance requirements for banking, taxation, and interstate commerce. The lack of coordinated federal messaging has delayed investment decisions and complicated state-level regulatory adjustments.

  State cannabis regulators reported receiving inconsistent directives regarding laboratory testing standards and product labeling under the new Schedule III classification. Iowa's Department of Health and Human Services noted that federal agencies had not yet published unified protocols for THC potency limits or contaminant testing methodologies, forcing states to maintain existing frameworks. Banking institutions remained hesitant to expand services to cannabis operators without explicit safe harbor provisions from the Financial Crimes Enforcement Network (FinCEN), perpetuating cash-based operations despite the reclassification.

  Tax practitioners highlighted that Internal Revenue Code Section 280E deductions remained unresolved for businesses operating between the rescheduling announcement and final IRS guidance publication. Operators who filed quarterly estimated tax payments faced potential penalties if they miscalculated allowable business expense deductions under the new Schedule III status. The American Institute of CPAs called for retroactive safe harbor provisions to protect compliant businesses from enforcement actions during the transition period.

  The confusion underscores the operational gap between policy announcements and regulatory implementation. Multi-state operators reported delaying expansion plans valued at over $400 million collectively until federal agencies publish coordinated compliance frameworks. Industry analysts noted that prolonged uncertainty could advantage established operators with legal resources to navigate ambiguity while disadvantaging smaller licensees and social equity applicants lacking comparable expertise.

  Update — June 15, 2026: Banking Compliance Costs Surge Under Schedule III Framework

  Cannabis operators reported unexpected banking compliance burdens following DEA rescheduling to Schedule III, according to a Forbes analysis published June 15, 2026. While rescheduling eliminated the threat of federal prosecution for state-licensed operators, banks now require enhanced due diligence protocols treating cannabis businesses as controlled substance handlers rather than ordinary commercial clients. Financial institutions cited ongoing obligations under the Bank Secrecy Act and FinCEN guidance that remain in effect regardless of scheduling classification.

  Compliance costs for cannabis businesses seeking traditional banking services increased between 40% and 65% compared to pre-rescheduling estimates, said industry consultants interviewed for the report. Banks now mandate quarterly audits verifying state license compliance, enhanced transaction monitoring systems, and dedicated compliance officers for cannabis accounts. Monthly account maintenance fees at participating institutions range from $2,500 to $8,000, substantially higher than the $500 to $1,200 fees anticipated under initial rescheduling projections.

  The increased scrutiny stems from Schedule III substances remaining subject to DEA manufacturing quotas and distribution tracking requirements under the Controlled Substances Act. Financial institutions must verify that deposited funds originate from properly licensed operations complying with both state regulations and federal quota allocations. This creates operational complexity absent in fully descheduled scenarios, where standard commercial banking protocols would apply without controlled substance oversight layers.

  Industry advocates noted that rescheduling alone does not trigger SAFE Banking Act protections, which require separate congressional authorization to shield financial institutions from federal penalties. Without statutory safe harbor provisions, banks maintain heightened risk management protocols regardless of scheduling classification. The discrepancy between anticipated banking normalization and actual compliance requirements has forced operators to allocate additional capital reserves for financial services infrastructure rather than operational expansion.

  This matters because elevated banking costs directly impact operator profitability and competitive positioning against illicit markets. Smaller licensees lacking capital reserves to absorb compliance expenses face continued reliance on cash operations or exit from regulated markets entirely, undermining rescheduling's intended goal of strengthening legal cannabis infrastructure.

  Update — June 16, 2026: Industry Attorney Acknowledges D.C. Circuit Could Reverse Rescheduling

  A cannabis industry attorney publicly conceded that pending litigation before the U.S. Court of Appeals for the D.C. Circuit could overturn the DEA's rescheduling of marijuana, according to statements reported June 16, 2026. The acknowledgment marked a shift in tone among industry advocates who had previously downplayed legal challenges to the administrative rulemaking process that moved cannabis from Schedule I to Schedule III under the Controlled Substances Act.

  The D.C. Circuit consolidated multiple petitions for review filed by state attorneys general, medical associations, and cannabis advocacy groups challenging both the procedural adequacy of the DEA's notice-and-comment period and the substantive scientific basis for rescheduling. Oral arguments were scheduled for September 2026, with a three-judge panel expected to rule by year-end. Legal observers noted that the court could remand the rule to the DEA for additional proceedings, vacate it entirely, or uphold the agency's determination.

  The attorney's comments followed amicus briefs filed by 14 state governments opposing rescheduling, which argued the DEA failed to adequately address public comments questioning the FDA's medical utility findings and the agency's departure from prior scheduling criteria. Industry stakeholders expressed concern that a reversal would create immediate compliance chaos for operators who had restructured tax positions and capital arrangements based on anticipated relief from Internal Revenue Code Section 280E.

  Financial analysts warned that a judicial reversal could trigger material impairment charges for multi-state operators who had capitalized deferred tax assets on balance sheets assuming Schedule III treatment. The uncertainty prompted several institutional investors to delay planned capital deployments into the sector pending resolution of the appellate litigation, according to investor disclosures filed with the SEC.

  Update — June 17, 2026: Former DEA Section Chief Challenges Rescheduling Process

  A former DEA section chief stepped forward on June 17, 2026, to formally challenge the agency's marijuana rescheduling process, according to newswire.com. The challenge marks the first public opposition from a former senior DEA official since the Department of Justice proposed moving cannabis from Schedule I to Schedule III in 2024. The official's identity and specific legal grounds for the challenge were not disclosed in initial reports.

  The intervention comes as the DEA continues administrative proceedings on the rescheduling proposal. Former agency personnel rarely file formal challenges to DEA rulemaking, making this development unusual in the context of Controlled Substances Act enforcement history. The challenge could introduce procedural delays or require additional agency responses during the public comment and review phases.

  Legal experts noted that standing requirements for administrative challenges typically require demonstration of direct injury or regulatory impact. Whether a former official retains sufficient legal interest to challenge current agency actions remains an open procedural question. The DEA has not yet issued a formal response to the challenge or indicated whether it will affect the rescheduling timeline.

  This matters because internal agency dissent—even from former personnel—can complicate the administrative record and provide ammunition for external legal challenges. Courts reviewing agency actions examine the full administrative record, including objections raised during the rulemaking process. If the challenge raises substantive scientific or procedural concerns, it could strengthen arguments from state attorneys general or industry groups opposing Schedule III classification.

  The DEA has not announced a final decision date for the rescheduling proposal, which remains subject to review under the Administrative Procedure Act. The former official's challenge adds another layer of complexity to a process already involving multiple federal agencies, state governments, and thousands of public comments.

  Update — June 17, 2026: Washington State Regulator Questions Federal Rescheduling Applicability

  Washington state cannabis regulators warned that federal rescheduling of cannabis may not automatically apply within state borders, according to statements reported by MJBizDaily on June 17, 2026. The warning introduces uncertainty for operators in one of the nation's oldest adult-use markets, which has operated under state law since 2012. State officials indicated that Washington's regulatory framework may require independent legislative or administrative action to align with any DEA schedule change.

  The regulator's position stems from Washington's unique statutory structure, where cannabis legalization occurred through voter initiative rather than legislative statute. Initiative 502, passed in 2012, established cannabis as legal under state law independent of federal classification. This creates a potential gap where federal rescheduling—moving cannabis from Schedule I to Schedule III under the Controlled Substances Act—would not automatically trigger changes to Washington's state-level controls, licensing requirements, or tax structures.

  The operational implication centers on tax treatment and interstate commerce eligibility. If federal rescheduling proceeds but Washington maintains its existing framework, operators in the state may face continued restrictions on banking access, interstate transport, and federal tax deductions under Internal Revenue Code Section 280E—even as competitors in other states gain those advantages. Washington collected approximately $559 million in cannabis excise taxes in fiscal year 2025, revenue that depends on the current closed-loop system.

  The warning signals that state-level coordination will be essential for operators to realize rescheduling benefits. Washington's Legislature would need to pass conforming amendments, or the Liquor and Cannabis Board would require explicit statutory authority to modify regulations in response to federal changes. Without such action, Washington cannabis businesses could operate under a hybrid regime where federal law permits Schedule III activities but state law continues to treat cannabis as a controlled substance requiring separate licensing and compliance infrastructure.

  Update — June 18, 2026: DEA Begins On-Site Inspections of Registered Cannabis Businesses

  The Drug Enforcement Administration began conducting on-site inspections at marijuana businesses that registered for federal protections following cannabis rescheduling under the Trump administration. The Mississippi Medical Marijuana Association reported that two member businesses received DEA visits last week after submitting registration applications, according to Marijuana Moment.

  The inspections represent the first operational enforcement of the Schedule III registration framework established when marijuana was rescheduled from Schedule I. Businesses that applied for federal registration under the new classification are now subject to DEA facility audits to verify compliance with controlled substance handling requirements, including security protocols, record-keeping systems, and inventory tracking procedures mandated for Schedule III substances.

  The Mississippi visits signal that DEA is actively processing the backlog of registration applications submitted since rescheduling took effect. Industry observers noted that on-site inspections are standard procedure for Schedule III registrants but mark a significant shift for state-licensed cannabis operators previously operating outside federal oversight. The inspections assess whether facilities meet DEA security standards under 21 CFR Part 1301, which require physical safeguards, employee background checks, and theft prevention measures.

  For cannabis operators, the inspections carry financial and operational implications. Businesses that fail DEA compliance reviews risk denial of federal registration, which would prevent them from legally handling marijuana under the new Schedule III framework and potentially expose them to enforcement action. The Mississippi association said inspected members were evaluating whether to maintain state-only licenses or pursue full federal compliance, a decision that involves capital investments in security infrastructure and ongoing reporting obligations that exceed state regulatory requirements.

  Update — June 18, 2026: Eight Days Remain for Medical Operators to Meet DEA Registration Deadline

  State-licensed medical cannabis operators have until June 26, 2026 to submit Drug Enforcement Administration registration applications and preserve expedited review protections under the Blanche rescheduling order, according to industry guidance published June 18. The business deadline applies to all segments of the medical supply chain, including cultivators, manufacturers, distributors, and dispensaries operating under state medical programs.

  The expedited review pathway emerged from the DEA's final rescheduling rule moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Operators who submit complete applications by the June 26 cutoff receive priority processing and provisional operating authority while the DEA reviews documentation, preserving continuity for existing state-licensed medical businesses. Applications filed after the deadline face standard DEA registration timelines, which historically average 90 to 180 days without provisional protections.

  The registration requirement represents the first federal licensing mandate for state-legal cannabis operators and creates a bifurcated regulatory framework distinguishing medical programs from adult-use markets. Medical cannabis businesses must obtain DEA registration numbers to maintain legal status under federal law, while adult-use operators remain outside the rescheduling framework. The distinction matters for banking access, tax treatment under Internal Revenue Code Section 280E, and interstate commerce eligibility.

  Industry operators face logistical challenges completing applications within the compressed timeline. DEA registration forms require detailed facility security plans, inventory tracking protocols, and background checks for all key personnel with access to controlled substances. State regulators in California, Colorado, and Michigan reported increased inquiries from licensees seeking guidance on federal compliance documentation in the week preceding the deadline.

  The June 26 cutoff establishes operational urgency for medical cannabis businesses seeking to maintain federal compliance and access banking services previously restricted under Schedule I classification. Operators who miss the deadline face potential supply chain disruptions and delayed access to the financial and tax benefits accompanying Schedule III status.

  Update — June 18, 2026: Ohio Reports Lack of Federal Guidance on Rescheduling Implementation

  Ohio state cannabis regulators reported that federal agencies have not provided clear guidance or feedback on implementing cannabis rescheduling at the state level, according to statements made in June 2026. The absence of federal direction has left state-licensed operators and regulatory bodies uncertain about compliance requirements under the anticipated Schedule III classification. Ohio's medical cannabis program, operational since 2019, serves approximately 30,000 registered patients through 57 licensed dispensaries.

  The lack of federal communication extends to critical operational questions including banking compliance, tax treatment transitions, and interstate commerce protocols. State officials said they have submitted multiple inquiries to the Drug Enforcement Administration and Department of Health and Human Services without receiving substantive responses. This regulatory vacuum affects Ohio's $400 million annual medical cannabis market, where operators face immediate decisions about inventory management, financial reporting structures, and facility modifications ahead of any rescheduling effective date.

  Industry stakeholders in Ohio expressed concern that delayed federal guidance could create compliance gaps when rescheduling takes effect. Operators must reconcile existing state regulations—which govern product testing, packaging, and distribution—with forthcoming federal Schedule III requirements that may impose different standards. The timing uncertainty complicates capital planning for the state's 28 licensed cultivators and 54 processors, many of which operate on thin margins under current 280E tax burdens.

  Ohio's experience reflects broader challenges facing the 38 states with operational medical or adult-use programs. Without coordinated federal-state implementation frameworks, each jurisdiction must independently interpret how rescheduling affects licensing, product standards, and enforcement priorities. The absence of advance guidance increases the risk of conflicting interpretations that could expose compliant operators to federal enforcement or force costly mid-stream operational changes when final rules emerge.

  Update — June 18, 2026: DEA Selects Hearing Participants, Invites Only Rescheduling Opponents

  The Drug Enforcement Administration notified selected participants on June 18, 2026, that they have been invited to testify at the agency's cannabis rescheduling hearing scheduled to begin later this month. All invited participants oppose the Trump administration's proposal to move cannabis from Schedule I to Schedule III, according to notices sent by DEA. The agency did not invite any proponents of rescheduling to participate in the formal hearing process.

  DEA's selection follows a public comment period in which thousands of individuals and organizations requested participant status, including industry groups, medical researchers, patient advocates, and law enforcement organizations. The Administrative Procedure Act requires DEA to hold a hearing when objections are filed to a proposed rescheduling action, but the agency retains discretion over which objectors receive formal participant status with rights to present testimony, cross-examine witnesses, and submit evidence.

  The participant selection matters because formal hearing participants gain procedural rights unavailable to public commenters, including the ability to question DEA witnesses and challenge the evidentiary basis for rescheduling under oath. By limiting participation to opponents, DEA structured the hearing as a forum to test the strength of the rescheduling proposal against organized opposition rather than a balanced examination of arguments for and against the Schedule III classification.

  The hearing represents a mandatory procedural step under the Controlled Substances Act before DEA can finalize any rescheduling decision. DEA must address objections raised during the hearing in its final rule, and the administrative record created during the proceeding becomes the basis for any subsequent judicial review if parties challenge the agency's ultimate decision in federal court.

  Update — June 18, 2026: DEA Selects Only Opposition Witnesses for Rescheduling Hearings

  The Drug Enforcement Administration announced its final witness roster for upcoming administrative hearings on cannabis rescheduling, selecting exclusively participants who oppose moving marijuana from Schedule I to Schedule III. The roster includes representatives from law enforcement associations, anti-drug advocacy groups, and medical organizations that have historically opposed liberalization. No pro-rescheduling witnesses, industry representatives, or patient advocates received invitations to testify, according to the agency's June 18 notice.

  The witness selection follows the DEA's statutory obligation under the Administrative Procedure Act to conduct a public hearing when requested by interested parties. More than 43,000 public comments were submitted during the initial comment period, with the majority supporting the proposed Schedule III classification recommended by the Department of Health and Human Services in August 2023. The hearing format allows the DEA Administrative Law Judge to question witnesses and receive cross-examination from participating parties, but the agency retains final authority over witness approval.

  Industry attorneys said the one-sided roster creates procedural vulnerabilities that could strengthen future legal challenges if the DEA finalizes a rule contrary to HHS medical and scientific findings. The Controlled Substances Act requires the DEA to accept HHS determinations on medical utility and abuse potential as binding, limiting the agency's discretion to reject rescheduling based solely on law enforcement concerns. Several state attorneys general and cannabis trade associations have indicated they will file amicus briefs regardless of witness participation.

  The hearings are scheduled to begin in August 2026, with an estimated 12-18 month timeline before a final rule based on historical DEA rulemaking processes. The witness composition raises questions about whether the agency intends to use the administrative record to justify maintaining Schedule I status or imposing additional restrictions within a Schedule III framework, such as limiting THC potency or restricting distribution channels beyond traditional pharmacy dispensing.

  Update — June 20, 2026: DEA Announces Participant Selection for Rescheduling Hearing

  The Drug Enforcement Administration announced the selection of participants for its upcoming administrative hearing on cannabis rescheduling, according to Cannabis Wire. The hearing will examine the proposed move of cannabis from Schedule I to Schedule III under the Controlled Substances Act. DEA Administrative Law Judge John Mulrooney will preside over the proceedings, which are expected to begin in the coming months following standard pre-hearing procedures.

  The participant list includes representatives from medical associations, cannabis industry groups, patient advocacy organizations, and law enforcement entities. The American Medical Association, the National Organization for the Reform of Marijuana Laws (NORML), and Smart Approaches to Marijuana (SAM) received approval to present testimony. Several state-licensed cannabis operators also secured participant status to address operational and regulatory implications of the proposed schedule change.

  The DEA's selection process prioritized parties demonstrating direct material interest in the rescheduling outcome and technical expertise relevant to the eight-factor analysis required under 21 U.S.C. § 811(c). Participants must submit pre-hearing briefs within 60 days and witness lists within 90 days of the formal notice, according to DEA procedural rules. The agency rejected multiple applications from parties deemed to lack sufficient standing or whose proposed testimony duplicated other accepted participants.

  This hearing represents the first formal adversarial proceeding on cannabis scheduling since the DEA's 2016 denial of rescheduling petitions. The outcome will determine whether cannabis businesses gain access to standard tax deductions under Internal Revenue Code Section 280E and whether research restrictions under the Single Convention on Narcotic Drugs of 1961 are modified. Industry analysts estimate that Schedule III classification could reduce effective tax rates for licensed operators by 15-25 percentage points, materially affecting profitability across state-legal markets.

  The hearing timeline remains subject to procedural motions and discovery disputes typical of complex administrative proceedings. Legal observers noted that the participant selection marks a procedural milestone but does not indicate the DEA's substantive position on rescheduling merits, which will be determined following the complete evidentiary record and post-hearing briefing.

  Update — June 20, 2026: Former DEA Administrator Challenges Agency's Procedural Compliance in Rescheduling

  A former DEA administrator publicly questioned the agency's adherence to Administrative Procedure Act requirements during the cannabis rescheduling process, according to statements published June 20, 2026. The criticism focused on whether DEA followed mandatory notice-and-comment protocols and conducted the eight-factor analysis required under the Controlled Substances Act before advancing Schedule III classification. The former official said the agency appeared to prioritize political timelines over statutory obligations.

  The commentary highlighted concerns about financial conflicts of interest stemming from industry lobbying expenditures that exceeded $12 million in fiscal year 2025. Former enforcement leadership questioned whether economic pressure from state-licensed operators influenced the agency's scientific review process. DEA's final rule, published in May 2026, did not address these procedural objections in its 1,200-page regulatory impact analysis.

  Legal scholars noted the criticism could strengthen pending lawsuits challenging the rescheduling on procedural grounds. Three federal circuit courts currently have cases alleging DEA violated 5 U.S.C. § 553 notice requirements by limiting public comment periods to 60 days despite receiving over 43,000 submissions. The former administrator's statements provided potential expert testimony for plaintiffs arguing the agency departed from established rulemaking standards.

  This matters because procedural defects represent the most viable legal avenue to delay or reverse Schedule III implementation. Courts historically defer to agency scientific judgments but scrutinize process failures rigorously. If challengers demonstrate DEA shortcut mandatory steps, judges could remand the rule for supplemental proceedings, extending legal uncertainty for operators who invested in compliance infrastructure based on the May 2026 effective date.

  Update — June 22, 2026: Rescheduling Hearings Progress Amid Procedural Delays

  The DEA's administrative hearings on the proposed rescheduling of cannabis from Schedule I to Schedule III continued through mid-2026, with proceedings extending beyond initial timelines due to the volume of expert testimony and evidentiary submissions. Administrative Law Judge presiding over the hearings accepted testimony from over 40 witnesses, including pharmacologists, state regulators, and industry representatives, according to hearing transcripts. The hearings, which began in early 2026 following the formal notice of proposed rulemaking, addressed core questions about cannabis's accepted medical use and abuse potential under the Controlled Substances Act's five-factor analysis.

  Opponents of rescheduling, including several advocacy groups and medical organizations, focused testimony on the lack of FDA-approved cannabis formulations beyond Epidiolex, Marinol, and Syndros. Proponents presented data from state medical cannabis programs, citing over 8 million registered patients across 38 states as evidence of accepted medical use within the meaning of 21 U.S.C. § 812. The evidentiary record also included HHS's August 2023 scheduling recommendation, which found cannabis has a lower abuse potential than Schedule I or II substances.

  The procedural timeline matters significantly for operators holding state licenses but facing federal banking and tax restrictions. Section 280E of the Internal Revenue Code prohibits business expense deductions for Schedule I and II substances, costing state-legal cannabis businesses an estimated $1.8 billion annually in additional federal tax liability. Rescheduling to Schedule III would eliminate this prohibition, fundamentally altering the financial viability of licensed operations and potentially attracting institutional capital currently barred by federal illegality.

  Legal observers noted that the DEA retains final rulemaking authority regardless of the administrative hearing outcome, though the evidentiary record will constrain the agency's discretion under the Administrative Procedure Act. Any final rule faces near-certain judicial review in federal appellate courts, with challenges expected from both rescheduling opponents and advocates seeking full descheduling. The hearings were expected to conclude by August 2026, with a final DEA determination anticipated in late 2026 or early 2027.

  Update — June 22, 2026: NORML Challenges DEA Exclusion from Rescheduling Hearing

  The National Organization for the Reform of Marijuana Laws (NORML) filed a legal challenge on June 22, 2026, contesting its exclusion from the DEA's administrative hearing on cannabis rescheduling. The advocacy organization argued that its exclusion violated Administrative Procedure Act requirements for public participation in rulemakings with significant policy implications, according to court filings. NORML had submitted a formal request to participate as an interested party in March 2026, citing its five-decade history of cannabis policy advocacy and technical expertise in scheduling law.

  The DEA's hearing roster, published in May 2026, included 26 approved participants ranging from pharmaceutical manufacturers to state regulatory officials, but excluded multiple advocacy organizations that had requested standing. NORML's petition argued that the agency applied inconsistent criteria in selecting participants, granting access to industry stakeholders with commercial interests while denying representation to consumer advocacy groups. The organization's legal team cited precedent from Sierra Club v. EPA establishing that agencies must provide reasoned explanations for excluding parties with demonstrated interest in regulatory outcomes.

  The challenge creates procedural uncertainty for the rescheduling hearing, originally scheduled to commence in August 2026. Federal courts have authority to pause administrative proceedings pending resolution of participation disputes, potentially delaying the DEA's timeline for finalizing its scheduling determination. NORML requested expedited review to avoid disrupting the hearing schedule, proposing that the court rule on standing issues within 30 days.

  The exclusion dispute highlights broader tensions over stakeholder representation in cannabis rescheduling. Twenty-three state attorneys general submitted an amicus brief supporting NORML's position, arguing that federal scheduling decisions affecting state-legal markets require input from organizations representing consumer and patient interests. The DEA has not publicly commented on the litigation, but agency officials previously stated that hearing participation would be limited to parties offering "unique technical or scientific perspectives" on scheduling criteria under the Controlled Substances Act.

  Update — June 23, 2026: Stakeholder Influence on Trump Administration Rescheduling Examined

  Analysis of the Trump administration's approach to cannabis rescheduling highlighted the competing interests shaping federal policy deliberations in mid-2026. Industry lobbyists, state-level Republican governors, and pharmaceutical sector representatives maintained regular contact with White House policy staff according to disclosure records reviewed in June 2026. The administration faced pressure from cannabis operators seeking Schedule III classification while law enforcement groups advocated maintaining stricter controls.

  Multi-state operators spent approximately $4.2 million on federal lobbying in the first quarter of 2026, focusing on rescheduling advocacy and 280E tax reform. Trade associations including the U.S. Cannabis Council and National Cannabis Roundtable coordinated messaging emphasizing economic benefits and state-level success stories. Republican governors from states with operational medical programs, including Florida and Ohio, communicated support for federal classification changes that would reduce banking barriers.

  Opposition remained concentrated among the National Association of Assistant United States Attorneys and portions of the pharmaceutical industry concerned about regulatory pathways for cannabis-derived medications. These groups emphasized the need for FDA approval processes and expressed concerns about Schedule III placement bypassing traditional drug development standards. The DEA's administrative law judge continued reviewing public comments submitted during the formal rescheduling proceeding initiated in 2024.

  The competing pressures created uncertainty for operators planning capital expenditures and expansion timelines. Publicly traded cannabis companies reported delaying merger activity and facility construction pending clarity on federal classification, according to second-quarter earnings calls. The administration had not announced a timeline for final rescheduling decisions, leaving the industry in a prolonged regulatory holding pattern that affected investment flows and strategic planning across the sector.

  Update — June 22, 2026: Academic Experts Clarify Rescheduling Mechanics Amid Public Confusion

  Academic researchers issued a public Q&A briefing on June 22, 2026, addressing widespread misunderstandings about the federal cannabis rescheduling process, according to a Newswise release. The briefing emphasized that rescheduling does not legalize cannabis for recreational use and that state-licensed operators remain subject to federal prosecution even if the Drug Enforcement Administration moves cannabis from Schedule I to Schedule III under the Controlled Substances Act. Experts noted that confusion persists among patients, investors, and operators about the practical implications of any DEA classification change.

  The briefing highlighted that Schedule III status would eliminate Internal Revenue Code Section 280E tax penalties for state-licensed dispensaries, allowing standard business deductions for rent, payroll, and marketing expenses. However, interstate commerce would remain prohibited absent separate congressional action, meaning multi-state operators could not transport products across state lines without violating federal law. Researchers said the distinction between tax relief and operational legality has been poorly communicated in industry media and investor presentations.

  Experts also addressed the timeline uncertainty inherent in DEA administrative rulemaking, noting that the agency faces no statutory deadline to complete its review of the Department of Health and Human Services' August 2023 rescheduling recommendation. The briefing referenced historical precedents where DEA scheduling decisions took 18 to 36 months from initial petition to final rule publication in the Federal Register. Researchers said operators should not base capital deployment decisions on assumed rescheduling timelines.

  The Q&A format was designed to provide factual clarity for university administrators, healthcare providers, and state regulators navigating federal-state cannabis policy conflicts. The briefing underscored that FDA approval would still be required for any cannabis-derived pharmaceutical product marketed with therapeutic claims, regardless of DEA scheduling status. This matters because many CBD and delta-8 THC products currently sold in retail channels operate in regulatory gray areas that rescheduling would not resolve.

  Update — June 23, 2026: Legal Practice Implications of Ongoing Rescheduling Uncertainty

  The extended timeline for DEA rescheduling has created significant demand for specialized cannabis legal expertise, according to analysis published in The National Law Review. Cannabis law practitioners now navigate a complex dual-compliance environment where state-legal operations remain federally prohibited under Schedule I, requiring expertise in both regulatory frameworks simultaneously. The practice area has expanded beyond traditional regulatory compliance to encompass banking law, tax litigation under Section 280E, and interstate commerce planning contingent on federal classification changes.

  Law firms reported increased client demand for rescheduling scenario planning as businesses prepare for potential Schedule III classification. This planning includes restructuring corporate entities to qualify for standard tax deductions, negotiating banking relationships anticipating reduced federal enforcement risk, and drafting supply agreements with conditional terms tied to classification outcomes. The indefinite regulatory timeline has made contingency-based legal structures standard practice in cannabis transactions exceeding $5 million.

  The National Law Review analysis noted that cannabis attorneys must maintain expertise across administrative law, controlled substances regulations, and state-specific licensing regimes. Practitioners handle DEA registration applications for research facilities, defend clients in federal tax court over 280E deductions, and advise on compliance with both state medical programs and adult-use frameworks. The rescheduling process itself has generated litigation over procedural timelines, public comment periods, and agency rulemaking authority under the Administrative Procedure Act.

  For operators, this legal complexity translates to higher compliance costs and extended deal timelines. Mergers and acquisitions in the cannabis sector now routinely include rescheduling contingency clauses that adjust valuations or terminate agreements if federal classification changes fail to materialize within specified timeframes. The uncertain regulatory environment has made specialized legal counsel essential for capital raises, licensing applications, and multi-state expansion strategies that must account for both current Schedule I restrictions and potential Schedule III opportunities.

  Update — June 23, 2026: Media Outlet Petitions for Live Video Access to DEA Rescheduling Hearing

  Marijuana Moment filed a formal motion with the DEA administrative law judge presiding over the cannabis rescheduling hearing, requesting permission to livestream the proceedings for public access. The petition argues that transparent real-time coverage serves the public interest given the national significance of the DEA's review of marijuana's classification under the Controlled Substances Act. According to the motion, the hearing's outcome will affect millions of patients, thousands of state-licensed operators, and billions of dollars in existing cannabis commerce.

  The request arrives as the DEA administrative hearing enters its evidentiary phase, with expert witnesses scheduled to testify on marijuana's medical utility and abuse potential. DEA administrative hearings traditionally occur behind closed doors or with limited in-person seating, restricting media and stakeholder observation. Marijuana Moment's motion cited precedents from other federal agencies that have adopted video streaming for high-profile rulemakings, including FDA advisory committee meetings and FCC spectrum auctions.

  The administrative law judge has not yet ruled on the livestream request, and DEA procedural rules do not explicitly authorize or prohibit video broadcasting of administrative hearings. Legal observers said approval would mark a departure from DEA practice but align with broader federal transparency trends. If granted, the livestream would allow cannabis industry stakeholders, researchers, and advocacy groups to monitor witness cross-examination and legal arguments in real time, rather than relying on post-hearing transcripts that can take weeks to publish.

  The motion matters because hearing transparency directly affects industry confidence in the rescheduling process. Investors and operators have expressed concern that limited public access to DEA deliberations fuels speculation and misinformation about the agency's timeline and criteria. A livestreamed hearing would provide unfiltered documentation of the evidentiary record that will form the basis for the DEA's final scheduling determination, expected later in 2026.

  Update — June 25, 2026: Rescheduling Finalized, Market Uncertainty Persists

  The Drug Enforcement Administration formally reclassified marijuana from Schedule I to Schedule III of the Controlled Substances Act, marking the first federal change to cannabis scheduling since the drug's placement in 1970. The move, finalized after a multi-year administrative review initiated by the Department of Health and Human Services in August 2023, takes effect immediately and allows cannabis businesses to deduct ordinary operating expenses under Internal Revenue Code Section 280E. Cannabis remains federally controlled, however, and interstate commerce, FDA approval pathways, and state-federal enforcement conflicts persist under the new classification.

  Financial analysts noted that publicly traded cannabis companies saw muted stock price reactions in the 48 hours following the announcement, with major multi-state operators trading within 3-5% of pre-announcement levels. According to a June 24 report from Viridian Capital Advisors, investor caution stems from ongoing restrictions: Schedule III substances require DEA manufacturing quotas, prescriptions from licensed practitioners, and compliance with Good Manufacturing Practice standards that most state-licensed cultivators do not currently meet. Banking access remains constrained absent separate legislative action, as the Bank Secrecy Act's suspicious activity reporting requirements still apply to proceeds from federally controlled substances.

  The American Trade Association for Cannabis and Hemp said the reclassification provides estimated annual tax savings of $1.2 billion to $1.8 billion across the industry, based on 2025 revenue figures and typical cost-of-goods-sold ratios. These savings accrue primarily to vertically integrated operators in high-tax states like California and Illinois, where effective tax rates previously exceeded 70% when combining federal disallowances with state excise and sales taxes. Smaller operators without significant federal tax liabilities see minimal immediate benefit, according to the association's economic impact analysis released June 24.

  Legal experts emphasized that rescheduling does not preempt state law or create a federal right to cultivate, distribute, or possess cannabis. The 37 states with medical or adult-use programs continue to operate under the Rohrabacher-Farr appropriations rider, which prohibits the Department of Justice from using funds to interfere with state-compliant medical cannabis activities. The DEA's June 24 guidance memo confirmed that enforcement priorities remain unchanged for diversion to minors, interstate trafficking, and operations on federal lands, regardless of Schedule III status. The agency also noted that existing state licenses do not satisfy DEA registration requirements for Schedule III handlers.

  Industry observers now focus on whether Congress will advance the SAFER Banking Act or similar legislation to address the banking and interstate commerce gaps that rescheduling leaves unresolved. No floor votes are currently scheduled in either chamber, according to congressional leadership offices contacted June 25. The operational reality for most cannabis businesses—state-licensed, cash-intensive, and unable to access traditional capital markets—remains largely unchanged despite the historic scheduling shift.

  Update — June 26, 2026: Opponents File Pre-Hearing Briefs Ahead of DEA Rescheduling Proceeding

  Marijuana reform opponents submitted briefs to the Drug Enforcement Administration outlining arguments against the Trump administration's proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. The filings preview testimony scheduled for a formal administrative hearing set to begin the following week. DEA is formally listed as the proponent of the rescheduling reform, a procedural designation required under the Administrative Procedure Act for agency-initiated rule changes.

  The pre-hearing briefs signal coordinated opposition from anti-legalization advocacy groups, though specific organizational names and argument details were not disclosed in the initial filings. Administrative law judges typically use such briefs to structure hearing schedules and identify disputed factual or legal issues. The hearing represents a mandatory procedural step before DEA can finalize any schedule change under 21 U.S.C. § 811(a).

  This matters because formal opposition testimony can extend administrative timelines by months or years if opponents raise substantial scientific or treaty compliance questions. The 1986 rescheduling petition for MDMA, for example, required three years of hearings and appeals before final denial. Industry stakeholders and state-licensed operators face continued federal-state legal conflicts and limited banking access until any Schedule III reclassification becomes effective through final rule publication in the Federal Register.

  The hearing format allows cross-examination of government witnesses, including potential testimony from Department of Health and Human Services officials who recommended rescheduling in 2023. Opponents may challenge HHS's eight-factor analysis under the Controlled Substances Act, particularly findings on abuse potential and accepted medical use. Financial markets have priced in rescheduling expectations since mid-2024, making procedural delays a material risk for cannabis equity valuations and M&A timelines.

  Update — June 26, 2026: Six-Week Assessment Shows Limited Operational Impact

  Six weeks after cannabis moved to Schedule III, industry participants reported minimal immediate changes to day-to-day operations, according to Business of Cannabis. The rescheduling took effect on May 15, 2026, but banking access, interstate commerce restrictions, and state-level licensing requirements remained unchanged. Operators described the federal regulatory apparatus as "a giant ship with a rusty rudder," referencing the slow pace of implementing guidance from the Drug Enforcement Administration and Food and Drug Administration.

  Section 280E tax deductions became available for the 2026 tax year, but accountants said businesses would not realize cash benefits until filing 2026 returns in early 2027. Multi-state operators began restructuring cost-of-goods-sold accounting to maximize newly permissible deductions for rent, salaries, and marketing expenses. The Internal Revenue Service had not yet issued formal guidance on documentation requirements for cannabis-related business expenses under the new schedule.

  The FDA had not published draft regulations for cannabis products as of June 26, leaving manufacturers uncertain about labeling, testing, and interstate shipment protocols. State regulators in 38 adult-use and medical markets continued enforcing existing frameworks without federal preemption. Industry attorneys noted that the Controlled Substances Act's Schedule III placement did not override state authority or create a pathway for federally legal sales outside approved research contexts.

  Banking relationships showed no expansion in the six-week period, with the Financial Crimes Enforcement Network maintaining existing suspicious activity report filing requirements for cannabis transactions. Credit unions and regional banks serving the industry reported no change in federal examiner scrutiny. The lack of movement on the SAFE Banking Act meant depository institutions treated Schedule III cannabis identically to the former Schedule I classification for anti-money-laundering purposes.

  The assessment matters because it quantified the gap between rescheduling's theoretical benefits and practical implementation timelines. Operators planning capital raises or expansion based on anticipated regulatory relief faced continued restrictions, while tax savings remained prospective rather than immediate. The slow federal response underscored the need for explicit congressional action to address banking, interstate commerce, and state-federal conflicts beyond administrative rescheduling.

  Update — June 26, 2026: DEA Witness List Includes Medical Benefits Testimony

  The Drug Enforcement Administration filed a witness list for the cannabis rescheduling hearing set to begin on Monday, June 29, 2026, naming a physician who will testify that "medical marijuana provides a medical benefit to pain patients." The government's second witness is a Food and Drug Administration official, according to the filing. The inclusion of medical benefit testimony marks a significant shift in DEA's public posture, as the agency historically maintained that cannabis lacks accepted medical use under Schedule I criteria.

  The hearing will adjudicate the proposed move of cannabis from Schedule I to Schedule III of the Controlled Substances Act. Schedule III classification requires demonstrating "currently accepted medical use in treatment in the United States," a standard the physician's testimony appears designed to satisfy. The FDA witness is expected to address the agency's scientific and medical evaluation that supported the Department of Health and Human Services' August 2023 recommendation to reschedule.

  DEA's decision to lead with medical benefits testimony signals the agency's litigation strategy for defending rescheduling against objections from parties seeking to maintain Schedule I status or push for descheduling. The hearing operates under Administrative Procedure Act rules, with an administrative law judge presiding over evidence presentation before DEA Administrator makes a final determination. Multiple stakeholders, including state attorneys general and industry groups, have petitioned to participate as intervenors.

  The medical benefit focus matters operationally because Schedule III status would preserve federal research restrictions and FDA approval requirements while reducing criminal penalties and enabling IRC Section 280E tax deductions for state-licensed cannabis businesses. The hearing's evidentiary record will form the basis for judicial review if parties challenge DEA's ultimate rescheduling decision in federal court.

  Update — June 26, 2026: DEA Announces Expert Witnesses for Rescheduling Hearing

  The Drug Enforcement Administration disclosed plans to call a pain management physician and an FDA official as expert witnesses at the upcoming administrative hearing on cannabis rescheduling, according to a June 26 notice. The witness list signals the agency's focus on medical utility and abuse potential assessments, the two statutory criteria under the Controlled Substances Act that determine scheduling classification. The hearing, required under 21 U.S.C. § 811(a) when objections are filed to a proposed rule, will allow cross-examination of government experts and submission of contrary evidence by registered parties.

  The pain management specialist is expected to address cannabis efficacy for chronic pain conditions, a key component of the "currently accepted medical use" standard under Schedule III criteria. FDA's witness will likely defend the agency's August 2023 recommendation to reschedule cannabis from Schedule I to Schedule III, which concluded that marijuana has lower abuse potential than Schedule I or II substances and accepted medical use in treatment. Industry observers noted the witness selection suggests DEA intends to build a clinical record supporting the rescheduling proposal rather than relitigate the underlying science.

  The hearing date has not been finalized, but administrative law procedures require at least 60 days' notice to registered participants following publication of the final witness list in the Federal Register. Approximately 43,000 public comments were submitted during the initial comment period that closed in July 2024, with objections triggering the formal hearing requirement. Licensed operators and state regulatory agencies have sought intervenor status to present evidence on operational impacts of rescheduling, including Section 280E tax deduction eligibility and interstate commerce implications.

  The hearing represents the final procedural step before DEA Administrator can issue a final rule on rescheduling. Legal analysts noted that calling FDA's expert as a government witness strengthens the administrative record against potential judicial review, as courts afford substantial deference to agency scientific determinations under the Administrative Procedure Act. Multi-state operators have estimated Schedule III classification could reduce effective tax rates by 20-40 percentage points by restoring ordinary business expense deductions currently barred under Internal Revenue Code Section 280E.

  Update — June 26, 2026: Louisiana Withdraws from Multi-State Legal Challenge to Schedule III Rescheduling

  Louisiana withdrew from the multi-state coalition challenging the DEA's rescheduling of cannabis to Schedule III, reducing the number of plaintiff states in the ongoing litigation. The state filed a notice of voluntary dismissal in federal court, according to court records reviewed by MJBizDaily. Louisiana's exit leaves 14 states actively pursuing the lawsuit, which argues the rescheduling exceeds DEA authority and conflicts with state-level prohibition frameworks.

  The withdrawal follows Louisiana's enactment of a medical cannabis expansion bill in May 2026 that broadened qualifying conditions and increased licensed dispensary counts from 10 to 25 statewide. State officials did not provide a formal explanation for the dismissal, but the timing coincides with the legislature's shift toward regulated medical access rather than maintaining absolute prohibition. Louisiana Attorney General Liz Murrill's office confirmed the state "no longer has standing to challenge federal rescheduling" given the expanded medical program, according to a spokesperson.

  The remaining plaintiff states—including Nebraska, Idaho, and Kansas—continue to argue that Schedule III classification undermines their criminal enforcement regimes and creates operational conflicts with federal banking and tax provisions. The consolidated case remains pending in the U.S. Court of Appeals for the D.C. Circuit, with oral arguments scheduled for September 2026. Legal analysts noted that Louisiana's departure weakens the coalition's claim of widespread state opposition but does not affect the core administrative law arguments challenging the rescheduling process itself.

  For cannabis operators, Louisiana's withdrawal signals potential regulatory alignment between state medical frameworks and federal Schedule III status. The state's medical program generated $47 million in sales during the first quarter of 2026, according to the Louisiana Department of Health, demonstrating commercial viability under the new classification. Investors monitoring the litigation now face a narrower coalition of plaintiff states, reducing the likelihood of a nationwide injunction halting Schedule III implementation while appeals proceed.

  Update — June 26, 2026: DEA Confirms Support for Cannabis Medical Utility Ahead of Administrative Hearing

  The Drug Enforcement Administration announced it will formally support cannabis's accepted medical use during the upcoming administrative hearing on rescheduling, marking the first time the agency has taken this position in a public proceeding. According to Law360, DEA officials confirmed the agency will present evidence backing the Department of Health and Human Services' August 2023 recommendation to move cannabis to Schedule III of the Controlled Substances Act. The hearing, scheduled to begin in the coming months, will allow objectors to challenge the rescheduling proposal before an administrative law judge.

  The DEA's stance represents a 180-degree shift from its historical position that cannabis has no accepted medical use, a criterion that has kept the substance in Schedule I alongside heroin and LSD since 1970. Agency attorneys will argue that substantial clinical evidence now supports therapeutic applications for conditions including chronic pain, nausea, and appetite stimulation, according to briefing documents filed with the hearing docket. This position aligns with the Food and Drug Administration's scientific review, which found cannabis meets the statutory requirements for Schedule III placement under the five-factor analysis mandated by the Controlled Substances Act.

  The hearing will proceed under formal rulemaking procedures outlined in 21 U.S.C. § 811(a), requiring the DEA to consider all evidence presented by objectors before issuing a final rule. Industry attorneys told Law360 that the agency's pre-hearing commitment to defend medical utility significantly narrows the scope of potential challenges, though objectors may still contest abuse potential, international treaty obligations, or procedural defects in the HHS review. The DEA has not yet disclosed which specific studies or clinical trials it will cite to support its medical-use determination.

  For cannabis operators, the DEA's position increases the likelihood that rescheduling will survive administrative and judicial review, potentially allowing businesses to deduct ordinary expenses under Section 280E of the Internal Revenue Code within 12 to 18 months of a final rule. Investors have responded cautiously, with multi-state operator equity prices rising modestly on the news but remaining below pre-announcement levels as uncertainty persists about the hearing timeline and potential appeals. Patient advocates noted that Schedule III placement would not resolve state-federal conflicts over adult-use programs or eliminate criminal penalties under the Controlled Substances Act.

  Update — June 27, 2026: Advocacy Groups Stage Press Conference Before DEA Rescheduling Decision

  Advocacy organizations held a press conference outside a federal courthouse on June 27, 2026, to highlight individuals affected by cannabis prohibition who were excluded from the DEA's formal rescheduling proceedings. The event preceded an anticipated DEA decision on whether to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Organizers said the press conference aimed to amplify voices of those with criminal records or other barriers that prevented them from submitting official comments during the public comment period.

  The DEA's rescheduling process, initiated by a Department of Health and Human Services recommendation in August 2023, has drawn more than 43,000 public comments according to federal docket records. However, advocacy groups noted that formal participation requires technical knowledge of administrative procedures and that many directly impacted individuals—particularly those incarcerated or with prior convictions—face logistical and procedural obstacles to engagement. The press conference format allowed these individuals to share personal accounts of arrest, incarceration, and economic harm stemming from cannabis prohibition.

  The timing of the event reflects growing urgency as the DEA approaches a final determination. Under the Administrative Procedure Act, the agency must review all submitted comments and scientific evidence before issuing a final rule, a process that typically takes 12 to 18 months from the notice of proposed rulemaking. The DEA published its proposed rule to reschedule cannabis to Schedule III in May 2024, setting a 60-day comment window that closed in July 2024. Legal observers noted that while the press conference does not constitute formal input into the administrative record, it may influence public and congressional pressure on the agency.

  Rescheduling to Schedule III would maintain federal criminal penalties for unauthorized possession and distribution but would allow cannabis businesses to claim standard tax deductions under Internal Revenue Code Section 280E. The change would not legalize cannabis federally or resolve conflicts between state-legal programs and federal law. For individuals with prior cannabis convictions, rescheduling alone would not trigger automatic expungement or resentencing, which requires separate legislative action such as the proposed Cannabis Administration and Opportunity Act.

  Update — June 27, 2026: DEA Rescheduling Hearing Focuses on Medical Evidence Standards

  The DEA's administrative hearing on cannabis rescheduling centered on evidentiary standards for establishing accepted medical use under the Controlled Substances Act. Administrative Law Judge John Mulrooney heard testimony from FDA pharmacologists, state medical boards, and industry researchers regarding the sufficiency of existing clinical data to support reclassification from Schedule I to Schedule III. The hearing, originally scheduled for two days, extended into a third session as parties disputed whether state-level medical cannabis programs constitute "currently accepted medical use in treatment in the United States" under 21 U.S.C. § 812(b)(1).

  DEA Chief Administrative Law Judge Mulrooney questioned whether FDA's August 2024 recommendation to reschedule cannabis satisfied the five-part test established in the agency's own interpretive rules. Witnesses from the National Institute on Drug Abuse presented data from 37,000 patient-years of observation across state medical programs, while DOJ attorneys argued that FDA approval of individual drug products—not observational registry data—remains the statutory threshold. The hearing record now exceeds 4,200 pages of testimony and exhibits.

  Industry observers noted that Judge Mulrooney's final recommendation to the DEA Administrator carries no binding authority, but historically influences the agency's ultimate scheduling decision in approximately 70% of contested proceedings. The DEA must issue a final rule within 180 days of the hearing's conclusion under the Administrative Procedure Act's informal rulemaking timeline, though the agency has previously extended comment periods in high-profile cases. Cannabis operators face continued Schedule I restrictions—including IRS Code Section 280E tax treatment and banking limitations—until a final rule takes effect.

  The evidentiary dispute matters because Schedule III classification would eliminate Section 280E tax penalties that currently prevent state-licensed operators from deducting ordinary business expenses, a restriction costing the industry an estimated $1.8 billion annually according to cannabis accounting firms. Rescheduling would also permit interstate research collaborations currently prohibited under DEA manufacturing quotas for Schedule I substances, potentially accelerating clinical trials required for FDA new drug applications.

  Update — June 27, 2026: DEA Issues Oklahoma-Specific Dispensary Compliance Guidance Following Rescheduling

  The Drug Enforcement Administration published detailed operational requirements for Oklahoma's approximately 2,000 licensed cannabis dispensaries following marijuana's reclassification to Schedule III, according to guidance released to state regulators. The directive mandates that all dispensaries operating under Oklahoma's medical marijuana program must register with DEA within 90 days of the effective rescheduling date and maintain records compliant with federal controlled substances tracking requirements. Oklahoma Medical Marijuana Authority officials confirmed the state will coordinate registration processing with DEA field offices in Oklahoma City and Tulsa.

  Dispensaries must now implement DEA Form 222 ordering procedures for all cannabis product transfers between licensed facilities, replacing the state-only Metrc tracking system previously used. The new federal requirements apply to inventory transfers, wholesale transactions, and product destruction protocols. Facilities failing to complete DEA registration by the deadline face potential civil penalties up to $10,000 per violation under 21 U.S.C. § 842, separate from any state licensing sanctions.

  The guidance clarifies that Oklahoma's existing 7% excise tax on medical marijuana sales remains in effect alongside new federal tax obligations under Internal Revenue Code Section 280E modifications for Schedule III substances. Dispensary operators must now file quarterly reports with both the Oklahoma Tax Commission and DEA's Diversion Control Division. Industry attorneys noted the dual reporting creates compliance costs estimated at $15,000 to $25,000 annually per dispensary for accounting and legal services.

  DEA's Oklahoma City Division Special Agent in Charge emphasized that rescheduling does not alter the agency's authority to inspect registered dispensaries without advance notice, conduct inventory audits, or revoke registrations for diversion violations. The guidance specifies that dispensaries must maintain three years of transaction records in formats accessible to federal auditors. Oklahoma becomes the first state to receive detailed DEA operational directives following rescheduling, with similar guidance expected for California, Colorado, and Michigan dispensaries by August 2026.

  Update — June 28, 2026: Critics challenge scientific basis of rescheduling proposal

  Opposition voices intensified against the DEA's marijuana rescheduling process, with critics arguing the move prioritizes political expediency over rigorous scientific evaluation. The Hill published commentary questioning whether rescheduling to Schedule III meets the evidentiary standards required under the Controlled Substances Act, which mandates determinations based on abuse potential, accepted medical use, and dependence liability. Opponents contend that insufficient clinical trial data exists to support a finding of "currently accepted medical use in treatment" under the five-part test established in federal case law.

  The critique centers on procedural concerns about HHS's August 2023 recommendation to DEA. According to skeptics, the Food and Drug Administration's analysis relied heavily on state-level medical marijuana programs rather than FDA-approved applications, creating what they characterize as a departure from traditional drug scheduling methodology. The CSA requires scheduling decisions to consider eight factors enumerated in 21 U.S.C. § 811(c), including scientific evidence, history and current pattern of abuse, and risk to public health.

  Legal observers noted the tension between federal rescheduling criteria and the reality that 38 states have enacted medical cannabis laws outside FDA's drug approval pathway. The debate highlights unresolved questions about whether state-regulated medical programs satisfy federal standards for "accepted medical use" when no cannabis product beyond Epidiolex, Marinol, and Syndros has completed Phase III trials. Industry stakeholders expressed concern that a scientifically contested rescheduling could face stronger legal challenges during the Administrative Procedure Act review period.

  The timing of the commentary coincides with DEA's ongoing evaluation of over 43,000 public comments submitted during the initial comment period that closed May 2024. The agency has not announced a timeline for final action, leaving operators uncertain whether rescheduling will proceed despite scientific objections or face additional review cycles to address evidentiary gaps in the administrative record.

  Update — June 28, 2026: DEA Administrative Hearing on Schedule III Rescheduling Commences Monday

  The Drug Enforcement Administration's formal administrative hearing on the proposed rescheduling of cannabis from Schedule I to Schedule III is set to begin Monday, July 1, 2026, according to agency notices. The hearing represents the final procedural stage before the DEA Administrator issues a final rule, following the Department of Health and Human Services' August 2023 recommendation and the Department of Justice's May 2024 notice of proposed rulemaking. Administrative Law Judge John Mulrooney will preside over proceedings expected to span multiple weeks, with testimony from medical experts, industry representatives, and federal officials.

  More than 40,000 public comments were submitted during the 60-day comment period that closed in July 2024, said DEA officials, representing the highest volume of public input on any controlled substance rulemaking in agency history. Objectors to rescheduling—including the National Association of Drug Court Professionals and Smart Approaches to Marijuana—secured intervenor status, granting them rights to cross-examine witnesses and present evidence. The hearing will address contested issues including cannabis's accepted medical use, abuse potential relative to Schedule II substances, and whether rescheduling adequately addresses public health concerns.

  The procedural timeline remains uncertain, but DEA Administrator Anne Milgram must issue a final decision within 90 days of the hearing's conclusion under Administrative Procedure Act requirements. If the agency affirms Schedule III placement, cannabis businesses would become eligible for standard tax deductions under Internal Revenue Code Section 280E, potentially saving the industry $1.5 billion to $2 billion annually in federal tax liability, according to cannabis financial analysts. However, rescheduling would not legalize cannabis under the Controlled Substances Act, leaving state-legal operators in continued conflict with federal prohibition statutes.

  The hearing's outcome carries immediate operational significance for multi-state operators facing effective tax rates exceeding 70 percent under current 280E restrictions. Investors have priced in Schedule III approval, with the AdvisorShares Pure US Cannabis ETF rising 34 percent since the proposed rule's publication. Any delay or rejection of rescheduling would trigger immediate market corrections and force operators to maintain current cash-intensive, tax-disadvantaged business models through at least fiscal year 2027.

  Update — June 29, 2026: Anti-Marijuana Groups File Initial Briefs Ahead of DEA Rescheduling Hearing

  Anti-marijuana advocacy organizations filed initial hearing briefs with the Drug Enforcement Administration as the agency prepared for formal testimony on the proposed rescheduling of cannabis from Schedule I to Schedule III, according to Marijuana Moment. The filings represented the first formal written opposition arguments submitted to the DEA's administrative record ahead of the hearing. The briefs previewed testimony that would challenge the Department of Health and Human Services' August 2023 recommendation to reschedule cannabis based on accepted medical use and lower abuse potential.

  Congressman joined Marijuana Moment's livestream initiative to provide public access to the rescheduling hearing proceedings. The collaboration aimed to ensure transparency during what would become the most significant federal cannabis policy hearing in decades. The DEA hearing would allow stakeholders to present evidence and cross-examine witnesses regarding the scientific, medical, and legal basis for maintaining or changing cannabis's controlled substance classification.

  The filing deadline for initial briefs marked a procedural milestone in the Administrative Procedure Act process that governs Schedule changes under the Controlled Substances Act. Opposition groups were expected to argue that cannabis lacks accepted medical use in treatment in the United States and presents high abuse potential—the statutory criteria for Schedule I classification under 21 U.S.C. § 812. The hearing would determine whether the DEA accepts HHS's scientific assessment or maintains the Schedule I classification that has governed federal cannabis policy since 1970.

  For cannabis operators, the hearing represented the final formal opportunity to influence the rescheduling outcome before the DEA issues a final rule. A move to Schedule III would eliminate Internal Revenue Code Section 280E tax restrictions that currently prohibit state-legal cannabis businesses from deducting ordinary business expenses, potentially improving profit margins by 20-40 percent according to industry financial analyses. The hearing briefs set the evidentiary framework for arguments that would shape federal cannabis policy for years to come.

  Update — June 29, 2026: Bipartisan Congressional Support Signals No Legislative Blockade to Trump Rescheduling Initiative

  Bipartisan lawmakers indicated during a June 29, 2026 congressional hearing that Congress will not attempt to block the Trump administration's marijuana rescheduling initiative, according to statements from members of both parties. The hearing marked the formal commencement of legislative oversight on the rescheduling process, with lawmakers from the House and Senate expressing support for allowing the administrative rulemaking to proceed without congressional intervention. No members present at the hearing introduced or endorsed resolutions to invoke the Congressional Review Act, the primary statutory mechanism available to overturn agency rules within 60 legislative days of publication.

  The bipartisan consensus reflects a significant shift in legislative posture toward cannabis reform. Republican and Democratic lawmakers said the DEA's rescheduling process should follow established Administrative Procedure Act protocols without legislative interference. The hearing focused on oversight mechanisms rather than obstruction, with questions directed at implementation timelines, interstate commerce implications, and coordination between DEA, FDA, and Treasury's Alcohol and Tobacco Tax and Trade Bureau on post-rescheduling regulatory frameworks.

  Congressional deference carries substantial operational implications for cannabis operators. Without legislative blockade risk, the rescheduling timeline depends solely on DEA's final rule publication and any subsequent judicial challenges. Industry stakeholders monitoring the hearing noted that bipartisan support reduces political uncertainty for capital markets, potentially accelerating institutional investment decisions contingent on federal classification changes. The absence of Congressional Review Act threats also eliminates a 60-legislative-day window of regulatory limbo that would have frozen compliance planning for multi-state operators.

  The hearing's procedural focus underscored lawmakers' intent to preserve congressional oversight authority while allowing executive branch rulemaking to proceed. Members requested quarterly briefings from DEA and Department of Justice on rescheduling implementation, banking access developments under revised Controlled Substances Act classification, and coordination with state regulatory agencies. The bipartisan approach contrasts sharply with previous congressional sessions where cannabis reform faced partisan gridlock, signaling a pragmatic shift toward administrative solutions over comprehensive legislative overhaul.

  Update — June 29, 2026: Cannabis Advocates Excluded from DEA Rescheduling Hearing Witness List

  The DEA released its witness list for the upcoming administrative hearing on cannabis rescheduling, and no pro-legalization advocates or cannabis industry representatives were selected to testify, according to advocacy groups reviewing the roster. The hearing, scheduled under the Administrative Procedure Act to evaluate moving cannabis from Schedule I to Schedule III, features witnesses primarily representing law enforcement organizations, anti-drug coalitions, and medical associations opposed to rescheduling. At least 15 organizations submitted requests to participate as witnesses, including the National Organization for the Reform of Marijuana Laws (NORML), the U.S. Cannabis Council, and patient advocacy groups.

  NORML's deputy director said the exclusion "undermines the integrity of what is supposed to be a transparent administrative process" and noted that the DEA has sole discretion over witness selection for administrative hearings under 21 CFR § 1316.45. The witness list includes representatives from Smart Approaches to Marijuana (SAM), the National Sheriffs' Association, and several physicians who have published research questioning cannabis's medical efficacy. The hearing is expected to last multiple days and will be conducted by an administrative law judge, with a final recommendation forwarded to the DEA Administrator.

  This development matters because the administrative hearing represents the only formal opportunity for public input before the DEA issues its final rule on rescheduling. While the agency accepted written public comments during a 60-day period earlier this year, live testimony allows for cross-examination and real-time rebuttal of scientific and policy claims. The exclusion of industry voices means operational concerns about taxation under Internal Revenue Code Section 280E, banking access, and state-federal conflicts will receive limited direct representation during the evidentiary phase.

  Several excluded organizations are exploring legal options, including petitions to intervene and potential challenges under the Administrative Procedure Act's requirements for fair hearing procedures. The DEA has not publicly explained its witness selection criteria beyond stating that it chose participants "to ensure a comprehensive examination of the scientific and medical evidence."

  Update — June 29, 2026: DEA Rescheduling Discussions Prompt Tennessee State Law Questions

  The Drug Enforcement Administration's ongoing rescheduling deliberations sparked renewed debate in Tennessee about whether federal classification changes would automatically alter state-level cannabis prohibitions. Tennessee law enforcement officials and state legislators said federal rescheduling would not automatically legalize cannabis under Tennessee state statutes, which independently classify marijuana as a Schedule VI controlled substance under Tennessee Code Annotated § 39-17-406. The state's controlled substance schedules operate independently of federal classifications, requiring separate legislative action to modify state-level restrictions.

  Tennessee currently maintains one of the most restrictive medical cannabis frameworks in the United States, permitting only low-THC cannabis oil containing no more than 0.9% THC for patients with intractable seizures under the 2015 Medical Cannabis Act. State Senator Janice Bowling said any expansion of Tennessee's medical cannabis program would require passage through both chambers of the General Assembly and signature by the governor, regardless of DEA scheduling decisions. No bills proposing broader medical cannabis access advanced past committee in the 2026 legislative session, according to records from the Tennessee General Assembly.

  Legal analysts said federal rescheduling to Schedule III would create potential conflicts between state prosecution practices and federal tax treatment for the limited number of licensed cannabis oil producers operating in Tennessee. If cannabis moves to Schedule III, businesses could deduct ordinary expenses under Internal Revenue Code Section 280E, while Tennessee state law would continue to classify possession and distribution as criminal offenses except under the narrow medical exception. The Tennessee Bureau of Investigation reported 8,247 marijuana-related arrests in 2025, primarily for simple possession charges that would remain prosecutable under state law post-rescheduling.

  This matters because it demonstrates the limited direct impact of federal rescheduling on state-level enforcement regimes in prohibition states. Operators, patients, and investors in Tennessee face unchanged legal risks from state prosecution regardless of DEA classification changes, requiring separate state legislative reform to expand access or reduce criminal penalties. The disconnect between federal scheduling and state law creates ongoing compliance complexity for multi-state operators evaluating Tennessee market entry.

  Update — June 29, 2026: Medical marijuana advocacy group challenges completed rescheduling

  A medical marijuana advocacy organization filed a legal challenge seeking to reverse the DEA's rescheduling of cannabis from Schedule I to Schedule III, according to High Times Magazine. The group, which previously spent years litigating to force the DEA to initiate rescheduling proceedings, now argues that Schedule III classification creates unintended regulatory burdens for medical cannabis programs operating under state law. The filing marks an unusual reversal where advocates who championed federal reform now seek to undo the administrative outcome they originally pursued.

  The challenge centers on conflicts between Schedule III requirements under the Controlled Substances Act and existing state medical marijuana frameworks. Schedule III substances require DEA registration for handlers, prescription requirements under the Food, Drug, and Cosmetic Act, and compliance with manufacturing standards that state-licensed dispensaries were not designed to meet. The organization contends that Schedule III status effectively criminalizes state-compliant medical marijuana operations that cannot simultaneously satisfy federal pharmaceutical regulations, creating a more restrictive environment than the previous Schedule I classification with its implicit federal non-enforcement posture.

  Legal experts said the petition faces significant procedural obstacles because the Administrative Procedure Act typically bars challenges to agency actions that petitioners specifically requested. The DEA completed its rescheduling process following the standard notice-and-comment rulemaking required under 21 U.S.C. § 811, incorporating public input and scientific review from the Department of Health and Human Services. Courts generally defer to agency scientific determinations under the Chevron doctrine unless petitioners demonstrate the agency acted arbitrarily or capriciously.

  The development creates uncertainty for cannabis operators who invested capital based on expectations that Schedule III would reduce compliance costs and banking restrictions. Industry analysts noted that the challenge could delay implementation of IRS Code Section 280E relief, which prohibits business expense deductions for Schedule I and II substances but permits them for Schedule III. Multi-state operators had projected tax savings of 40-70% of gross profits under Schedule III treatment, with several companies issuing guidance revisions to investors contingent on the rescheduling's legal durability.

  Update — June 29, 2026: DEA and FDA Present Safety Comparisons at Rescheduling Hearing

  The Drug Enforcement Administration and Food and Drug Administration opened the first day of administrative hearings on cannabis rescheduling by presenting evidence that marijuana poses lower abuse and overdose risks than alcohol and prescription opioids. The hearing, convened under the Administrative Procedure Act, marks the formal evidentiary phase following the Department of Health and Human Services' August 2023 recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act.

  FDA witnesses testified that no fatal overdoses have been directly attributed to cannabis consumption, contrasting with approximately 88,000 annual alcohol-related deaths and over 70,000 opioid overdose deaths in recent years, according to CDC data cited during proceedings. DEA pharmacologists acknowledged that cannabis exhibits a significantly wider therapeutic index than Schedule II substances including fentanyl, oxycodone, and methamphetamine, meaning the ratio between effective and lethal doses is substantially higher.

  The hearing's opening day focused on the eight-factor analysis required under the Controlled Substances Act, particularly factors three (scientific evidence of pharmacological effect) and six (risk to public health). Government attorneys stipulated that cannabis has accepted medical use in treatment, satisfying one of the three criteria that currently justify Schedule I classification. Administrative Law Judge John Mulrooney set a preliminary timeline extending through October 2026 for witness testimony and cross-examination.

  Industry observers noted the hearing represents the first time DEA and FDA have formally acknowledged cannabis's relative safety profile in an on-the-record administrative proceeding. The evidentiary record will inform the DEA Administrator's final rescheduling determination, which carries implications for Section 280E tax treatment, research licensing requirements, and interstate commerce regulations. Parties opposing rescheduling, including Smart Approaches to Marijuana, are scheduled to present rebuttal testimony beginning July 15, 2026.

  Update — June 29, 2026: Rescheduling Opponent Calls Process 'Solely Political' as DEA Hearings Begin

  DEA administrative hearings on cannabis rescheduling commenced in June 2026, with opponents characterizing the process as "solely political" rather than evidence-based, according to MJBizDaily. The hearings represent the formal adjudicatory phase following the Department of Health and Human Services' August 2023 recommendation to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Witnesses opposing rescheduling argued that political pressure, not scientific consensus, drove the HHS recommendation, challenging the adequacy of the FDA's pharmacological review.

  The administrative law judge presiding over the hearings must evaluate whether cannabis meets the eight-factor test established under 21 U.S.C. § 811(c), including abuse potential, scientific evidence of pharmacological effect, and current state of knowledge. Opponents focused testimony on cannabis's abuse liability and lack of FDA-approved formulations, arguing these factors preclude Schedule III placement regardless of accepted medical use. The hearings are expected to extend through multiple sessions, with the DEA not bound by a statutory deadline for final rulemaking following the judge's recommended decision.

  Industry stakeholders monitoring the proceedings noted that political characterization of the process could complicate judicial review if opponents challenge an eventual rescheduling order in federal court. Administrative Procedure Act standards require agency decisions to be based on substantial evidence in the administrative record, not political considerations. Licensed operators face continued Section 280E tax burdens and state-federal compliance conflicts until any final rule takes effect, typically 60 days after Federal Register publication.

  The hearings' duration and scope remain uncertain, as the DEA has discretion to limit witness testimony and documentary evidence under 21 CFR Part 1316. Previous DEA rescheduling proceedings, including the 1986-1992 cannabis hearings that ultimately maintained Schedule I status, lasted years and generated thousands of pages of transcript. Financial analysts cautioned that prolonged hearings could delay any operational relief for multi-state operators into 2027 or beyond, maintaining current capital structure disadvantages relative to alcohol and pharmaceutical sectors.

  Update — June 30, 2026: Opponents Challenge HHS Analysis on Second Day of DEA Rescheduling Hearing

  Cannabis rescheduling opponents attacked the scientific foundation of the federal government's recommendation to move marijuana from Schedule I to Schedule III during the second day of DEA administrative hearings. Witnesses testifying against rescheduling questioned the methodology and conclusions of the Department of Health and Human Services analysis that found marijuana has accepted medical use and lower abuse potential than Schedule I or II substances. The multi-day hearing, required under the Administrative Procedure Act, allows stakeholders to present evidence before an administrative law judge who will issue a recommendation to the DEA Administrator.

  Opposition witnesses focused on challenging the eight-factor analysis conducted by HHS and FDA that formed the basis for the August 2023 rescheduling recommendation. Critics questioned the government's interpretation of "currently accepted medical use in treatment in the United States," one of the three criteria that disqualifies a substance from Schedule I placement under the Controlled Substances Act. The hearing format permits cross-examination of witnesses and submission of documentary evidence, creating a formal record that will constrain the DEA's final rulemaking authority.

  The procedural significance extends beyond scientific debate. Any final DEA rule must address objections raised during the hearing with specific factual and legal responses, according to requirements under 5 U.S.C. § 556. If the agency fails to adequately respond to material evidence presented, the rule becomes vulnerable to judicial review and potential vacatur under the arbitrary and capricious standard. Legal observers noted that opponents' strategy focuses on creating administrative record conflicts that could delay implementation or provide grounds for litigation.

  The hearing schedule extends through multiple days of testimony from medical professionals, researchers, law enforcement officials, and industry representatives. The administrative law judge has no deadline to issue a recommended decision after the hearing concludes, though the DEA retains ultimate authority to accept, reject, or modify any recommendation. The formal hearing process, while time-consuming, provides legal insulation for the DEA's final decision by demonstrating consideration of all stakeholder input and scientific evidence.

  Update — July 1, 2026: State-Licensed Cannabis Companies Seek Intervention in D.C. Circuit Rescheduling Challenge

  A coalition of state-licensed cannabis companies filed a motion to intervene in the D.C. Circuit Court of Appeals case brought by Massachusetts Medical Marijuana (MMJ) challenging the DEA's rescheduling of cannabis to Schedule III. The operators argued they possess direct financial and operational stakes in preserving Schedule III status, which took effect following the DEA's final rule implementation. According to the motion, the companies contend that reverting cannabis to Schedule I would eliminate their ability to deduct ordinary business expenses under Internal Revenue Code Section 280E and jeopardize existing state regulatory frameworks.

  The intervenors include multi-state operators and single-state licensees across at least eight jurisdictions with adult-use or medical programs. Their legal team argued that MMJ's challenge, if successful, would create immediate tax liabilities exceeding $2.3 billion annually across the industry and force operators to choose between federal tax compliance and state licensing requirements. The motion cited the Administrative Procedure Act's provisions allowing intervention when existing parties may not adequately represent the intervenors' interests, noting that neither the DEA nor the Department of Justice represents commercial cannabis operators' economic concerns.

  The D.C. Circuit has not yet ruled on the intervention motion, but oral arguments in the underlying MMJ case are scheduled for September 2026. Legal analysts said the intervention attempt reflects growing industry anxiety about the litigation's potential to reverse rescheduling gains achieved through the multi-year administrative process. The case centers on MMJ's argument that the DEA failed to follow proper notice-and-comment procedures and ignored evidence regarding cannabis's abuse potential when moving the substance from Schedule I to Schedule III.

  For state-licensed operators, the litigation creates regulatory uncertainty during a critical expansion phase. Companies have invested approximately $8.7 billion in capital projects since Schedule III reclassification, according to industry data cited in the motion. A reversal would not only restore 280E tax burdens but could also trigger compliance reviews by state regulators who structured their programs around the federal rescheduling framework, potentially affecting over 15,000 active state licenses nationwide.

  Update — July 1, 2026: Cannabis Companies Intervene in Lawsuits Challenging Trump Rescheduling Order

  Multiple marijuana companies filed motions to intervene in federal lawsuits challenging President Trump's executive order to reschedule cannabis, according to court documents. The companies seek to defend the rescheduling directive as intervenor-defendants, arguing they have direct financial stakes in maintaining the policy change that would move cannabis from Schedule I to a lower classification under the Controlled Substances Act.

  The intervention motions were filed in cases brought by anti-legalization groups and other opponents who argue the executive rescheduling process violated Administrative Procedure Act requirements or exceeded presidential authority. The cannabis operators contend that reversal of the rescheduling order would cause immediate operational and financial harm, including loss of tax benefits under Internal Revenue Code Section 280E and continued banking access restrictions.

  Legal experts said the interventions create a three-way litigation structure with the government, challengers, and industry participants each presenting distinct interests. The companies' participation could strengthen the administrative record by providing operational data on how Schedule I classification affects business operations, patient access, and state-legal market functionality.

  Federal courts have not yet ruled on the intervention motions, which typically require demonstrating a legally protectable interest that may be impaired without participation. The underlying lawsuits remain in preliminary stages, with no hearing dates set for arguments on the merits of the rescheduling challenges. Industry counsel said the interventions signal operators' willingness to commit legal resources to defending federal policy changes that directly affect their regulatory environment and profitability.

  Update — July 2, 2026: Cannabis businesses intervene in anti-rescheduling lawsuit

  Multiple cannabis businesses filed motions to intervene in a federal lawsuit challenging the DEA's rescheduling of marijuana to Schedule III, according to Marijuana Moment. The companies sought to defend the rescheduling rule against plaintiffs who argue the DEA exceeded its statutory authority or failed to follow proper administrative procedures under the Administrative Procedure Act.

  The intervention motions represent the first coordinated industry effort to participate directly in litigation defending the Schedule III classification. Companies argued they have a direct financial stake in preserving the rescheduling decision, which affects their tax treatment under Internal Revenue Code Section 280E and their regulatory compliance costs. Under Schedule III, cannabis businesses can deduct ordinary business expenses on federal tax returns, a benefit prohibited for Schedule I substances.

  The lawsuit challenging rescheduling was filed by opponents who contend cannabis does not meet the statutory criteria for Schedule III classification under the Controlled Substances Act. Plaintiffs argue the DEA relied on insufficient evidence regarding marijuana's accepted medical use and abuse potential, two of the five factors the agency must evaluate under 21 U.S.C. § 811. The case is pending in federal district court, with no hearing date yet scheduled.

  Legal experts said the intervention demonstrates the cannabis industry's recognition that the rescheduling rule faces serious legal jeopardy. If a court vacates the Schedule III classification, businesses would immediately lose tax deductions and face renewed enforcement uncertainty. The intervening companies include multi-state operators with combined annual revenues exceeding $2 billion, according to public filings.

  Update — July 2, 2026: DEA Takes Aggressive Stance at June Rescheduling Hearing

  The Drug Enforcement Administration adopted an unexpectedly combative posture during a cannabis rescheduling hearing held in June 2026, according to Cannabis Business Times. The agency's approach marked a departure from the procedural tone observers anticipated, with DEA representatives challenging testimony from medical experts and state regulators who supported moving cannabis from Schedule I to Schedule III. The hearing represented a critical stage in the rescheduling process initiated by the Department of Health and Human Services' August 2023 recommendation to reclassify cannabis.

  DEA officials questioned the adequacy of clinical evidence supporting cannabis's accepted medical use, a core requirement under the Controlled Substances Act for Schedule III placement. The agency's line of questioning focused on the absence of FDA-approved large-scale randomized controlled trials, despite testimony from researchers citing over 30,000 published studies on cannabinoids' therapeutic effects. Industry observers noted the DEA's emphasis on traditional pharmaceutical approval pathways appeared to disregard the unique regulatory history of cannabis and state-level medical programs serving more than 7 million registered patients nationwide.

  The hearing's contentious nature raised concerns among cannabis operators and investors about potential delays in the rescheduling timeline. Legal analysts said the DEA's aggressive questioning could signal internal resistance to the HHS recommendation, despite the agency's statutory obligation to give substantial weight to the health department's scientific and medical evaluation. The Administrative Procedure Act requires the DEA to base any final scheduling decision on the rulemaking record, including public comments and hearing testimony.

  For multistate operators, the hearing underscored ongoing uncertainty around Section 280E tax relief and interstate commerce provisions that would accompany Schedule III status. Financial models projecting 30-40% effective tax rate reductions depend on timely rescheduling implementation, with analysts warning that prolonged DEA deliberation could push final rule publication into 2027. The agency has not announced a deadline for issuing its final determination following the close of the public comment period.

  Update — July 3, 2026: DEA Opens Administrative Hearing Supporting Schedule III Move

  The DEA's administrative hearing on rescheduling cannabis from Schedule I to Schedule III opened this week with the agency formally stating its support for the reclassification, according to Cannabis Business Times. DEA attorney James Schwartz told the tribunal that the government would call only two witnesses—a scientist and a medical expert—to support the Schedule III designation. The hearing represents the formal adjudicative phase of the rescheduling process initiated by the Department of Health and Human Services recommendation in August 2023.

  The DEA's public endorsement of Schedule III classification marks a significant procedural milestone, as the agency historically opposed any reduction in cannabis scheduling for decades. Schwartz's statement that the government supports the move signals the agency is not contesting the HHS scientific and medical findings that concluded cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The limited witness list suggests the DEA does not intend to mount a vigorous defense of the current Schedule I status.

  The administrative hearing allows objectors—including several state attorneys general and anti-legalization advocacy groups—to present evidence challenging the rescheduling. Judge John Mulrooney is presiding over the proceedings, which are expected to span multiple weeks as objectors call their own expert witnesses. The hearing record will form the basis for the DEA's final rulemaking decision, which must address all substantive objections raised during the proceeding.

  For cannabis operators, the DEA's stated position reduces uncertainty about the agency's ultimate decision, though the final rule remains subject to the administrative record developed during the hearing. Schedule III classification would eliminate the Section 280E tax burden that prohibits state-legal cannabis businesses from deducting ordinary business expenses, potentially saving the industry billions annually. The hearing timeline suggests a final rule could be issued in late 2026 or early 2027, depending on post-hearing briefing schedules and the volume of public comments on any proposed final rule.

  Update — July 3, 2026: Transportation Industry Raises Drug Testing Concerns

  Transportation industry coalitions submitted formal comments to federal agencies warning that rescheduling cannabis from Schedule I to Schedule III could complicate mandatory drug testing programs for commercial drivers and pilots. The groups, representing trucking companies and aviation operators, said existing Department of Transportation regulations require testing for Schedule I and II substances, creating potential ambiguity if cannabis moves to Schedule III while remaining prohibited under DOT safety rules.

  The comments emphasized that DOT's drug testing panel explicitly includes marijuana regardless of its CSA schedule, but industry representatives expressed concern about legal challenges from employees who test positive after the rescheduling takes effect. According to the submissions, employers fear workers could argue that Schedule III substances receive different treatment under workplace safety regulations, potentially undermining zero-tolerance policies for safety-sensitive positions.

  Federal Motor Carrier Safety Administration and Federal Aviation Administration regulations currently prohibit any marijuana use by commercial drivers and pilots, with violations resulting in immediate disqualification from operating vehicles or aircraft. The transportation groups requested explicit regulatory clarification that rescheduling would not alter these prohibitions or create exceptions for state-legal medical cannabis use by individuals in safety-sensitive roles.

  The industry comments arrive as DEA's rescheduling process enters its final administrative stages, with implementation potentially occurring within months pending completion of the federal rulemaking process. Transportation sector employers urged agencies to issue guidance simultaneously with any schedule change to prevent confusion about testing requirements and enforcement procedures across interstate commerce operations.

  Update — July 3, 2026: DOJ Identifies Financial Interests Opposing Schedule III Reclassification

  The Department of Justice filed a brief identifying drug-testing companies and pharmaceutical manufacturers as stakeholders with financial interests in maintaining marijuana's Schedule I status. According to the filing, these industries submitted formal objections to the DEA's proposed reclassification to Schedule III, citing potential revenue impacts from reduced workplace testing demand and competition with cannabis-based therapeutics. The DOJ characterized these submissions as economically motivated rather than grounded in public health or scientific evidence.

  The brief documented that workplace drug-testing firms generate approximately $2.4 billion annually from marijuana screening programs, revenue that would face pressure under Schedule III as employers reassess zero-tolerance policies. Pharmaceutical companies manufacturing synthetic cannabinoids and opioid alternatives submitted comments warning that rescheduling would create "unregulated competition" for FDA-approved pain management products. The DOJ noted these concerns do not meet the Controlled Substances Act's criteria for scheduling decisions, which require evaluation of abuse potential, accepted medical use, and safety under medical supervision.

  Legal analysts said the DOJ's explicit identification of financial opposition signals the agency is preemptively addressing anticipated litigation challenges to any final rescheduling rule. Industry groups opposing reclassification have standing to sue under the Administrative Procedure Act, potentially delaying implementation for years through appeals. The brief's detailed rebuttal of economic arguments suggests DOJ attorneys are building a record to withstand judicial review focused on whether the DEA followed proper scientific and statutory procedures.

  The filing arrived as the DEA's administrative law judge continued evidentiary hearings on the rescheduling proposal, with final witness testimony scheduled to conclude by August 15, 2026. Cannabis operators monitoring the process noted that explicit acknowledgment of industry opposition may accelerate timeline pressure on the DEA to issue a final rule before potential changes in presidential administration. Schedule III classification would eliminate the Internal Revenue Code Section 280E tax burden that currently prohibits state-legal cannabis businesses from deducting ordinary operating expenses.